Latent Variable Modelling for Complex Observational Health Data by Harrison, Wendy Jane
 Latent Variable Modelling for 
Complex Observational Health Data  
 
 




Submitted in accordance with the requirements for the degree of 
Doctor of Philosophy 
 
 
The University of Leeds 





- i - 
Intellectual Property Statement 
The candidate confirms that the work submitted is her own, except where 
work which has formed part of jointly-authored publications has been 
included. The contribution of the candidate and the other authors to this work 
has been explicitly indicated below. The candidate confirms that appropriate 
credit has been given within the thesis where reference has been made to 
the work of others.  
 
Chapter 3 contains work based on the following publication: 
1. Harrison, W.J., Gilthorpe, M.S., Downing, A., Baxter, P.D. 2013. 
Multilevel latent class modelling of colorectal cancer survival status at 
three years and socioeconomic background whilst incorporating stage of 
disease. International Journal of Statistics and Probability; 2(3), pp.85-95. 
Wendy J. Harrison conceived and developed the idea, performed all 
analyses and drafted the manuscript. The other authors made 
contributions to the draft manuscript. 
 
Chapter 4 contains work based on the following publication: 
2. Gilthorpe, M.S., Harrison, W.J., Downing, A., Forman, D., West, R.M. 
2011. Multilevel latent class casemix modelling: a novel approach to 
accommodate patient casemix. BMC Health Services Research. 11(53). 
As an earlier investigation of greater complexity, the idea and plan was 
conceived by Professor Mark S. Gilthorpe. Wendy J. Harrison developed 
the idea, performed all analyses and drafted the manuscript. The other 
authors made contributions to the draft manuscript. 
 
Chapters 2, 3 and 4 contain work based on the following publication: 
3. Harrison, W.J., West, R.M., Downing, A., Gilthorpe, M.S. 2012. Chapter 
7: Multilevel Latent Class Modelling. In: Greenwood, D.C. and Tu, Y-K. 
eds. Modern Methods for Epidemiology. London: Springer, pp.117-140. 
A book chapter containing elements of the previous two publications; 
Wendy J. Harrison performed all additional analyses and drafted the 
chapter. The other authors made contributions to the draft chapter. 
- ii - 
This copy has been supplied on the understanding that it is copyright 
material and that no quotation from the thesis may be published without 
proper acknowledgement. 
 
The right of Wendy Jane Harrison to be identified as Author of this work has 
been asserted by her in accordance with the Copyright, Designs and Patents 
Act 1988. 
 
© 2016 The University of Leeds and Wendy Jane Harrison 





- iv - 
Acknowledgements 
I would like to thank my supervisors Professor Mark S. Gilthorpe and Dr Paul 
D. Baxter for their advice and encouragement throughout. Without your 
unwavering support, this thesis would not have been submitted. 
 
Thank you to Dr Graham R. Law and all members of the Division of 
Epidemiology & Biostatistics for your help and advice through this process. 
 
I would also like to thank the Northern and Yorkshire Cancer Registry and 
Information Service (NYCRIS) for access to the routinely collected data for 
the purposes of this research. 
 
Finally, thank you to Mum, and to John, for believing I could do this. 
 
 
- v - 
Abstract 
Observational health data are a rich resource that present modelling 
challenges due to data complexity. If inappropriate analytical methods are 
used to make comparisons amongst either patients or healthcare providers, 
inaccurate results may generate misleading interpretations that may affect 
patient care. Traditional approaches cannot fully accommodate the 
complexity of the data; untenable assumptions may be made, bias may be 
introduced, or modelling techniques may be crude and lack generality. 
Latent variable methodologies are proposed to address the data challenges, 
while answering a range of research questions within a single, overarching 
framework. Precise model configurations and parameterisations are 
constructed for each question, and features are utilised that may minimise 
bias and ensure that covariate relationships are appropriately modelled for 
correct inference. Fundamental to the approach is the ability to exploit the 
heterogeneity of the data by partitioning modelling approaches across a 
hierarchy, thus separating modelling for causal inference and for prediction.  
In research question (1), data are modelled to determine the association 
between a health exposure and outcome at the patient level. The latent 
variable approach provides a better interpretation of the data, while 
appropriately modelling complex covariate relationships at the patient level. 
In research questions (2) and (3), data are modelled in order to permit 
performance comparison at the provider level. Differences in patient 
characteristics are constrained to be balanced across provider-level latent 
classes, thus accommodating the ‘casemix’ of patients and ensuring that any 
differences in patient outcome are instead due to organisational factors that 
may influence provider performance.  
Latent variable techniques are thus successfully applied, and can be 
extended to incorporate patient pathways through the healthcare system, 
although observational health datasets may not be the most appropriate 
context within which to develop these methods. 
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Preface 
Prior to commencing this research activity in 2007, I was employed within 
the National Health Service (NHS) as a medical statistician at the Northern 
and Yorkshire Cancer Registry and Information Service (NYCRIS), where I 
was responsible for the provision of specialist statistical input relating to all 
cancer information outputs for the local geographical region. I became 
involved in a project to investigate the changing effect of socioeconomic 
deprivation on colorectal cancer incidence rates, which highlighted concerns 
about the potential introduction or exacerbation of bias when using 
regression techniques to model imprecise or incomplete covariates.  
My honorary contract with the University of Leeds allowed me to collaborate 
with academic statisticians on the exploration and development of statistical 
methodologies, thus I became aware of Latent Class Analysis (LCA) as an 
emerging new method that may be able to address these covariate issues. I 
worked with Professor Mark S. Gilthorpe to assess the utility of LCA to 
model cancer registry data, and initial results were promising, potentially 
showing the approach to be unbiased in estimating the impact of key 
covariates, when compared with regression analysis. 
I commenced my career at the University of Leeds in 2007, but maintained 
links with NYCRIS, as I was keen to continue to explore and develop 
innovative approaches to the analysis of cancer registry data specifically, 
and of routinely collected observational health service data in general. My 
PhD studies have thus allowed me to apply my developing knowledge of 
latent variable modelling approaches in an attempt to provide empirical 
answers to important health service questions, using the cancer registry data 
as an exemplar. Over time, my interest has expanded to consider also the 
latent variable approaches from a methodological perspective, and to reflect 
upon the use of observational datasets as a context within which to develop 
such methods. Chapters 3 and 4 of this thesis contain earlier, application-
based work while Chapter 5 offers a more methodological approach. 
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A list of detailed definitions of key terms, phrases and abbreviations follows, 
to set the scene for their later use within this thesis. They are presented in 
order of their consideration within the abstract and main thesis. 
 
Observational health data. Within this thesis, I classify ‘observational health 
data’ as any set of data that is generated by observing patients as they 
progress through the healthcare system. This progression is termed the 
‘patient journey’ (described in section 2.3.5). These datasets are commonly 
generated by routine data collection i.e. healthcare organisations record 
events (e.g. diagnoses, deaths or treatment received) and these events may 
then be linked together using appropriate identification codes. Thus, 
observational health datasets may be generated from multiple data sources. 
Their structure is inherently complex, as described in section 1.2.1. 
Observational also refers to the healthcare setting or framework, i.e. data 
are not obtained from within a clinical trial setting, where patients are 
typically allocated to treatments based on randomisation; rather, each 
patient receives care specific to their individual circumstances. It is 
anticipated that this care may vary by patient, disease group and / or 
healthcare provider. 
Traditional. I use this term to reflect the type of analyses that are most 
commonly used to examine observational health data within healthcare 
organisations. Typically, for instance, regression analyses are employed 
(see section 3.2.2), which may be single level (see section 1.3.1) or 
multilevel (see section 1.3.2). Traditional strategies are also often utilised to 
accommodate differences in patient characteristics across healthcare 
providers (termed ‘casemix’; see sections 1.2.3 and 1.3.4). Other terms were 
considered (e.g. ‘standard’ or ‘established’), but as none seemed ideal, I 
chose ‘traditional’ as a general term to describe the more conventional 
approach to these type of data evaluation approaches.  
I do not suppose that other analytical methods are not available, feasible, or 
utilised; rather, that ‘traditional’ approaches are those most often employed 
in the healthcare environment, which may thus benefit from comparison with 
less commonly adopted or novel analytical approaches. 
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Methodology. I use this term, defined as “a system of methods and 
principles used in a particular discipline” (Hanks et al., 1986), when referring 
to a broad spectrum of methods. For example, latent variable ‘methodology’ 
or traditional ‘methodology’, may each comprise many possible methods. 
The latent variable ‘methodology’ (also ‘approach’, or ‘technique’) may thus 
refer to any modelling that is performed within a latent variable framework, 
whether with continuous or discrete observed or latent variables. Specific 
methods, such as latent class analysis (LCA) or multilevel modelling (MLM), 
lie within the framework of latent variable methodologies. 
Patient pathway. As part of the ‘patient journey’ (see section 2.3.5), the 
patient pathway reflects the progress of a patient through the healthcare 
system and may include, for example, tests, medication or surgery. This 
pathway may be influenced by characteristics of the patient and / or of the 
disease, and may also be affected by processes within the healthcare 
organisation(s) attended. Therefore, the patient pathway may differ for each 
patient, and may differ for two patients of identical socio-demographic 
backgrounds with identical health conditions when entering the healthcare 
system. 
Causal framework. This term refers to a framework within which modelling 
for causal inference (see section 1.4.2) is performed. As discussed in 
section 1.2.1, questions posed within healthcare research commonly relate 
to causal factors (upon which one might intervene), necessitating a causal 
inference perspective, rather than merely invoking a predictive modelling 
approach. Research questions (1) and (3) (see section 1.2.3) explicitly 
consider causal effects at the patient and provider level respectively. 
Patient casemix. This term refers to differences in patient characteristics 
across healthcare providers. As raised in research question (2) (see section 
1.2.3), patient characteristics may vary geographically and hence may vary 
with respect to circumstances affecting (or even driving) their health status, 
reflecting different patient combinations across providers that are situated in 
different geographical locations. In order to make a fair comparison across 
healthcare providers, patient casemix should be accommodated. Traditional 
approaches to patient casemix adjustment are discussed in section 1.3.4. 
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MLM. As described in section 1.3.2, this term refers to the extension of 
single level regression modelling, where lower-level observations are 
clustered within higher-level groups. This approach is defined initially within 
this thesis as a ‘traditional’ technique, as it is commonly utilised within the 
healthcare environment (see section 3.2.2). It can, however, also be 
considered as a simple example of a latent variable model, as indicated in 
section 1.4.1, with homogeneous subgroups at each level of the hierarchy. 
LCA. As described in section 1.4.3, I use this term to refer to any statistical 
analysis where the model allows for parameters to differ across latent 
subgroups, following the definition offered by Vermunt and Magidson 
(Vermunt and Magidson, 2003). The single level LCA approach is explained 
in detail in section 2.2.1. 
Multilevel latent class (MLLC) analysis. Also described as MLLC modelling, I 
use this term as an extension of LCA, to refer to any statistical analysis 
where discrete latent variables may be incorporated at multiple levels of a 
hierarchy. The MLLC approach is explained in detail in section 2.2.2. 
 
 




This thesis explores the utility of unexploited, novel statistical techniques to 
analyse complex observational health data. Latent variable approaches lie 
within an overarching causal framework, where modelling may be performed 
either to adjust for confounding factors and hence make causal inference 
(i.e. to determine the effect (and magnitude of effect) of an independent 
variable as an assumed cause of a dependent variable), or to account for 
differential selection (i.e. to  accommodate differences in characteristics 
(commonly within patients) and thus improve estimates of effect). There is 
much scope to model complex data configurations, with latent variable 
methodologies able to account for generic data challenges, such as non-
homogeneity, measurement error and causal relationships between 
covariates, while maintaining a framework that may also be utilised to model 
patient pathways through the healthcare system, including treatment effects 
and other institutional characteristics. While traditional methodologies may 
be appropriate to address some of the fundamental challenges within 
observational health data, there is no other current methodology available 
that is able to provide such a comprehensive approach. Further, no other 
applications have, as yet, similarly exploited the capabilities of the 
techniques to be addressed within this thesis (evidenced in section 1.4.5). 
In order to demonstrate the utility of the latent variable approach, three 
research questions are considered, representing questions that may be 
asked about differing aspects of the patient pathway through the healthcare 
system. An example of a clinical dataset is utilised. Multilevel latent class 
(MLLC) models are constructed, with model parameterisations tailored to be 
specific to each research question, yet standard in approach. Where 
- 2 - 
feasible, approaches are contrasted with traditional modelling techniques to 
demonstrate proof of principle and to either illustrate comparable results, or 
generate improved estimates (due, perhaps, to appropriate model 
construction), and hence an enhanced interpretation. 
Chapter 1 introduces all key aspects of the thesis, including background and 
rationale, and establishes the context for the following chapters.  
Section 1.2 examines observational health data, considering its inherent 
structural complexity and generic data challenges. The three research 
questions and the example dataset are introduced. 
Section 1.3 describes the traditional modelling approaches, with a focus on 
regression analysis as the most commonly used method, and the ability of 
these techniques to respond either to the generic data challenges, or to 
account for differential selection. 
Section 1.4 introduces the latent variable methodologies, with consideration 
of their use within causal inference modelling, a brief history of the 
techniques and a literature review. The applicable statistical software is 
introduced. 
Section 1.5 details the content of the following chapters. 
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1.2 Observational health data 
1.2.1 Structural complexity 
Observational health data are a rich resource, commonly collected as part of 
an ongoing process of data collection by a healthcare provider, such as in an 
audit, rather than in a more structured manner as would be seen in a clinical 
trial setting, for example. Sources are numerous: for example, the National 
Health Service (NHS) holds national datasets compiled from records of 
patient care (NHS Digital, 2017), which may be used to support 
commissioning services or service planning, and disease specific datasets 
are available based on registrations (e.g. Cancer Outcomes and Services 
Dataset (COSD) (National Cancer Intelligence Network, 2010)). Much 
related information may be collected together, such as patient 
characteristics, disease onset and progression, treatment and care 
pathways, and attendance at one or more healthcare provider locations for 
diagnosis, treatment or specialist opinion. There are therefore connections 
between the different aspects of information collected, i.e. the patients, the 
treatment or care received, and the healthcare provider attended, and the 
relationships between these aspects may be complex. Figure 1.1 shows how 
these relationships may be perceived graphically. 
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Examples of patient characteristics may be age at diagnosis, sex and stage 
of disease, while examples of treatment characteristics may be the type of 
treatment received, and time from diagnosis to treatment. The holistic 
provision of healthcare means that variation in any part of the patient care 
pathway may impact on patient outcomes. For example, if patients from a 
homogeneous group receive the same treatment for the same condition, 
they may still respond differently if they are attending different healthcare 
providers, possibly due to organisational characteristics such as surgeon 
specialism or available beds. In an observational setting, it is not feasible to 
standardise all aspects of care. Different diseases are also not identically 
managed, therefore there is inherent heterogeneity surrounding patient entry 
to the healthcare system. 
While the assessment of treatment effects is usually the domain of clinical 
trials, many research questions may be asked of observational health data 
that are of interest to the patient (e.g. what factors affect disease survival?), 
or to the healthcare provider (e.g. what constitutes good practice?). Any 
analysis performed must fully accommodate the complexity of the data and 
the healthcare environment in order to ensure correct inference, as 
inappropriate interpretation may have a direct impact on patient care. In an 
observational health framework, these questions may not be set at the start 
of the data collection process, meaning that when they are posed later, there 
may be data challenges in addition to the structural complexity that must be 
addressed prior to, or as part of, the analysis. Challenges generic to many 
observational health datasets are discussed in section 1.2.2. 
“Big data” is becoming widely recognised as an all-encompassing term used 
to describe extremely large and complex datasets that are stored and 
analysed digitally (Boyd and Crawford, 2012), and it has been designated as 
one of the “eight great technologies that support UK science strengths and 
business capabilities” (Department for Business, Innovation and Skills, 
2013). These datasets may be linked, further extending their size and scope. 
Research applications are therefore extensive, with involvement from many 
academic and research institutions, including the University of Leeds 
(University of Leeds, 2017). 
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There is much promise inherent in being able to access and examine such 
expansive data, however these datasets suffer from the same data 
challenges seen in observational health data, and the use of automated 
techniques that do not correctly address these challenges may result in 
results being based on predictive modelling (i.e. predicting the value of a 
dependent variable, based on values of independent variables) rather than 
causal inference. While a predictive modelling approach may be appropriate 
in many research areas, healthcare research is an inherently causal 
framework as questions commonly relate to ‘causes’ either of disease, or of 
relief from disease.  
1.2.2 Generic data challenges 
In addition to structural complexity, observational health data suffer from 
many data challenges generic to routinely collected data. Appropriate 
accommodation of each is essential in order to make correct inference, and 
avoid misleading interpretations, perhaps due to biased results. The generic 
data challenges are introduced here, and the consequences of inappropriate 
modelling with respect to these challenges are examined in section 1.3.3. 
(i) Structure. Observational health data are commonly structured in a 
hierarchical manner, for example, patients living in the same geographical 
area may attend the same clinic or hospital for treatment, and these patients 
may attend multiple times. Therefore, patients can be said to be ‘clustered’ 
within the relevant healthcare provider, and measurements may also be 
‘clustered’ within the patient.  
(ii) Non-homogeneity. There may be differences within the population 
studied at any level of the hierarchy, i.e. samples may be heterogeneous at 
any level. For example, patients may vary in their characteristics (Office for 
National Statistics, 2016b) or in their response to treatment (Roden and 
George Jr, 2002), and healthcare providers may utilise different resources 
dependent on the route of admission (Simmonds et al., 2014), potentially 
leading to differences in the level of care received by the patient.  
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(iii) Measurement error. Measurements may also be imprecise, perhaps 
due to variations within a patient during their care; increased levels of 
anxiety may increase blood pressure (Sheppard et al., 2016), for example. 
Measurements taken by different clinicians (Wallis et al., 2015), or using 
different equipment (Wiesel et al., 2014), may also be interpreted differently.  
(iv) Unmeasured variables. Despite recording a large amount of 
information, there may remain variables that are not included in a dataset, 
perhaps because their association is unknown, but which may affect the 
outcome. Because they are unidentified, any effect due to their exclusion is 
unknown.  
(v) Complex observed relationships. The observed variables collected on 
patients as part of routine data collection, such as age, sex and stage, may 
have complex relationships with each other within a population, and these 
relationships may differ across populations. For any given research question 
where inference of an exposure (independent variable) on an outcome 
(dependent variable) is required, there may be any number of other 
variables that may either confound, mediate, or moderate, this relationship.  
(vi) Missing data. There may be missing data, and the data that are not 
recorded may be related to some quality of the population to be studied. For 
example, basic measurements such as height, weight and blood pressure 
are commonly taken when a patient is admitted to hospital (Evans and Best, 
2014), but if a patient is very ill on admission, it may not be feasible to take 
these measurements. Missing data may therefore be predictive of an 
underlying health state.  
(vii) Area-based measurements. Individual measures of deprivation are 
rarely available, especially when using routine data. Indices of 
socioeconomic status (SES) such as the Townsend Deprivation Index (TDI) 
(Townsend et al., 1987) or the Index of Multiple Deprivation (Noble et al., 
2004) are all that are routinely available. These indices are measured at the 
small-area level, such as electoral ward or super output area (SOA). Their 
use can lead to the ecological fallacy (Robinson, 1950) if area-based 
findings are extrapolated to individuals living within each area. 
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1.2.3 Three research questions 
Three research questions are posed. These questions, although conceived 
to demonstrate the latent variable approach, represent typical enquiries 
commonly made of observational health data. Each question concerns a 
different aspect of the patient journey through the healthcare system. 
(1) What is the relationship between a health exposure and outcome, and 
what other factors affect this relationship? 
This is an example within epidemiology where interest lies in determining the 
association between a health exposure or risk factor (e.g. SES) and an 
outcome (e.g. survival), where it is difficult, if not impossible, to conduct a 
randomised controlled trial. Causal inference is sought within a multilevel 
framework where focus is on the patient level and variation at all other levels 
is effectively ‘nuisance’, i.e. upper-level variation must be accounted for, but 
inference is not required.  
An intractable problem within causal inference modelling is also raised, 
where a potential interaction (e.g. between SES and stage) may be of 
interest, but may introduce bias if not sought carefully. Inappropriate 
adjustment of alleged confounders that may lie on the causal path between 
exposure and outcome can invoke bias (Kirkwood and Sterne, 2003), known 
as the reversal paradox (Stigler, 1999), and this bias has been shown to be 
a potentially serious problem in epidemiology (Hernández-Díaz et al., 2006; 
Tu et al., 2005). A Directed Acyclic Graph (DAG) (Pearl, 2000) is essential to 
assess covariate relationships. 
(2) How does the performance of a healthcare provider vary after 
accommodating patient differences? 
One area of interest in healthcare provision is performance monitoring, 
where indicators are used to measure, and compare, outcomes at an area 
level, for example by NHS Trust (Raleigh et al., 2012; Abel et al., 2014; 
Gomes et al., 2016). Different patient characteristics (e.g. age, sex and 
stage) may, however, lead to different outcomes (e.g. survival from disease), 
therefore these characteristics should be balanced across providers to 
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ensure a fair comparison of performance. Patient population characteristics 
may vary geographically (e.g. by age and sex (Office for National Statistics, 
2016b)), and as patients commonly attend a healthcare provider close to 
their geographical location (Dixon et al., 2010), patient characteristics may 
therefore vary across healthcare providers, which is termed ‘casemix’, and 
thus leads to differential access to care, a form of differential selection.  
This is a major topic of interest, as there are few strategies that can 
overcome the uncertainties associated with patient casemix differences (see 
section 1.3.4). To establish this approach within a framework that can extend 
to accommodate patient pathways (e.g. treatment effects) is challenging, 
and original. Initially, no provider-level covariates are examined in answering 
this question, in order to make comparison to existing methods. This 
extension is possible, however, as explored in research question (3). 
(3) Can causal provider-level covariate effects be identified, after 
accommodating patient differences? 
This is an extension of research question (2), where modelling for prediction 
at the patient level (i.e. accounting for casemix differences), is separated 
from causal inference at the provider level, in order to examine 
organisational factors (e.g. surgeon specialism or available beds) that may 
affect patient outcomes. A deliberate limitation at this stage is not 
considering multivariable DAGs at the provider level in order to first establish 
the principle that a single provider-level causal effect can be recovered. 
This novel application demonstrates the flexibility of a methodological 
framework that must account for a hierarchical data structure, accommodate 
uncertainty due to both measured and unmeasured variables, adjust for 
patient casemix, and exploit the complexity (i.e. heterogeneity) of the data in 
order to partition prediction and causal inference. 
1.2.4 Example dataset 
To investigate the three research questions, an example dataset is utilised, 
containing routinely collected data for patients diagnosed with colorectal 
cancer between 1998 and 2004. The dataset is thoroughly described in 
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Chapter 2. It is an example of a dataset available within observational health 
data, and is utilised here to demonstrate the latent variable techniques; 
many other observational health datasets could be analysed in the same 
manner, with appropriate compensation for data-specific challenges. This 
dataset is utilised to answer research questions (1) and (2), using available 
patient-level covariates.  
For research question (3), however, the example dataset cannot be used as 
it does not contain any provider-level covariates. Furthermore, a real-world 
dataset would not be amenable to evaluation of the effectiveness of the 
proposed techniques, as simulation is ideally required to assess the 
effectiveness of the approach before evaluating the latent variable 
methodology in practice. Simulations are therefore undertaken to explore the 
proof of principle for the inclusion of provider-level covariates, which is 
essential to evaluate the robustness of the proposed strategy of analysis. 
1.2.5 Simplifications 
Certain deliberate simplifications are made to the data for the purposes of 
analysis. They are described here and their implications are explored further 
in Chapter 6. 
Missing data  
Not addressed within any of the research questions is how to accommodate 
missing data. Within the example dataset, stage at diagnosis suffers from 
missing data, with 13.1% of patients having missing values for stage. As 
only a minor concern within this dataset, data are therefore simplified by 
generating a separate category for the missing values; thus all stage data 
are included in the analysis. In general, however, methods to address 
missing data should be employed, which is feasible as a separate extension 
that could then be combined with latent variable modelling approaches. 
There are methodological challenges, however, as the tools are not yet 
available to impute missing values within a multilevel framework. This is not 
the focus of this thesis, and the simplified approach is thus considered 
sufficient to demonstrate proof of principle for each of the research 
questions. Missing data challenges are discussed further in section 6.3.2. 
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Health outcome 
The outcome is selected to be whether or not the patient survives at three 
years following diagnosis, as this is clinically meaningful and facilitates ready 
comparison with other studies. It is, however, a simplification for what is 
potentially a survival measure. While survival analysis may be a desirable 
alternative, it would not be as comparable to other literature, hence the 
binary outcome is selected instead. There are also methodological 
challenges. The methods and associated principles proposed within this 
thesis will extend to a survival analysis context, although only in a different 
statistical software package to that used throughout for the latent variable 
modelling. This extension is discussed further in section 6.3.2. 
Area-based measurements  
SES is measured at the small-area level, but is attributed to individuals, 
which may provoke the ecological fallacy as described in section 1.2.2. For 
this reason, another level should ideally be introduced into any model – the 
small-area level – and this would be cross-classified with healthcare 
providers, i.e. patients from one small area might attend different providers, 
and similarly patients attending one provider may be drawn from different 
small areas of residence. Theoretically, it is possible to conduct a cross-
classified latent variable model, where small areas may also be grouped into 
latent classes, although this is not a currently supported option within the 
statistical software used. 
Of primary interest, however, is the illustration of the latent variable 
methodology, and the primary research questions also pertain to the 
population or sub-population (i.e. latent classes), not individuals. The 
simplified approach of attributing small-area scores of SES to individual 
patients is therefore adopted, omitting the cross-classified small-area level 
completely. Alternative modelling approaches are discussed in section 6.3.2. 
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1.3 Traditional methodologies 
1.3.1 Single level regression analysis 
Traditional modelling techniques, such as regression analysis, are 
commonly used to analyse observational health datasets (see section 3.2.2). 
Regression (linear and logistic) is a well-documented approach (Normand et 
al., 2005) where the relationship between an outcome and one or more 
exposures is modelled, effectively to ‘adjust’ the predicted outcome in 
relation to the likely influences of these factors. For example, the exposures 
may be patient characteristics such as age, sex and stage of disease, while 
the outcome may be survival from a disease. These covariates, however, 
also modify the estimated coefficient effects of each other, which may not 
always be appropriate, dependent on the research question. Regression 
analysis identifies a ‘best-fit’ model where the effect of covariates is the 
same over the whole sample, however individual measurements will vary, 
giving residual error. A linear regression model is traditionally identified using 
the ‘least squares’ approach, where the differences between the regression 
line and each observation are squared and minimised over all observations. 
An equation is then generated for the regression line in the form: 
𝑌 = 𝛽0 + 𝛽1𝑋1 + 𝛽2𝑋2 + ⋯ + 𝛽𝑛𝑋𝑛 
where 𝑌 is the outcome, 𝛽0 is the intercept, and 𝛽𝑗 (for j=1 to n) is the slope 
for each of the 𝑋𝑗 model covariates. This equation may be used for 
prediction, to predict the likely outcome for a specific set of observations. In 
a regression model, the intercept and slope parameters are estimated as 
fixed, giving a fixed-effects model.  
1.3.2 Multilevel modelling (MLM) 
Regression modelling is often extended to a multilevel framework in order to 
incorporate differences across healthcare providers (Leyland and Goldstein, 
2001; Leyland and Groenewegen, 2003). This approach is utilised for 
hierarchical data, where lower-level observations (e.g. patients) are 
‘clustered’ within higher-level groups (e.g. healthcare providers). In contrast 
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to single level regression modelling, the ‘best-fit’ model may differ dependent 
on which upper-level group is considered, and so both the intercept and 
slope are allowed to vary across these groups, giving a random-effects 
model. The variations of the intercepts and slopes are assumed to be 
normally distributed about a mean of zero and these variations are also 
assumed to be independent of the variation in the individual measurements. 
1.3.3 Traditional approach to the data challenges 
Neither single level regression analysis nor MLM are able to address all of 
the data challenges inherent within observational health data, as introduced 
in section 1.2.2. Specific challenges that remain unaccounted for by use of 
these techniques are described here. 
Structure and non-homogeneity 
Single level regression analysis does not take into account any hierarchical 
structure of the data, and homogeneity is assumed at the single level. 
Maintenance of the data structure during analysis is important in order to 
correctly estimate standard errors associated with estimates of effect, as 
underestimation of standard errors leads to overestimation of statistical 
significance, i.e. a type I error (Normand et al., 2005). Non-homogeneity 
generates residual error which may also increase standard errors. As both 
challenges are inherent within observational health data, modelling with 
single level regression analysis is not appropriate. 
While MLM does account for a hierarchical data structure, and provides 
improved estimates compared with regression (Cohen et al., 2009; Damman 
et al., 2009), the assumptions of normality and independence may not be 
valid in observational health data, as patients are not randomly assigned to 
healthcare providers, and providers are not randomly allocated 
geographically. MLM also assumes that a study sample is homogeneous at 
every level of the hierarchy, i.e. the same model would be applied to all 
members of the sample and the effects of covariates would be the same 
throughout. This may not be valid in observational health data due to 
differential selection, as raised in section 1.2.3, relating specifically to 
research question (2). 
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Observed and unobserved variation 
Regression techniques only allow for variation in the outcome, not in the 
model covariates, hence they are a poor choice to incorporate uncertainty in 
any of the observed variables, for example due to imprecise measurements. 
Studies have shown that statistical analyses using regression modelling 
(single level or multilevel) may yield biased results where model covariates 
have measurement error (Greenwood, 2012) or missing values (Carroll et 
al., 2006; Fuller, 1987). Furthermore, as regression is performed using 
observed covariates only, no adjustment can be made for unmeasured 
differences across the observations. 
Complex observed relationships 
Within a regression model, statistical adjustment is commonly sought for all 
potential confounders (i.e. variables that may affect both the exposure and 
the outcome) in order to assess the impact of an exposure on an outcome. 
Inclusion of a covariate that is instead an effect mediator (i.e. it potentially 
lies on the causal path between exposure and outcome) may introduce bias 
due to the reversal paradox, however, as introduced in section 1.2.3. For 
confounders that are also potential effect modifiers (i.e. they exhibit an 
interaction with the main exposure), product interaction terms are commonly 
included. If this confounder is also measured with error, however, or has 
missing values, bias may be exacerbated (Greenwood et al., 2006). 
As the use of multiple covariates within regression modelling modifies both 
the predicted outcome and the coefficient effects of these covariates, 
regression is therefore best placed for use within predictive modelling, where 
the focus remains on the predicted outcome. In causal inference modelling, 
where there is a primary exposure of interest, for example to answer 
research question (1), it is the modification of model coefficients that is the 
focus and, in the circumstances just described, traditional regression 
approaches cannot fully model the complex relationships within the data. 
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1.3.4 Casemix adjustment strategies 
There are a number of alternative strategies that adjust for differential 
selection, each effective within their own constraints, but none that are 
adaptable to analysis within an extended modelling framework. 
Measurement uncertainty within observed covariates cannot be 
accommodated, potentially untestable assumptions may be made, and they 
cannot accommodate provider-level variation. Patient variation is 
accommodated through measured covariates only, which is crude, as 
models ought to reflect the uncertainty associated with patient casemix 
characteristics. Further, no casemix-adjustment strategy will eliminate all 
bias, due to unmeasured differences amongst patients (Nicholl, 2007), and 
some procedures increase bias (Deeks et al., 2003).  
Well-established techniques include matching (Rothman et al., 1986), 
stratification (Normand et al., 2005) and regression analysis.  
In matching, pairs of subjects are matched, based on their observed 
characteristics, to generate subgroups for comparison (e.g. by treatment); 
unmatched patients are excluded from analysis. Both identifying and 
recording all factors that are required for matching to be effective is 
challenging, and near impossible in the area of routine data collection. 
Measurement error cannot be accounted for, and differential selection 
cannot be addressed due to the limited variables available. 
With stratification, homogeneous subgroups are identified using strata 
defined from observed covariates. Each patient is assigned to one stratum, 
and no patients are excluded. Distributions of covariates are thus balanced 
across subgroups, and analysis is performed within the defined strata. 
Similar to the challenges described for matching, it is not realistic to expect 
to stratify on all relevant factors. Further, stratification on numerous variables 
can lead to small numbers within strata, which introduces increased 
uncertainty that is not directly compensated for in any way. Bias due to 
differential selection is not explicitly addressed. 
Regression techniques, as described in sections 1.3.1 and 1.3.2, are 
commonly used to model variables relating to patient characteristics (see 
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section 3.2.2), thus adjusting the outcome with respect to these factors. 
Whilst care is required to model appropriately complex relationships in order 
to make causal inference, and to minimise bias due to the reversal paradox, 
no such concern is necessary when modelling for prediction. Viewing 
differential selection as a prediction problem (as indicated in section 1.2.3), 
therefore indicates the utility of regression techniques in casemix 
adjustment. They cannot, however, be used to model together both causal 
inference and purely prediction. 
A balancing score, such as the propensity score (Rosenbaum and Rubin, 
1983; Rosenbaum and Rubin, 1984), may be utilised. Such a score is 
calculated from all observed covariates; patients with the same propensity 
score will thus have approximately the same distributions of their observed 
covariates. It is commonly used in combination with matching, stratification 
or regression to increase precision and produce unbiased estimates 
(Rosenbaum and Rubin, 1983). Within matching, the propensity score may 
be utilised as the matching variable, while for stratification, equal sized 
subgroups may be defined by values of the propensity score (D'Agostino, 
1998). In regression modelling, the propensity score may be modelled alone 
for a more parsimonious model, or in combination with a subset of observed 
covariates (Rubin, 1979). Complete case data are usually required when 
calculating the propensity score, as missing values cannot be included and 
their exclusion may bias the calculated score. The propensity score may 
also not be appropriate for subgroups with very different prediction 
covariates, for example across different disease groups. Fundamentally, 
however, propensity score analysis conflates confounding (i.e. for causal 
inference modelling) and differential selection (i.e. within predictive 
modelling), and there remains the possibility that this technique may actually 
introduce bias in some instances (Pearl, 2009; Pearl, 2011). 
Alternative composite risk scores may be utilised, and disease specific 
scores are commonly available (e.g. Acute Physiology and Chronic Health 
Evaluation II (APACHE II) (Knaus et al., 1981); calculated from age plus 
twelve routine physiological measurements). These scores may also be 
utilised within matching, stratification or regression analysis techniques. 
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Direct or indirect standardisation approaches may also be employed 
(Rothman et al., 1986; Breslow and Day, 1987). These techniques 
essentially adjust the outcome using a reference (standard) population, thus 
enabling direct comparison across populations with differing casemix 
structures. The direct approach uses a population distribution (e.g. an age 
distribution) as the standard, while the indirect approach uses a common set 
of specific rates. Both methods compare the number of expected events 
(e.g. deaths) calculated from the standard population with those observed. 
Indirect standardisation utilises a standardised mortality ratio (SMR), which 
will be considered as the traditional comparison to a latent variable approach 
in Chapter 4. Direct standardisation is widely used (National Cancer 
Institute, 2016; International Agency for Research on Cancer, 2010) as it 
preserves consistency between populations, although it cannot be 
performed if standard population distribution figures are unknown. Indirect 
standardisation may be used without these figures, but the associated 
weightings reflect the casemix of the local population, meaning that it may 
not be appropriate to directly compare populations with very different patient 
casemix.  
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1.4 Introduction to latent variable methodologies 
1.4.1 Latent variable framework 
The latent variable terminology and framework are introduced here, together 
with the key advantages of using these methodologies. Comprehensive 
exploration of the specific modelling approaches and features, suitability of 
the methodologies to address the generic data challenges, and 
parameterisations appropriate to answer the three research questions are 
presented in Chapter 2. 
Latent variable modelling is an inclusive term covering the identification of an 
unobserved (latent) structure within observational data. Underpinning the 
theory is the concept that observations can be grouped within latent 
variables, which may be continuous and distributed as per a standard 
cumulative distribution function (typically assumed to be normal; latent 
variable), discrete (latent classes), or a mixture of both, and that there is a 
mathematical relationship between the observed values and the latent 
structure. Early analyses separated latent variables and latent classes, while 
contemporary modelling allows combinations of both (Vermunt and 
Magidson, 2003). 
As discussed in section 1.3.4, regression methods cannot separate 
modelling for prediction from causal inference, as is ultimately required when 
accounting for both patient casemix and potentially causal factors at the 
provider level. Use of a latent variable approach can separate the prediction 
focus (i.e. accommodation of differential selection) at the patient level, and 
the causal inference focus at the provider level, which serves to overcome 
this potential conflict between two distinctly separate analytical strategies. 
This is a fundamental advantage over traditional techniques, and ensures 
that the overarching methodology can be retained when answering a wide 
range of research questions.  
The traditional MLM is a simple example of a latent variable model, with a 
single, homogeneous group at the lower level and a continuous, normally 
distributed, latent variable at the upper level. Incorporating discrete latent 
classes extends the utility, as described in detail in sections 2.2.1 and 2.2.2. 
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There are a number of features unique to latent variable approaches that 
can be utilised to model appropriately complex observational data. Class 
membership models, introduced in section 2.2.3, allow for variables to be 
modelled separately to the main exposure-outcome relationship, thus 
minimising bias due to measurement error or the reversal paradox, for 
example. Class-dependent and class-independent features, introduced in 
section 2.2.4.3, are vital to ensure precise configuration of the model based 
on context and research question. The overarching approach, however, 
remains unchanged and hence similar in all its merits to address the data 
challenges. 
Sections 1.4.3 and 1.4.4 provide a brief history of the latent variable 
techniques for context, while section 1.4.5 provides a review of the literature 
to determine how these novel modelling approaches are being used in 
practice with observational data. 
1.4.2 Modelling for causal inference 
As indicated in section 1.4.1, latent variable modelling for either prediction or 
causal inference can be partitioned across levels of a hierarchy, which is 
fundamental to the applications addressed within this thesis. The approach 
to causal inference modelling incorporated here is well established within 
epidemiology (Greenland et al., 1999), where causal diagrams are explored 
as a method to identify relationships between modelled variables. The 
concept was formalised by Pearl (2000), in the use of DAGs (introduced in 
section 1.2.3) to display covariate relationships. These diagrams make 
explicit the causal assumptions made between model covariates, thus 
formally identifying confounders and other variables that may either mediate 
or modify the effect of an exposure on an outcome. These features were 
discussed briefly with respect to traditional modelling approaches in section 
1.3.3, and will be explored further within the latent variable framework in 
section 2.2.4.1.  
In more contemporary publications, Vanderweele (2015) emphasises 
methods to define and assess mediation and covariate interactions, while 
Pearl et al. (2016) provide a comprehensive introduction to causality. 
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1.4.3 A brief history of latent variable techniques 
This is not intended to be a systematic, or comprehensive, review of the 
historical literature, but rather a consideration of important publications within 
the subject area, to put the methodology into context. 
Latent variable approaches were first used in the field of social psychology, 
initially with a focus on interpretation rather than on statistical concerns. 
‘Factor analysis’ (Spearman, 1904; Thurstone, 1947) first utilised continuous 
variables for both the observed and latent variables, while ‘latent structure 
analysis’ (Lazarsfeld, 1950; Lazarsfeld, 1959), incorporated discrete classes 
for both. It was hypothesised that, instead of correlations between individual 
responses, the population studied was in fact heterogeneous, with different 
underlying latent groups (Lazarsfeld, 1950). Related approaches, termed 
‘latent trait analysis’ (Lord, 1952) (utilising continuous latent variables with 
discrete observed variables), and ‘latent profile analysis’ (Gibson, 1959) 
(utilising discrete latent classes with continuous observed variables) were 
soon introduced in practice. Latent trait analysis is commonly used in 
educational testing (Lord and Novick, 1968), as ‘item response theory’ (IRT). 
Parameter estimation procedures (commonly using matrix algebra) were 
developed by many, notably Green (1951), Anderson (1954; 1959), Gibson 
(1955; 1962), and Lazarsfeld and Henry (Lazarsfeld and Henry, 1968). 
However, Goodman (1974a; 1974b; 1979) formalised the methodologies by 
his development of the maximum likelihood (ML) parameter estimation 
algorithm, methods to determine whether estimated parameters are 
identifiable, and consideration of how well the models fit the data. Goodman 
also extended the analysis to include nominal observed variables 
(Goodman, 1974b), which was followed by further extensions for ordinal 
observed variables (Muthén, 1984) and for longitudinal data (Hagenaars, 
1990; Vermunt, 1997). 
There was a gradual move towards a more generalised approach, with 
‘mixture modelling’ allowing for models to contain mixtures of both 
continuous and discrete latent variables, explored for example in Anderson 
(1959), Bartholomew (1980), Muthén (1984; 2002), Arminger and Küsters 
(1989), and Skrondal and Rabe-Hesketh (2004). This, together with the 
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availability of more powerful computers towards the end of the 20th Century, 
made the methodologies widely available. Latent class analysis (LCA) 
became known as any statistical analysis where the model allows for 
parameters to differ across latent subgroups (Vermunt and Magidson, 2003), 
regardless of terminology or data type. Extensions to a multilevel framework 
were introduced by Vermunt (Vermunt, 2003; Vermunt, 2008a), which further 
widened the methodological scope, and effectively brings this historical 
summary up to date. 
1.4.4 Structural equation modelling (SEM) 
For completeness, SEM is addressed. This is also a latent variable 
methodology, with SEM itself incorporating many other approaches, such as 
‘confirmatory factor analysis’, ‘canonical correlation analysis’, and ‘latent 
growth curve models’. A full history of this broad methodology is not 
attempted here; two useful sources are Kaplan (2009) and Matsueda (2012), 
with Hox and Bechger (1998) providing a useful non-technical introduction to 
the techniques. There are two components to a SEM: the structural element 
that establishes a causal framework between observed variables, and the 
measurement element that specifies relationships between latent variables. 
Variation due to measurement error, for example, may be incorporated 
within the latent structures, while the causal framework is appropriate to 
address research questions commonly examined within observational health 
data. It may not, however, be as useful when considering differential 
selection i.e. to account for patient casemix, as path diagrams are designed 
to reflect all covariate relationships rather than to separate causal inference 
from prediction. It also becomes increasingly complex in a multilevel 
framework (Hox, 2013). SEM will not be utilised within this thesis. Rather, a 
more comprehensive approach is sought that addresses the generic data 
challenges, while distinguishing between causal inference and prediction 
within an overarching framework. 
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1.4.5 Review of comparable latent variable approaches 
Consideration is also given to the current usage of similar approaches as 
presented within this thesis, i.e. where latent variables (continuous or 
discrete) are used at multiple levels of a hierarchy to account for data 
challenges, such as heterogeneity, while modelling causal relationships 
between covariates at any level. Comparable articles are identified and 
summarised, without full critical appraisal as the primary intent is to 
recognise the scope of the published material, rather than to assess the 
strengths and weaknesses of each application. The strengths and 
weaknesses of latent variable approaches are discussed in Chapter 6. 
There is much differing terminology used across applications, which makes it 
complex to identify similar uses of the latent variable approach; the methods 
have evolved in isolation and terminology has developed independently 
within each context. A broad literature search is therefore performed initially, 
with all abstracts reviewed for their relevance. As applications within the 
social sciences are common, and those within the field of medicine are most 
relevant to the research questions, two databases are utilised: Medline and 
PsycINFO. Full search strategies can be seen in Appendix A. Book chapters 
are excluded as they generally focus on principles, rather than applications. 
The review spans ten years; as the techniques are still adapting, anything 
older than ten years is likely to have been superseded methodologically. 
A total of 174 results are found initially across the two databases. Duplicates 
(N=31) are excluded, together with irrelevant articles (e.g. teaching notes; 
N=16), and single level latent variable approaches (N=20). Two further 
articles are excluded: that detailing the research performed for Chapter 4 of 
this thesis (Gilthorpe et al., 2011), and the methodological-based paper cited 
in section 1.4.3 (Vermunt, 2008a). Four additional articles are sourced from 
other citations, thus a total of 109 results are available for consideration. 
Thirty-four results utilise multilevel factor analysis, for example Bostan et al. 
(2015) and Koch et al. (2016). As introduced in section 1.4.3, factor analysis 
is an early latent variable approach where continuous latent variables are 
used throughout. Although extended to incorporate a multilevel structure, 
latent classes are not permitted and as such, this technique is not 
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comparable to that adopted here. Of note, however, is an article by Varriale 
and Vermunt (2012), where multilevel factor models are extended to 
consider latent classes at the upper level, termed the multilevel mixture 
factor model. Although not discussed in detail here, as continuous latent 
variables remain at the lower level, this article highlights the overlap and 
emerging terminology across latent variable applications.  
A further 32 articles utilise SEM as the primary analytical technique, for 
example Geiser et al. (2015) and Preacher et al. (2016). As explained in 
section 1.4.4, the SEM approach is not appropriate for model extensions to 
include differential selection, for example, so is not considered here. 
Twenty-two results employ analyses to model longitudinal data, including 
investigation of ‘trajectories’, for example Mumford et al. (2013) and 
Sanfelix-Gimeno et al. (2015), and of ‘growth’, for example Tu et al. (2013), 
Smith et al. (2014) and Burns et al. (2015). These are special cases within 
the latent variable methodology; any longitudinal application will inherently 
be multilevel, but it is not analogous to the approach taken within this thesis.  
Three articles discuss the use of latent variables within multiple imputation, 
for example He at al. (2014). 
Of the remaining 18 papers, 10 can be considered to be simpler applications 
of the approach adopted for this thesis. Termed latent class ‘cluster’ 
analysis, this technique involves the profiling of attributes or characteristics 
into latent classes, or clusters, that may have utility. Measurement 
uncertainty is accommodated within the latent framework, while the 
multilevel approach accounts for the complexity of the data. Within these 
articles, the regression part of the model i.e. the relationship between 
exposure(s) and outcome, is not incorporated within the assignment to 
classes. Some employ follow up analysis to determine associations based 
on class membership, but none examine causal inference. There are 
applications in alcohol use (Rindskopf, 2006; van Lettow et al., 2013), with 
the former focusing on individual alcohol use within geographical sites, while 
the latter considers the classification of descriptive terms within groups of 
survey respondents. Van Horn et al. (2008) illustrate the techniques using an 
example in substance use, considering problem behaviours within 
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individuals and schools. Zhang et al. (2012) investigate the proportions of 
individuals who are obese within classes distinguished by individual 
consumption within the fast food environment. Three levels of analysis are 
considered within a study focusing on the family-level subtypes of patients 
with schizophrenia (Derks et al., 2012). There are applications within 
education, considering students’ attitudes within University groups (Mutz and 
Daniel, 2013), or pupils’ examination responses within teaching groups 
(Auer et al., 2016). A hierarchical approach to social exclusion (Pirani, 2013) 
considers classes of both individuals and geographical regions, while the 
perceptions of the causes of poverty within individuals and countries are 
similarly investigated by da Costa and Dias (2014; 2015). 
Finally, 8 papers are identified as containing analysis that can be considered 
comparable to that adopted within this thesis. Three are primarily 
methodological, and are not examined in detail. Two incorporate simulation 
studies; one assesses model selection (Yu and Park, 2014), while the other 
investigates the performance of methods of parameterisation (Finch and 
French, 2014). The third methodological paper explores model specification 
using an illustrative application within education testing (Vermunt, 2008b). 
Thus, 5 articles remain; each focuses on the application of multilevel latent 
variable approaches, using comparable techniques to those employed within 
this thesis, although none adopt exactly the same approach. They span a 
variety of disciplines, covering social science (Kalmijn and Vermunt, 2007), 
healthcare (Downing et al., 2010), behavioural research (Henry and Muthén, 
2010), political science (Morselli and Passini, 2012), and education (Bennink 
et al., 2014). 
In the earliest application, Kalmijn and Vermunt (2007) present an 
application investigating the homogeneity of social networks, where the age 
and marital status of individuals (the ‘ego’ level) are considered as a joint 
dependent variable, and are modelled to identify the association with 
individuals’ network contacts (the ‘alter’ level). A non-parametric 
specification is used at the upper level, i.e. ego-level latent classes are 
identified, and a single latent class is used at the lower level. The principle is 
thus similar to that adopted here, although different in consideration at the 
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lower level, and the context is wildly different. The latent class approach is 
seen to improve model fit and aid interpretation, with network contacts 
identified as more similar than would be expected based on the ego class. 
This finding may be partly explained by the accommodation of uncertainty 
due to unmeasured covariates within the latent constructs. 
In my collaborative work with Downing et al. (2010), a multilevel latent class 
approach is utilised to model the association between socioeconomic 
deprivation and breast cancer survival status at five years. Of primary 
interest is the utility of the approach to model appropriately stage at 
diagnosis, identified as a mediator of the deprivation-survival relationship. A 
continuous latent variable is utilised at the upper level for model fit and 
parsimony, and two patient-level classes are identified. Model fit improves 
when stage is excluded from the regression part of the model, and latent 
classes are clearly distinguished by disease severity. The research 
performed in Chapter 3 advances this work, by consideration of causal 
circularity and the inclusion of discrete latent classes at the upper level. 
Henry and Muthén (2010) identify typologies of adolescent smoking status, 
using data from 10,772 European females within one of 206 rural 
communities. Parametric and non-parametric approaches are investigated, 
with the parametric approach providing the best fit to the data, although the 
non-parametric approach allows community-level classes to be identified. 
The selected outcome variable is latent, rather than observed, and 
covariates are included at both levels. The probability of membership of the 
individual-level classes may vary across the upper-level communities, thus 
allowing for interpretation of upper-level classes by proportions of lower-level 
typologies. No accommodation is made for differential selection, however. 
In an unfamiliar context, that of political science, Morselli and Passini (2012) 
utilise the multilevel latent variable approach to model individuals within 
countries, in order to classify different types of political movement and 
protest. Unusually, the selection of four lower-level classes is based on an a 
priori hypothesis. The model is a good fit to the data, however, and classes 
are highly interpretable, with the inclusion of covariates again allowing 
investigation of class membership by characteristics. A non-parametric 
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approach is adopted at the upper level, and two classes are identified based 
on similarities in the lower-level class distribution. The latent class approach 
thus shows utility in the identification of differing attitudes towards 
democracy across protesters. Cross-country differences, however, are 
defined solely by protester characteristics.  
Finally, in an application to education, Bennink et al. (2014) investigate 
students nested within school groups, with 3,458 students from 60 schools 
classified based on their responses to a 24-item multiple-choice test. Focus 
is on a performance comparison at the school level, with adjustment for 
student ability using a continuous latent variable at the lower level. Both 
continuous and discrete latent variables are utilised at the upper level, and 
classes thus identify a small minority of schools where performance is poor. 
With a single latent variable at the student level, however, no explicit 
accommodation is made for differential selection, as student ability is 
assumed to be homogeneous. With a heterogeneous patient group, as 
considered within this thesis, accommodation for casemix must be modelled 
explicitly. Nevertheless, the mathematical framework is comparable. 
1.4.6 Statistical software 
The software Stata (StataCorp, 2015) is used for all data management 
operations on the example dataset, including data manipulation, summary 
statistics, and the production of tables and charts. It is also used to perform 
the data simulations, collation of results and linear regression analyses for 
the simulated data used in Chapter 5.  
The statistical software Latent GOLD (Vermunt and Magidson, 2005; 
Vermunt and Magidson, 2013) is used for all latent variable models. 
Technical specifications are set at a level where consistent results can be 
achieved without unduly extending analysis time due to computational 
requirements. 
The software R (2010) is used to identify threshold values for covariates in 
the example dataset, discussed specifically in relation to research question 
(2) in Chapter 4. Although Stata could also have been utilised in this 
situation, R was chosen to gain experience of its approach.  
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1.5 Content of following chapters 
The following chapters contain methods, data, results and interpretation that 
demonstrate the utility of the multilevel latent variable approach to answer a 
range of research questions. The overarching methodological framework is 
maintained throughout, while specific strategies and parameterisations are 
explored for each research question. 
Chapter 2 fully explores key aspects of the latent variable methodological 
approaches that may be utilised to model appropriately complex 
observational health data. This includes discrete latent classes, covariate 
modelling based on complex relationships, and model features vital to the 
construction of detailed model configurations. Modelling approaches are 
provided with respect to the research questions. The example dataset is 
described in full, with context specific data challenges identified with 
reference to the generic challenges introduced in section 1.2.2. 
Chapters 3, 4 and 5 contain methods, results and interpretation as required 
to answer research questions (1), (2), and (3) respectively. 
Chapter 3 uses multilevel latent class (MLLC) modelling to answer research 
question (1) using the example dataset, and directly compares results with 
those from a traditional multilevel modelling (MLM) approach. Latent classes 
are identified at both the patient and provider levels, with modelling for 
causal inference at the patient level and adjustment for heterogeneity at the 
provider level. The focus is on patients, and consideration is given to the 
context specific data challenges discussed in section 2.4.2. Provider-level 
classes are also interpreted to contrast the latent class approach with the 
use of a continuous latent variable at the upper level in MLM. 
Chapter 4 uses MLLC modelling to answer research question (2) using the 
example dataset, comparing performance rankings at the provider level with 
those generated by calculation of the standardised mortality ratio (SMR). 
Latent classes are again identified at both the patient and provider levels, 
however modelling techniques are partitioned across levels of the hierarchy, 
with the accommodation of differential selection at the patient level and 
causal inference at the provider level. Provider classes are thus ‘adjusted’ 
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for patient casemix. This approach provides a foundation for the extension of 
MLLC models to incorporate patient pathway and process characteristics. 
Chapter 5 extends the MLLC modelling approach established in Chapter 4 to 
answer research question (3) by incorporating provider-level covariates. The 
utility of the latent variable approach is demonstrated by accounting for 
differential selection at the patient level, while modelling for causal inference 
at the provider level. Data are simulated, including both binary and 
continuous provider-level covariates and both binary and continuous 
outcomes. As there is no appropriate comparison with a traditional 
approach, assessment is made of the ability of the MLLC models to recover 
simulated values of the provider-level covariate. 
Chapter 6 unites the approaches utilised in Chapters 3, 4 and 5. Methods 
are reviewed, and comprehensive suggestions for future development are 
included. 
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Chapter 2 
Latent Variable Methodologies and Example Dataset 
2.1 Introduction 
Chapter 1 introduced complex observational data, exploring the linked 
aspects of patient, treatment and healthcare provider, and also discussed 
the generic data challenges commonly seen in such datasets. Three 
research questions, typical of common enquiries, were posed with 
consideration of their utility in an observational data context, and the 
example dataset was introduced. The traditional methodologies, and their 
limitations, were described with reference to the data challenges, and 
specific strategies were examined that have traditionally been used to 
account for differential selection (i.e. patient casemix).  
The latent variable framework was then introduced as an overarching causal 
framework that allows modelling for both inference and prediction, with 
fundamental advantages over traditional methodologies; latent variable 
features may be used both to address the generic data challenges and to 
account for differential selection, while the framework has the capacity to 
extend beyond the scope of this thesis to incorporate patient pathways 
through the healthcare system. A literature search in section 1.4.5 
demonstrated that there are few other applications utilising the capabilities of 
this in-depth methodology. 
Chapter 2 considers the latent variable methodologies in depth, with focus 
on the use of discrete latent classes and their potential application to 
observational health data. Aspects of the latent variable methodologies are 
explored in detail, including appropriate adjustment for variables that may 
have a complex observed relationship with the exposure or outcome, such 
as those that may confound, modify or mediate the exposure-outcome 
relationship. Specific features that are utilised to precisely configure the 
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modelling approaches are introduced and described in detail, together with 
consideration of errors in classification and a suggested approach to model 
construction. Appropriate modelling approaches for the research questions 
are considered, utilising the overarching causal framework, and exploring 
their utility in addressing the generic data challenges. Broad modelling 
strategies and detailed parameterisations are included. The example dataset 
is described in detail, from source to summary statistics, and specific data 
challenges relevant to the data are included.  
Section 2.2 explores the latent class approaches in detail, introducing class 
membership models, key modelling features, errors in class assignment and 
optimum model construction. 
Section 2.3 revisits the example dataset to describe how the dataset is 
obtained and adapted for use within this research activity.  
Section 2.4 considers the modelling approach in detail, exploring the 
appropriate analytical methods with discussion of the data challenges, broad 
modelling strategies and detailed parameterisations. 
This chapter contains work based on a publication (Harrison et al., 2012). 
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2.2 Methods and features 
2.2.1 Latent Class Analysis (LCA) 
LCA, also known as ‘discrete latent variable modelling’, or ‘mixture 
modelling’ (Goodman, 1974b; Magidson and Vermunt, 2004), is well 
established within single level regression analysis. In LCA, a number of 
discrete latent variables (i.e. latent classes, or subgroups), are identified, the 
optimum choice of which is selected by the researcher, typically informed by 
log-likelihood (LL) statistics. The Bayesian Information Criterion (BIC) 
(Schwarz, 1978), the Akaike Information Criterion (AIC) (Akaike, 1974), and 
changes in LL are commonly used as model-evaluation indicators, though 
models may also be selected on the basis of interpretation (Gilthorpe et al., 
2009). Both the BIC and AIC incorporate a sense of model parsimony by 
accommodating the varying number of model parameters (Vermunt and 
Magidson, 2016), while the LL does not. Model parameters for each latent 
class are determined empirically, along with their contribution to the outcome 
distribution. 
Observations are probabilistically assigned to latent classes, i.e. each 
observation has a probability of belonging to each latent class, which sums 
to one, as each observation must be fully assigned across all classes. This 
assignment is based on similarities in characteristics; latent classes are 
therefore homogeneous, with similar effects of each covariate on 
observations in the same latent class, although covariate effects may differ 
across the classes. The relationship between outcome and associated risk 
factors can thus be determined within each latent class, rather than over all 
observations. As with single level regression, the intercept and slope within 
each class are fixed, so no distributional assumptions are required. 
Uncertainty surrounding class membership is incorporated within the latent 
classes, since observations may belong to all classes, with probabilities 
determined empirically. LCA thus manages the uncertainty associated with 
use of a limited number of predictors when determining subtypes of 
outcomes. Although accommodated implicitly within the latent framework, 
very few analytical research strategies seek clearly to exploit this aspect.  
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2.2.2 Multilevel Latent Class (MLLC) modelling 
MLLC models (Vermunt, 2003; Vermunt, 2008a) are an extension of LCA 
that incorporate discrete latent variables at all levels of a hierarchy. Latent 
classes are thus determined at more than one level, with the choice, as in 
LCA, informed by model-evaluation statistics, or based on interpretation. An 
optimum solution is sought for all classes at all levels simultaneously using 
ML estimation (Goodman, 1974b) obtained by an adapted expectation-
maximisation (EM) algorithm (Vermunt, 2003).  
Observations are probabilistically assigned to latent classes at all levels, i.e. 
they have a probability of belonging to each lower- and upper-level class, 
which sum to one at each level to reflect full assignment of each observation 
across all latent classes at all levels. Assignment to classes at the lower 
level is based on similarities in characteristics (Skrondal and Rabe-Hesketh, 
2004), while latent classes at the upper level may be based on either 
similarities or differences, dependent on model specification and research 
question. Latent classes at the lower level are thus homogeneous, while 
latent classes at the upper level may be either homogeneous or 
heterogeneous. Covariates can be included at any level and, as with single 
level LCA, their effect is the same within each latent class, but may differ 
across the classes (if deemed appropriate). The relationship between 
outcome and associated risk factors is again determined within each latent 
class, rather than over all observations and, if intercepts and slopes are fixed 
within the classes at all levels, no distributional assumptions are required. 
A richer mixture model can thus be represented, with latent classes adopted 
at any or all levels of the hierarchy. As the number of classes at the upper 
level is increased, a MLLC model can also be viewed as the traditional MLM 
but with a relaxation of normality assumptions, i.e. many upper-level latent 
classes can be viewed as a discrete approximation of a continuous latent 
variable that need not necessarily be normally distributed.  
The use of latent classes within a multilevel structure permits several 
complex model configurations, where each configuration may be designed to 
address a specific research question, within a specific context. Each 
parameterisation relates to different assumptions, and leads to different 
- 33 - 
interpretations, with the modelling choices lying with the researcher. Many 
potential models, however, would be meaningless in many instances, as 
some of these parameterisations may not be identifiable, and some 
identifiable models may not be interpretable. Careful consideration must 
therefore be used when specifying the model; decisions regarding model 
configuration must be justified and the implications of each parameterisation 
fully considered. These issues only become more complex in a multilevel 
setting. Analysis within this thesis illustrates how such complexity can be 
exploited to address otherwise challenging or even intractable problems, 
using novel analytical strategies to address a range of research questions. 
2.2.3 Class membership models 
Covariates can be entered into a latent class model as within a traditional 
regression model, i.e. as ‘predictors’ of the outcome variation. The same 
covariates may also enter the model as ‘predictors’ of the latent class 
structure; termed the ‘class membership model’. In either scenario, causality 
should not be inferred. The term ‘predictor’ is unfortunate in that it may 
mislead users to infer causality when it only implies an association between 
outcome variation and the covariate in question. With this in mind, the 
favoured nomenclature within this thesis is that covariates in the regression 
part of the model are referred to as ‘covariates’, whilst the covariates (same 
or different) in the class membership part of the model are referred to as 
‘class predictors’, though causality is not to be inferred. For MLLC models, 
covariates and class predictors may operate at any level. 
If variables are included both as covariates and as class predictors, their 
association with the outcome should not then be allowed to vary across the 
latent classes, as a model where a variable is both predicting class 
membership and where its effect differs across classes would be difficult to 
interpret. If a variable is included only as a class predictor, however, then the 
resultant latent classes at that level will have a graduated outcome 
analogous to that observed for different values of the class predictor, and the 
relationship between the outcome and associated risk factors can thus be 
explored across these classes. 
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2.2.4 Modelling features 
2.2.4.1 Confounding, effect modification and mediation 
Class predictors may be utilised to ‘remove’ variables from the regression 
part of the model, which may improve model precision due to measurement 
error or missing variables, or potentially minimise bias due to the reversal 
paradox. This has been shown explicitly in collaboration undertaken as part 
of my research activities (Downing et al., 2010), and is discussed in section 
1.4.5.  
Modelling a confounder that is also a potential effect modifier (e.g. alcohol 
consumption may modify the effect of smoking on cancer mortality) as a 
class predictor yields an implicit interaction, since the exposure-outcome 
relationship may vary across latent classes. This averts the need to include 
an explicit confounder-exposure product term in the regression part of the 
model, which would otherwise exacerbate any bias introduced if the 
confounder is measured with error or has missing values, as discussed in 
section 1.3.3 with respect to the traditional regression analytical approaches 
to the data challenges. Modelling effect modification this way minimises bias; 
uncertainty associated with confounder values is explicitly accommodated 
via the latent class part of the model. 
If an alleged confounder lies on the causal path between an exposure and 
an outcome, it is termed a ‘mediator’ (e.g. diet may mediate the effect of 
maternal deprivation on birthweight); statistical adjustment that includes a 
mediator as a covariate within a regression model may introduce bias due to 
the reversal paradox, as also discussed in section 1.3.3. It would then be 
wise to discard the mediator as a model covariate. This does not preclude 
the mediator becoming a class predictor however, though some implicit bias 
may remain. Modelling a mediator as a class predictor yields the potential for 
implicit interaction, as before, where the exposure-outcome relationship may 
vary across latent classes. The exposure may cause the mediator, which in 
turn part determines the latent class structure, within which the exposure-
outcome relationship may vary. Circularity thus arises in the causal interplay 
of exposure, mediator and outcome. This can be avoided if the exposure-
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outcome relationship is not allowed to vary across latent classes. In such 
instances, only the intercept varies across each latent class, not the 
exposure-outcome slope. The latent classes generated during modelling will 
then have a gradient that corresponds to specific patient features that can be 
labelled post-hoc according to outcome (e.g. ‘high’ or ‘low’ birthweight) or to 
class predictors (e.g. ‘good’ or ‘poor’ diet). 
2.2.4.2 Inactive covariates 
Covariates may also be included as ‘inactive’ within the model, whereby their 
distribution across the latent classes may be identified and interpreted, but 
they are not allowed to affect either the relationship between exposure and 
outcome, or class membership. This may be useful as a crude solution to 
enable the inclusion of covariates containing substantial amounts of missing 
data (e.g. treatment data where not all patients receive treatment). Their 
inclusion as inactive covariates aids interpretability of the model results, but 
ensures that additional bias is not introduced due to the missing data. 
2.2.4.3 Class-dependent and class-independent features 
Within latent variable models, parameter restrictions may be applied such 
that more (or less) parsimonious models may be estimated as required. This 
is achieved using ‘class-dependent’ or ‘class-independent’ features, thus 
determining how parameters at a lower level are set in relation to class 
structures at higher levels. A different interpretation is seen for each, and the 
choice of configuration is driven by both the context and research question. 
These features are what enables the flexibility that is exploited in the novel 
approaches proposed in this thesis, and their complexity therefore warrants 
a detailed exposition. 
Parameter restrictions may be set for intercepts, covariate effects, class 
sizes and error variances (where there is a continuous outcome); the class-
independent option applies the constraints, while the class-dependent option 
relaxes them. The technical detail is given here, while the practical use of 
these features is explored in section 2.4.4 with specific relevance to latent 
classes at patient and provider levels. 
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Intercepts 
Within a MLLC structure, latent class intercepts at the lower level may vary 
across latent classes at the upper levels. This is very broadly analogous to 
random intercepts within a traditional MLM. Latent class intercepts at a lower 
level, however, may be either class dependent or class independent in 
relation to class structures at higher levels, thus they may exhibit relative 
differences that are either identical or different within each upper-level class. 
In both cases, upper-level classes may differ in their overall outcome. 
Where relative differences are identical, lower-level class intercepts differ by 
the same degree, irrespective of which upper-level class the observations 
are assigned to; intercepts are thus class independent. This configuration 
therefore enables identical contrasts to be made among lower-level classes, 
within each upper-level class.  
Where lower-level class intercepts vary by different degrees across upper-
level classes, the intercepts are class dependent. This configuration 
indicates that lower-level differences can mean different things according to 
which upper-level class is being considered.  
Covariate effects 
Covariate effects can apply at any level of a latent class structure. Similar to 
the concept surrounding intercepts, covariate effects at the lower level may 
be modelled as either class dependent or class independent, in relation to 
the upper-level classes. In traditional MLMs, for example, the lower-level 
covariates could have estimated regression coefficients that remain fixed 
across the upper-level classes (hence the term ‘fixed-effects’). Alternatively, 
these covariates could be allowed to vary randomly across the upper-level 
classes, thereby yielding ‘random-effects’, sometimes referred to as random 
slopes. 
In a MLLC model, each lower-level covariate may be constrained to have 
identical estimated parameter values for each of the upper-level classes. 
This is the class-independent configuration. Alternatively, this constraint may 
be relaxed so that the covariate parameters may have different estimated 
values for each upper-level class. This is the class-dependent configuration. 
This configuration is akin to random slopes in the traditional MLM, but where 
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the random effects (represented by a continuous latent variable) are 
effectively categorised and multiple fixed-effects parameter values are 
estimated for each upper-level latent class. 
Not all covariate effects would necessarily be modelled in this way, so the 
number of lower-level covariates that are upper-level class dependent could 
be fewer than the total number of lower-level covariates. This can be much 
less parsimonious than the traditional MLM, since for the latter, only one 
continuous latent variable variance is estimated per covariate random slope, 
as opposed to multiple fixed-effects parameter values for each upper-level 
class. This is an example of why it becomes necessary to consider carefully 
the pros and cons of class-dependent versus class-independent covariate 
effects.  
Class sizes 
Lower-level class sizes may also be class dependent or class independent, 
with respect to upper-level classes. The number of lower-level classes per 
upper-level class is fixed during modelling, but the proportions of each may 
be either identical (class independent) or different (class dependent) within 
each of the upper-level classes.  
In the class-dependent configuration, some lower-level classes may contain 
no observations at all, indicating that some upper-level classes might 
actually favour fewer lower-level classes. This is a discretised version of the 
traditional MLM approach, with cluster imbalance.  
Alternatively, it is possible to constrain class sizes such that the proportion of 
each lower-level class remains the same for each upper-level class; the 
class-independent configuration. The total number of observations per 
upper-level class can still vary, but this configuration forces the upper-level 
classes to represent the entire spectrum; thus accommodating a structure 
that, in the specific circumstances considered in this thesis, accounts for 
differential selection. 
Error variance 
Appropriate for continuous outcomes only, error variance within lower-level 
classes may also be class dependent or class independent, in relation to 
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upper-level classes. The choice should be based both on the distribution of 
the data used, and on the concepts that are to be explored. 
The class-independent configuration constrains the estimates to be the 
same within each upper-level class, thus ensuring that the variance is held 
constant across all lower-level classes, i.e. homoscedasticity.  
The class-dependent configuration allows for different estimates of the 
variance of the outcome within each upper-level class, hence permitting 
unequal variance across the lower-level classes, i.e. heteroscedasticity. 
2.2.5 Classification error (CE) 
As introduced in sections 2.2.1 and 2.2.2, observations are probabilistically 
assigned to latent classes at all levels; termed ‘probabilistic assignment’. An 
alternative way of assigning observations to latent classes is known as 
‘modal assignment’, where an observation is allocated to a latent class at 
each level according to the highest membership probability. The CE is the 
proportion of observations that are estimated to be misclassified by their 
modal assignment, and this is usually expressed as a percentage. A CE 
value is thus observed at both the lower and upper levels. 
A small CE indicates that the latent classes are more ‘real’, i.e. they 
correspond to groups where upper- or lower-level observations are almost 
entirely assigned to a single class. A smaller CE may be favoured where it 
results in greater interpretability of the latent classes at any level. 
In contrast, a large CE indicates that the latent classes are more ‘virtual’, i.e. 
a construct of probabilistic assignment only, as they differ substantially from 
modal assignment. This may result in the identification of additional latent 
classes that reflect outliers, or unusual but minority (potentially latent) 
features. 
It therefore depends upon the context and purpose of the model as to 
whether or not one worries about CE values, low or high. It is important to be 
mindful of the magnitude of CEs, and in some instances models may be 
preferred where they are not too large, or not too close to zero. 
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2.2.6 The optimum model 
There is no single optimum model; rather the preferred model will differ 
dependent on context and research question. As introduced in section 2.2.1, 
model-evaluation criteria (such as the AIC and BIC) are commonly used to 
aid more parsimonious model selection, as these are penalised versions of 
the log-likelihood (LL) criterion. Lower values indicate better models but 
reflect better parsimony compared to LL. For the analyses described in this 
thesis, all model-evaluation criteria are used for guidance only, with optimum 
model selection based also on interpretability. Modelling the same data for 
different research questions may therefore yield differing optimum models. 
Being able to interpret meaningfully the latent class structure is crucial, as 
latent class model selection should not be determined solely on likelihood-
based statistics. There is, however, a general approach, described here, that 
may be utilised. Optimum model construction is discussed specifically in 
relation to each research question in sections 3.2.5, 4.2.4 and 5.3.4. 
To consider the construction of an optimum MLLC model using an initially 
simple approach, the latent class structures may be considered to be built 
one level at a time. Lower-level observations may first be assigned to latent 
classes, generating an optimum number of lower-level latent classes as 
selected by the researcher. Conditional on belonging to a given lower-level 
class, the upper-level observations may then also be assigned to latent 
classes based on model configuration, as driven by context and research 
question. 
Within the estimation process, there is no sense of ordering in terms of 
which level of latent classes are formed ahead of other levels, because this 
all happens simultaneously. Models are an optimum solution for all classes, 
at all levels, conditional on covariates considered in the model. Estimation 
procedures hence seek to maximise the likelihood function in a single 
process. 
In practice, however, a continuous latent variable may be adopted initially at 
the upper level as an approximation, while the latent class structure is 
explored for the lower level. Once the optimum number of lower-level 
classes is determined, the continuous latent variable at the upper level may 
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be switched to categorical and the optimum latent class structure determined 
at the upper level. Latent class models are commonly explored where the 
number of latent classes at all levels are sequentially increased from one to 
identify the required optimum model, with reference to model-evaluation 
criteria, parsimony, interpretability and CE.  
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2.3 The example dataset 
2.3.1 Source and extraction 
The colorectal cancer data were extracted from the Northern and Yorkshire 
Cancer Registry and Information Service (NYCRIS) database in November 
2006, using geographical boundaries defined at the 2001 census. Figure 2.1 
shows the boundaries of the regional cancer registries at this time point; 
Northern and Yorkshire marks the boundary for these data. At the 2001 
census, the total NYCRIS population was around 6.7 million, approximately 
12.4% of the total population of England and Wales (NYCRIS, 2007).  
 
Figure 2.1 Locations of the regional cancer registries at the 2001 Census 
ONS Cancer Statistics Registrations: Registrations of cancer diagnosed in 
2001, England. Series MB1 no. 32. © Crown copyright 2004. Contains public 
sector information licensed under the Open Government Licence v3.0. 
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Each regional cancer registry is responsible for collecting data on all cancer 
registrations within their geographical boundary, ensuring data are accurate 
and complete, and analysing and interpreting data for regional reference 
reports. The registration process is complex, with data obtained from 
multiple sources including medical records, tumour registers and death 
certificates, and so there is a time delay between the cancer diagnosis date 
and the availability of complete data. Prior to 2009, cancer registries were 
required to provide their registration data to the Office for National Statistics 
(ONS) within eighteen months following the end of the calendar year (Office 
for National Statistics, 2016a). Therefore, at November 2006, the latest 
available calendar year of registration data was 2004. 
Diagnosed cases of colorectal cancer (10th revision of the International 
Classification of Diseases (ICD-10) (World Health Organisation, 2005) codes 
C18, C19 and C20) were initially identified where the date of diagnosis was 
between 1 January 1991 and 31 December 2004, and the patient was 
resident in the Northern and Yorkshire regions. Due to issues concerning the 
completeness of these data prior to 1998, when NYCRIS merged two 
smaller cancer registries, diagnoses from 1 January 1998 only were 
retained.  
Data extraction and initial processing to obtain a non-identifiable dataset 
were performed in advance of commencement of this research activity and 
are therefore not described here.  
Variables available after initial processing were: age at diagnosis, sex, 
tumour site (either colon (C18), rectosigmoid junction (C19) or rectum 
(C20)), stage at diagnosis (using Dukes classification (Dukes, 1949); ranging 
from stage A (early stage) to stage D (late stage)), lower super output area 
(LSOA) (used to derive SES using the TDI (as described in section 1.2.2), 
recorded at the 2001 census), whether or not the patient was treated 
curatively, which hospital(s) were attended and whether the patient was alive 
or dead at the latest data download date. 
The laterality of the tumour was also determined from the tumour site, with 
rectosigmoid junction and rectal tumours identified on the left side of the 
body, while colon tumours may present on either side of the body. 
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2.3.2 Exclusions 
Figure 2.2 details all exclusions made to the original extracted dataset 
containing diagnosis dates from 1991 to 2004.  
Three years of follow up data are required, as the outcome is survival status 
at three years following diagnosis. A new download of death dates was 
obtained on 30 June 2007, meaning that diagnosis dates only up to 30 June 
2004 could be included. As such, patients who are diagnosed after this date 
are excluded; 1,982 patients are excluded. 
Townsend deprivation scores are imported into the dataset by matching to 
the LSOA of residence of the patient. One patient does not have a recorded 
LSOA, indicating that they are resident outside the NYCRIS area; this 
patient is therefore excluded from the dataset. 
Multiple tumours are excluded. Clinical information is not available in order 
to identify whether an additional recorded tumour for a patient is due to 
spread or recurrence of the original tumour, or if the patient has been 
diagnosed with a multiple primary tumour (MPT). A MPT occurs where more 
than one histologically distinct tumour is found in the same patient, and 
treatment may differ for these differing types of multiple tumour. There are 
540 patients diagnosed with between two and four tumours; 561 multiple 
tumours are therefore excluded.  
Patients with a recorded age at diagnosis of more than one hundred years 
are excluded; 7 patients are excluded. 
Patients identified by death certificate only (DCO) are excluded. This occurs 
where the death certificate has provided the only tumour notification, thus 
there is no information available regarding, for example, hospital visits or 
treatment received. DCO registrations are commonly used to measure data 
completeness (Hill, 1995). Where registration is initially provided by death 
certificate, the cancer registry attempts to add missing information from other 
sources, such as GP or hospital records, but if none can be found, 
registration is classified as DCO. 364 patients are excluded. 
Exclusions related to identification of the diagnostic centre are discussed in 
section 2.3.3. 
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Figure 2.2 Flowchart showing exclusions from the original extracted dataset 
  
Extraction 1991-2004 inclusive 
54,442 patients; 55,457 tumours; 90,599 hospital visits 
Extraction 1998-2004 inclusive 
28,437 patients; 29,046 tumours; 55,981 hospital visits 
Excluding date of diagnosis >30 June 2004 
26,455 patients; 27,016 tumours; 51,913 hospital visits 
Exclude multiple tumours 
26,454 patients and tumours; 50,918 hospital visits 
No recorded LSOA 
26,454 patients; 27,015 tumours; 51,910 hospital visits 
Exclude age > 100 years at diagnosis 
26,447 patients and tumours; 50,911 hospital visits 
Exclude registration by DCO 
26,083 patients and tumours; 50,547 hospital visits 
Identify diagnostic centre 
24,640 patients, tumours and hospital visits 
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2.3.3 Identification of diagnostic centre 
While interest may lie in investigating potential treatment centre 
characteristics associated with colorectal cancer survival, this can be 
complex to assess, as patients may attend multiple hospital visits at different 
hospitals throughout their care, and thus may receive treatment at more than 
one hospital. For these data, patients attend up to seven hospital visits for 
diagnosis, treatment or specialist opinion in total, with 16,549 patients 
(63.4%) attending more than once.  
Table 2.1 shows the number and percentage of hospital visits per patient 
where treatment is recorded; patients attend between zero and five 
treatment visits. Of the 26,083 patients currently in the dataset, most have 
only one treatment visit (14,437; 55.4%), although 7,323 patients (28.1%) 
have more than one treatment visit. Of the 7,323 patients, only 650 (8.9%) 
receive treatment at the same hospital each time, while 6,554 (89.5%) 
receive treatment at two different hospitals, and 119 (1.6%) receive 
treatment at three different hospitals. 4,323 patients (16.6% of the 26,083) 
do not receive curative treatment and would therefore be excluded from any 
analysis using treatment centres. 
Table 2.2 shows the number and percentage of hospital visits per patient 
where diagnosis is recorded. Although patients may also attend multiple 
diagnosis visits, there is less variability, with patients attending between zero 
and three diagnosis visits. Most patients have only one diagnosis visit 
(25,542; 97.9%), 220 patients (0.8%) have no diagnosis visits and 321 
patients (1.2%) have more than one diagnosis visit. Of the 321 patients, 228 
(71.0%) receive diagnosis at the same hospital each time, 92 (28.7%) 
receive diagnosis at two different hospitals and 1 (0.3%) receives diagnosis 
at three different hospitals. Diagnostic centres are therefore used in order to 
include all patients, whether treated or not, and to limit the variability 






Table 2.1 Number and percentage of treatment visits per patient 
No. hospital visits with 
treatment recorded 
No. patients 
(% of total patients) 
No. different hospitals attended per patient 
(% of patients with related number of visits) 
1 2 3 
0 4,323 (16.6%) N/A N/A N/A 
1 14,437 (55.4%) 14,437 (100.0%) N/A N/A 
2-5 7,323 (28.1%) 650 (8.9%) 6,554 (89.5%) 119 (1.6%) 
 26,083  
 
Table 2.2 Number and percentage of diagnosis visits per patient 
No. hospital visits with 
diagnosis recorded 
No. patients 
(% of total patients) 
No. different hospitals attended per patient 
(% of patients with related number of visits) 
1 2 3 
0 220 (0.8%) N/A N/A N/A 
1 25,542 (97.9%) 25,542 (100.0%) N/A N/A 
2-3 321 (1.2%) 228 (71.0%) 92 (28.7%) 1 (0.3%) 
 26,083  
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The diagnostic centre is initially defined as the hospital where the latest 
staging took place. For those 25,542 patients with only one diagnosis visit, 
this is straightforward. For those 321 patients attending more than one 
diagnosis visit, the location of the most recent diagnosis hospital is recorded 
at the diagnostic centre, as this is considered to provide the latest staging 
information. For those 220 patients with no diagnosis visit, the location of 
their first hospital visit is taken as the diagnostic centre. Although they have 
no recorded diagnosis visit, all of these patients have a recorded ICD-10 
diagnosis code of colorectal cancer.  
Each hospital is contained within an NHS Trust, and nineteen Trusts are 
identified in the NYCRIS geographical area. Trust codes are matched to the 
154 hospital codes in order to identify diagnostic centres at the Trust level. 
Of the 21,760 patients who receive treatment (83.4%), 17,598 (80.9%) are 
treated initially within the same hospital as they are diagnosed, with only 
12,879 (59.2%) remaining within this hospital throughout. This contrasts with 
19,368 patients (89.0%) who are treated initially within the same Trust as 
they are diagnosed, with 16,163 (74.3%) remaining within this Trust 
throughout. As the figures at the Trust level show improvement from those at 
the hospital level, the choice is made to analyse by Trust of diagnosis 
instead of by hospital. Increased movement between centres could introduce 
variability of care for the patient and thus mitigate the diagnostic centre 
effect. 
1,443 patients are found to be diagnosed at Trusts external to the NYCRIS 
geographical area and are thus excluded, leaving 24,640 patients available 
for analysis. While the diagnosis visit remains in the dataset, all other Trust 
visits are also excluded, leaving just one Trust visit per tumour, per patient, 
as shown in Figure 2.2. 
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2.3.4 Descriptive statistics 
There are 24,640 patients available in the final dataset for analysis; each 
patient is diagnosed at one of the nineteen NHS Trusts. Due to coding 
updates, there are minor differences in the number of deaths recorded in the 
final datasets adopted for each research question, although this has no 
material impact on the messages of each.  
For analyses in Chapter 3, 12,708 patients (51.6%) died within three years 
of diagnosis, while for analyses in Chapter 4 (which were initially performed 
before the material seen in Chapter 3), 12,856 patients (52.2%) died within 
three years of diagnosis. The number of patients available in the dataset 
remains the same, and the small differences in deaths do not impact on the 
demonstration of the utility of the MLLC analysis. Table 2.3 provides 
summary statistics for all explanatory variables available in the dataset, 
which remain the same across both versions of the dataset. Trusts are 
ordered alphabetically and allocated numbers one to nineteen. Differences 
in values across Trusts demonstrate the heterogeneity of the patient 
casemix. 
All variables contain complete data except for stage at diagnosis. As 
discussed in section 1.2.5, missing values for stage are categorised (overall 
3,223; 13.1% missing (coded ‘X’)). Age at diagnosis is centred on the study 











Trust 2  
N=1,028 
Trust 3  
N=1,280 
Trust 4  
N=648 
Mean (SD) 
Deprivation -0.04 (3.18) -1.46 (2.81) 1.31 (4.25) -0.32 (3.03) -2.32 (1.63) 
Age at diagnosis (years) 71.5 (11.6) 71.8 (11.6) 71.7 (11.9) 72.0 (11.7) 72.8 (11.7) 
Variable Categories Number (%) 
Sex  
Female 10,862 (44.1%) 249 (46.3%) 469 (45.6%) 577 (45.1%) 300 (46.3%) 
Male 13,778 (55.9%) 289 (53.7%) 559 (54.4%) 703 (54.9%) 348 (53.7%) 
Stage at 
diagnosis 
A 2,859 (11.6%) 62 (11.5%) 107 (10.4%) 154 (12.0%) 86 (13.3%) 
B 6,784 (27.5%) 143 (26.6%) 291 (28.3%) 353 (27.6%) 206 (31.8%) 
C 6,173 (25.1%) 174 (32.3%) 279 (27.1%) 271 (21.2%) 179 (27.6%) 
D 5,601 (22.7%) 106 (19.7%) 218 (21.2%) 316 (24.7%) 120 (18.5%) 
Missing (X) 3,223 (13.1%) 53 (9.9%) 133 (12.9%) 186 (14.5%) 57 (8.8%) 
ICD-10  
C18 (colon) 14,510 (58.9%) 312 (58.0%) 596 (58.0%) 701 (54.8%) 388 (59.9%) 
C19 (rectosigmoid junction) 2,585 (10.5%) 43 (8.0%) 137 (13.3%) 130 (10.2%) 75 (11.6%) 
C20 (rectum) 7,545 (30.6%) 183 (34.0%) 295 (28.7%) 449 (35.1%) 185 (28.5%) 
Laterality  
Left 16,261 (66.0%) 367 (68.2%) 673 (65.5%) 883 (69.0%) 443 (68.4%) 
Right 6,727 (27.3%) 137 (25.5%) 300 (29.2%) 343 (26.8%) 180 (27.8%) 
Split 1,652 (6.7%) 34 (6.3%) 55 (5.4%) 54 (4.2%) 25 (3.9%) 
Treated  
Y 20,582 (83.5%) 478 (88.8%) 873 (84.9%) 1,054 (82.3%) 555 (85.6%) 
N 4,058 (16.5%) 60 (11.2%) 155 (15.1%) 226 (17.7%) 93 (14.4%) 





Table 2.3 continued Summary statistics for all explanatory variables in the final dataset 
Variable 
Trust 5  
N=1,832 
Trust 6  
N=1,187 
Trust 7  
N=2,239 
Trust 8  
N=1,716 
Trust 9  
N=1,193 
Mean (SD) 
Deprivation -0.10 (2.88) -1.77 (2.15) 0.07 (3.25) 0.21 (3.59) -0.64 (2.90) 
Age at diagnosis (years) 71.1 (11.6) 71.6 (11.4) 72.3 (12.1) 71.7 (11.7) 71.7 (11.5) 
Variable Categories Number (%) 
Sex  
Female 794 (43.3%) 508 (42.8%) 1,022 (45.6%) 731 (42.6%) 537 (45.0%) 
Male 1,038 (56.7%) 679 (57.2%) 1,217 (54.4%) 985 (57.4%) 656 (55.0%) 
Stage at 
diagnosis 
A 275 (15.0%) 130 (11.0%) 224 (10.0%) 170 (9.9%) 142 (11.9%) 
B 451 (24.6%) 365 (30.7%) 638 (28.5%) 466 (27.2%) 296 (24.8%) 
C 433 (23.6%) 343 (28.9%) 601 (26.8%) 495 (28.8%) 261 (21.9%) 
D 447 (24.4%) 239 (20.1%) 520 (23.2%) 387 (22.6%) 303 (25.4%) 
Missing (X) 226 (12.3%) 110 (9.3%) 256 (11.4%) 198 (11.5%) 191 (16.0%) 
ICD-10  
C18 (colon) 1,016 (55.5%) 678 (57.1%) 1,363 (60.9%) 1,035 (60.3%) 654 (54.8%) 
C19 (rectosigmoid junction) 247 (13.5%) 138 (11.6%) 245 (10.9%) 91 (5.3%) 99 (8.3%) 
C20 (rectum) 569 (31.1%) 371 (31.3%) 631 (28.2%) 590 (34.4%) 440 (36.9%) 
Laterality  
Left 1,270 (69.3%) 778 (65.5%) 1,471 (65.7%) 1,143 (66.6%) 804 (67.4%) 
Right 490 (26.7%) 353 (29.7%) 643 (28.7%) 492 (28.7%) 332 (27.8%) 
Split 72 (3.9%) 56 (4.7%) 125 (5.6%) 81 (4.7%) 57 (4.8%) 
Treated  
Y 1,535 (83.8%) 1,028 (86.6%) 1,886 (84.2%) 1,480 (86.2%) 979 (82.1%) 
N 297 (16.2%) 159 (13.4%) 353 (15.8%) 236 (13.8%) 214 (17.9%) 





Table 2.3 continued Summary statistics for all explanatory variables in the final dataset 
Variable 
Trust 10  
N=774 
Trust 11  
N=661 
Trust 12  
N=1,567 
Trust 13  
N=1,937 
Trust 14  
N=1,258 
Mean (SD) 
Deprivation -0.97 (2.10) 2.35 (3.18) -0.03 (3.64) -0.33 (2.55) -0.97 (2.45) 
Age at diagnosis (years) 72.6 (11.7) 72.0 (10.8) 70.9 (11.4) 72.1 (11.4) 71.6 (11.4) 
Variable Categories Number (%) 
Sex  
Female 352 (45.5%) 290 (43.9%) 645 (41.2%) 859 (44.3%) 583 (46.3%) 
Male 422 (54.5%) 371 (56.1%) 922 (58.8%) 1,078 (55.7%) 675 (53.7%) 
Stage at 
diagnosis 
A 86 (11.1%) 88 (13.3%) 190 (12.1%) 210 (10.8%) 155 (12.3%) 
B 244 (31.5%) 187 (28.3%) 409 (26.1%) 594 (30.7%) 351 (27.9%) 
C 158 (20.4%) 155 (23.4%) 419 (26.7%) 458 (23.6%) 293 (23.3%) 
D 156 (20.2%) 155 (23.4%) 354 (22.6%) 387 (20.0%) 287 (22.8%) 
Missing (X) 130 (16.8%) 76 (11.5%) 195 (12.4%) 288 (14.9%) 172 (13.7%) 
ICD-10  
C18 (colon) 481 (62.1%) 374 (56.6%) 883 (56.3%) 1,158 (59.8%) 792 (63.0%) 
C19 (rectosigmoid junction) 88 (11.4%) 90 (13.6%) 183 (11.7%) 239 (12.3%) 131 (10.4%) 
C20 (rectum) 205 (26.5%) 197 (29.8%) 501 (32.0%) 540 (27.9%) 335 (26.6%) 
Laterality  
Left 496 (64.1%) 466 (70.5%) 1,021 (65.2%) 1,292 (66.7%) 808 (64.2%) 
Right 206 (26.6%) 145 (21.9%) 399 (25.5%) 539 (27.8%) 377 (30.0%) 
Split 72 (9.3%) 50 (7.6%) 147 (9.4%) 106 (5.5%) 73 (5.8%) 
Treated  Y 628 (81.1%) 577 (87.3%) 1,307 (83.4%) 1,590 (82.1%) 1,084 (86.2%) 
N 146 (18.9%) 84 (12.7%) 260 (16.6%) 347 (17.9%) 174 (13.8%) 





Table 2.3 continued Summary statistics for all explanatory variables in the final dataset 
Variable 
Trust 15  
N=1,208 
Trust 16  
N=2,009 
Trust 17  
N=1,255 
Trust 18  
N=771 
Trust 19  
N=1,539 
Mean (SD) 
Deprivation 1.25 (3.12) -0.21 (2.35) 0.65 (3.34) 0.89 (3.05) 0.90 (3.63) 
Age at diagnosis (years) 70.5 (11.0) 70.9 (11.6) 70.3 (11.4) 72.1 (11.3) 71.3 (11.6) 
Variable Categories Number (%) 
Sex  
Female 504 (41.7%) 889 (44.3%) 533 (42.5%) 354 (45.9%) 666 (43.3%) 
Male 704 (58.3%) 1,120 (55.7%) 722 (57.5%) 417 (54.1%) 873 (56.7%) 
Stage at 
diagnosis 
A 127 (10.5%) 214 (10.7%) 171 (13.6%) 74 (9.6%) 194 (12.6%) 
B 291 (24.1%) 547 (27.2%) 302 (24.1%) 212 (27.5%) 438 (28.5%) 
C 324 (26.8%) 478 (23.8%) 334 (26.6%) 167 (21.7%) 351 (22.8%) 
D 287 (23.8%) 459 (22.8%) 301 (24.0%) 193 (25.0%) 366 (23.8%) 
Missing (X) 179 (14.8%) 311 (15.5%) 147 (11.7%) 125 (16.2%) 190 (12.3%) 
ICD-10  
C18 (colon) 713 (59.0%) 1,245 (62.0%) 762 (60.7%) 471 (61.1%) 888 (57.7%) 
C19 (rectosigmoid junction) 137 (11.3%) 155 (7.7%) 106 (8.5%) 72 (9.3%) 179 (11.6%) 
C20 (rectum) 358 (29.6%) 609 (30.3%) 387 (30.8%) 228 (29.6%) 472 (30.7%) 
Laterality  
Left 801 (66.3%) 1,279 (63.7%) 772 (61.5%) 476 (61.7%) 1,018 (66.2%) 
Right 320 (26.5%) 492 (24.5%) 347 (27.6%) 213 (27.6%) 419 (27.2%) 
Split 87 (7.2%) 238 (11.8%) 136 (10.8%) 82 (10.6%) 102 (6.6%) 
Treated  
Y 969 (80.2%) 1,642 (81.7%) 1,031 (82.2%) 624 (80.9%) 1,262 (82.0%) 
N 239 (19.8%) 367 (18.3%) 224 (17.8%) 147 (19.1%) 277 (18.0%) 
Deprivation (measured using TDI) is inversely related to social status. 
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2.3.5 Patient journey 
As defined in the preface to this thesis, the patient journey reflects the 
progression of a patient through the healthcare system, starting from their 
first interaction, including all referrals, and ending with completion of their 
treatment. Figure 2.3 shows a theorised patient journey for patients receiving 
treatment or care for colorectal cancer, with reference to the clinical 
pathways produced by the National Institute for Health and Care Excellence 
(NICE) (NICE, 2017a). Entry points to the healthcare system are outlined in 
red. 
Patients may visit their GP with concern regarding symptoms, and may then 
be referred for a specialist appointment, which is required to take place 
within two weeks (NICE, 2017b). Alternatively, patients may receive a 
positive result following screening. Screening is included to ensure the 
patient journey reflects current experience, although it was not available in 
the United Kingdom until 2006, as discussed in section 3.2.2, thus none of 
the patients in the example dataset described were diagnosed via the 
screening route. Emergency admission of patients with worsening symptoms 
may lead to immediate surgery, which may be a risk factor for poor 
outcomes, as also discussed in section 3.2.2. 
Once diagnosed, patients may undergo further investigation to establish the 
spread of the disease, i.e. to determine the stage of the tumour. Treatment 
options are then discussed, and a combination of different treatments may 
be performed, based on both patient and tumour characteristics. Patients 
are followed up to either monitor tumour recurrence (where curative surgery 
was performed), or to receive palliative care (where the tumour was 
considered inoperable). 
Not all aspects of the illustrated patient journey are reflected in the example 
dataset. In this dataset, patients are identified at their diagnosis visit and 
followed up as they receive specialist advice or treatment. Detailed 
treatment information is not included, nor do the data reflect ongoing 
monitoring or palliative care received. 




Figure 2.3 Theorised patient journey through the healthcare system for 
patients receiving treatment or care for colorectal cancer; entry points 
outlined in red 
  
Patient visits GP with 
symptoms 
Positive screening result 
Patient referred for specialist 
appointment within 2 weeks 
Further investigation to establish spread of disease (e.g. CT scan) 
Detailed examination and diagnostic investigation (e.g. colonoscopy) 
Discussion of treatment options 
Treatment: combination of surgery (for local cancers) and / or other 
treatments as appropriate (e.g. chemotherapy) 
Follow-up tests to monitor 
potential disease recurrence 
after curative surgery (e.g. CT 
scan, measurement of 
biomarkers) 
Palliative care for incurable 
disease (e.g. pain relief) 
Emergency admission 
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2.4 Modelling approach to the research questions 
2.4.1 Appropriate analytical method 
Three research questions were posed in section 1.2.3, representing 
common enquiries that may be made of observational health data, with each 
question relating to a different aspect of the patient journey within the 
healthcare system. The questions are: 
(1) What is the relationship between a health exposure and outcome, and 
what other factors affect this relationship? 
(2) How does the performance of a healthcare provider vary after 
accommodating patient differences? 
(3) Can causal provider-level covariate effects be identified, after 
accommodating patient differences? 
Two-level MLLC modelling is utilised to answer these questions, with 
patients at the lower level of the hierarchy and healthcare providers (i.e. 
NHS Trusts) at the upper level. Multiple discrete latent classes are therefore 
identified at both levels. MLLC analysis is supported by an overarching latent 
variable framework, as introduced in section 1.4.1, that is inherently causal, 
and that can accommodate the separation of modelling for causal inference 
and modelling for prediction (i.e. differential selection). This comprehensive 
approach can thus be retained to answer all three research questions. As 
introduced in section 2.2.2, patient classes are determined according to 
similarities in characteristics, while Trust classes are determined either 
according to similarities or differences, dependent on the research question. 
This leads to two broad modelling strategies as described in section 2.4.3. 
The use of unique features within latent variable methodologies, as 
described in section 2.2.4.3, can be exploited to ensure a precise model 
configuration is adopted for each research question. Detailed 
parameterisations are described in section 2.4.4.  
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2.4.2 Data challenges 
Generic data challenges inherent within observational health data were 
introduced in section 1.2.2, and the traditional approach to these challenges 
was discussed in section 1.3.3. Unlike traditional regression approaches, 
MLLC analysis is fully able to address these challenges, which are 
discussed here with specific reference to the example dataset. 
Structure and non-homogeneity 
Data complexity is incorporated through a multilevel structure. Within the 
example dataset, different groups of patients attend different diagnostic 
centres (i.e. NHS Trusts), dependent on factors such as their area of 
residence. Patients are thus clustered within Trusts. 
The ability to assign latent classes to subgroups of observations allows for 
non-homogeneity at both levels of a MLLC model. Assumptions of normality 
and independence, as required for MLM, are not necessary when discrete 
latent classes are incorporated in place of continuous latent variables. In the 
example dataset, neither patients nor Trusts are likely to be homogeneous, 
for reasons explored in sections 1.2.2 (considering variability in patient and 
provider characteristics), and 1.2.3 (considering differential selection). 
Observed and unobserved variation 
While traditional regression approaches cannot accommodate uncertainty in 
model covariates, latent variable techniques allow for covariates that may be 
measured with error, or that have missing values, to be modelled as class 
predictors within the class membership part of the model. They may 
therefore be removed from the regression part of the model, thus improving 
precision and minimising bias due to uncertainty or to measurement error. 
Within the example dataset, stage at diagnosis suffers from missing values 
and, although these values are categorised, variation remains due to 
imprecise classification. Variability in the quality of pathology can lead to 
patients being classified incorrectly (Quirke and Morris, 2007); classification 
is thus prone to error. There is also potential bias in the grading of stage as 
the quality of pathology can sometimes lead to patients being ‘understaged’ 
(i.e. incorrectly assigned an earlier stage at diagnosis due to unidentified 
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lymph node metastases) (Morris et al., 2007a). For example, for the tumour 
to be classified at stage C, lymph nodes must be involved. The number of 
lymph nodes retrieved, however, is highly variable and if few nodes are 
available, this limits the likelihood of identifying node involvement, so the 
tumour may instead be classified at stage B. This has an impact on the 
treatment received, as patients diagnosed with a stage B tumour may not 
receive beneficial chemotherapy (Morris et al., 2007b). The recording of 
stage has also changed somewhat over time. If a tumour is initially graded at 
stage C, but clinical evidence of metastatic disease is then found, the policy 
in the NYCRIS region at time of data extraction was to ‘up-stage’ the tumour 
to stage D. This may not have occurred in previous years, leading to 
potential bias. Stage should therefore be included as a class predictor, when 
modelling for causal inference, in order to minimise bias due to 
measurement error. Use of a latent variable modelling approach may help to 
incorporate the additional uncertainty of having a missing stage category.  
Considering unobserved variation, the latent constructs of a MLLC model 
implicitly accommodate unmeasured differences across observations, 
thereby minimising bias due to unmeasured covariates. The example 
dataset contains only a small selection of possible variables that may be 
associated with survival from colorectal cancer. As such, its use within 
traditional modelling techniques may introduce bias if, for example, matching 
was undertaken on limited covariates. The MLLC approach does not have 
this disadvantage. 
Complex observed relationships 
Variables that may either moderate or mediate the main exposure-outcome 
relationship may be modelled as class predictors, thus removing them from 
the regression part of the model and minimising exacerbated bias due to 
measurement error (i.e. interaction terms are not required for effect 
modifiers) or due to the reversal paradox. Traditional regression approaches 
cannot accommodate these complex observed relationships without the risk 
of invoking bias. 
Previous studies investigating the association between survival from 
colorectal cancer and known potential risk factors, such as age, sex and 
- 58 - 
SES, have typically considered stage of disease at diagnosis (where 
available) as a potential confounder, for example Morris et al. (2011) and 
Downing et al. (2013). However, a higher level of socioeconomic deprivation 
may result in patients presenting with a more advanced stage at diagnosis 
(Jones et al., 2008; McPhail et al., 2015), which may also be associated with 
survival (Morris et al., 2011; Downing et al., 2013). SES therefore causally 
precedes stage at diagnosis and consequently stage does not qualify as a 
genuine confounder if causal inference modelling of the SES-survival 
relationship is required; it is a mediator. As such, if modelling for causal 
inference is required, stage should be removed from the regression part of 
the MLLC model. 
Covariate relationships are explored in further detail in sections 3.2.1 and 
3.2.2.  
2.4.3 Broad modelling strategies 
Two broad modelling strategies are sought. They are the basis for the 
construction of detailed modelling configurations that are unique for each 
research question, yet standard in approach.  
(i) Grouping together providers in terms of similar patient characteristics 
This yields provider-level latent classes that are homogeneous with respect 
to patient outcome and its relationship with model covariates. The focus is 
on patients and each provider-level class may contain differing proportions 
of patient classes; heterogeneity is thus accounted for at the provider level. 
This strategy allows for the exposure-outcome relationship to be determined 
at the patient level and is therefore utilised to answer research question (1). 
(ii) Grouping together providers in terms of different patient characteristics 
This yields provider-level latent classes that are heterogeneous with respect 
to patient characteristics. The focus is on providers and each provider-level 
class will contain the same proportions of patient classes, i.e. the provider 
classes are effectively patient casemix ‘adjusted’. These classes must differ 
with respect to non-patient-level characteristics, however, in order to be 
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separate classes; differences will be due to provider-level patient outcome 
differences, which in turn are due to underlying organisational factors. This 
strategy allows the researcher to assess difference in performance across 
providers, based on underlying provider-level factors rather than by patient 
casemix, and is therefore utilised to answer research questions (2) and (3). 
2.4.4 Detailed parameterisations 
Patient-class intercepts, covariates, class sizes and error variances can be 
either provider-class dependent or independent, as discussed in section 
2.2.4.3. An overview of the specific parameterisations necessary to answer 
the research questions is given here, with full consideration within the 
following chapters. 
Intercepts. For all research questions, class-independent intercepts are 
adopted to enable identical contrasts to be made amongst patient classes 
within provider classes, in a relative sense, i.e. the patient classes with ‘best’ 
and ‘worst’ mortality differ in relative terms identically for each provider class. 
If class-dependent intercepts were adopted instead, contrasts in survival 
amongst patient classes in one provider could, relatively speaking, mean 
different things according to which provider class is considered. In both 
instances, provider classes may differ in their overall outcome. It is helpful 
for illustration and ease of interpretation, though not essential, to adopt 
class-independent model intercepts. In other circumstances (especially for 
different datasets), class-dependent intercepts may be more appropriate. 
Covariate effects. Initially, class-dependent covariate effects are adopted, to 
allow for random effects, although this may be switched to class 
independent for parsimony (if there is little evidence that a parameter value 
varies across the classes), or to avoid causal circularity between a covariate, 
mediator and outcome. A combination of configurations is possible; 
parameter estimates may be constrained to take one value over a number of 
classes and another value over the remaining classes. Although technically 
possible, a priori knowledge of how the data are generated is essential 
before utilising such complex model structures. 
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Class sizes. Modelling strategy (i) requires that patient-class sizes are 
provider-class dependent, so that the provider classes are grouped by their 
similarities with respect to patient outcome and its relationship with model 
covariates. Each provider class may therefore be made up of differing 
proportions of patient classes. Modelling strategy (ii) requires that patient-
class sizes are provider-class independent; thus generating heterogeneous 
latent classes at the provider level and so accounting for differential 
selection. 
Error variance. This is not applicable to research questions (1) or (2) as a 
binary outcome only is considered. For research question (3), class-
independent error variances are adopted, based on the choices made during 
the simulation approach (as detailed in section 5.2). Patient classes are thus 
constrained to be homoscedastic, i.e. the variance of the outcome is fixed 
across the patient classes.  
Class-dependent error variances may be more appropriate for other 
datasets, for example when utilising an observational dataset where the 
outcome may be expected to vary differently for different patient subgroups. 
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Chapter 3 
Research Question (1); Focus on Patients  
3.1 Introduction 
Chapters 1 and 2 explored the overarching latent variable approach to 
modelling complex observational health data, making contrasts with 
traditional techniques with respect both to the comprehensive framework 
and to the generic data challenges. Distinctive aspects of the latent variable 
methodology were thoroughly examined, including: the use of discrete latent 
classes at all levels of a hierarchy (e.g. to account for heterogeneity), class 
predictors (e.g. to minimise bias due to effect modifiers or mediators), 
inactive covariates (e.g. to aid interpretability without affecting the primary 
relationship), and class-dependent or class-independent features (e.g. to 
precisely define model parameter requirements). 
Three research questions were presented, reflecting queries commonly 
made within observational health data, with each question concerning a 
different aspect of the patient journey within the healthcare system. MLLC 
modelling was identified to provide a suitable approach to answer all of the 
research questions; rationale (considering the overarching framework and 
generic data challenges), broad modelling strategies and detailed 
parameterisations were presented in Chapter 2, and these specifications will 
be explored further in Chapter 3, with relevance to research question (1): 
(1) What is the relationship between a health exposure and outcome, and 
what other factors affect this relationship? 
The example dataset was also introduced, and explored in detail in Chapter 
2, including specific data challenges (as examples of the generic data 
challenges discussed in section 1.2.2) that must be addressed within the 
modelling approaches to the research questions: data are hierarchical, with 
non-homogeneous groups at patient and Trust levels, there is variation due 
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to measurement error and unmeasured variables, and covariates have a 
complex observed relationship structure. 
The latent variable approach to this research question is to account for 
heterogeneity at the provider level in order to make causal inference at the 
patient level. Careful assessment of the relationship between model 
covariates is essential to ensure appropriate adjustment for confounders. 
For example, as identified in section 2.4.2, stage at diagnosis is thought to 
be a mediator of the primary exposure-outcome relationship, and is 
measured with error. 
Certain simplifications are implemented, as discussed in section 1.2.5; a 
binary outcome variable is utilised (i.e. whether or not the patient survived at 
three years following diagnosis) instead of a continuous survival measure, 
and the cross-classified effect of the small-area level is ignored. 
Section 3.2 summarises the data and methods relevant to this research 
question, including construction of a DAG, consideration of related literature, 
the modelling approach, parameterisation, and optimum model construction. 
MLM is identified as the traditional comparison; assessment of MLM 
assumptions can also be made. 
Section 3.3 presents all results, starting with the MLM analysis, through 
MLLC model construction to interpretation of the results for the latent 
classes at both patient and Trust levels, making appropriate contrasts with 
MLM.  
Section 3.4 provides a discussion of the methods and results. 
This chapter contains work based on two publications (Harrison et al., 2012; 
Harrison et al., 2013). 
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3.2 Data and methods 
3.2.1 Example Dataset 
The example dataset described in Chapter 2 is utilised, containing data on 
24,640 patients diagnosed with colorectal cancer between 1998 and 2004; 
12,708 patients (51.6%) died within three years of diagnosis. A literature 
search to identify factors that have been shown to impact on survival within 
this disease area is described in section 3.2.2. Interest lies in the association 
between SES (measured in these data using the TDI) and three-year 
mortality; the research question specific to these data is thus: 
(1) What is the relationship between SES and three-year mortality from 
colorectal cancer, and what other factors affect this relationship? 
As identified in section 2.4.2, these data are hierarchical with patients at the 
lower level and NHS Trusts at the upper level, and neither patient nor Trust 
groups are likely to be homogeneous. Stage at diagnosis suffers from 
missing data, imprecise classification, and may also lie on the causal path 
between SES and survival.  
A DAG, as introduced in section 1.2.3, is essential to assess the key 
covariate relationships. There are, however, many ways to construct a DAG, 
based on differing theorised relationships between covariates; thus, a range 
of alternatively specified DAGs are presented in figures 3.1, 3.2 and 3.3.  
Figure 3.1 illustrates a simplified approach. Stage at diagnosis is considered 
to lie on the causal path between SES and survival (represented in these 
data as three-year mortality); stage is therefore operating as a mediator of 
the exposure-outcome relationship. If included as a covariate in the 
regression part of a model, bias may be introduced due to the reversal 
paradox, as discussed in section 1.3.3. Age at diagnosis and sex are shown 
as competing exposures, with stage at diagnosis also potentially mediating 
their relationships with survival.  
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Figure 3.1 DAG (1) showing the inferred causal relationships amongst key 
variables at the population level  
 
Figure 3.2 also includes whether or not the patient receives treatment 
(curative only, in these data), which is dependent upon stage at diagnosis, 
as discussed in section 2.4.2. Treatment may then also affect survival, as 
will be described in section 3.2.2.  
 
Figure 3.2 DAG (2) showing the inferred causal relationships amongst key 
variables at the population level  
 
Solid lines indicate causality, while 








Solid lines indicate causality, while 
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Figure 3.3 additionally shows a causal relationship between age at diagnosis 
and SES. Age at diagnosis is a complex measurement, as it comprises risks 
due both to the time period within which the patient was born and to the 
patient’s age at which the tumour was diagnosed; differences in age at 
diagnosis have been seen to impact upon socioeconomic inequalities in 
colorectal cancer survival (Nur et al., 2015). 
 
Figure 3.3 DAG (3) showing the inferred causal relationships amongst key 
variables at the population level  
 
While any one of many DAGs, including those illustrated, may be 
appropriate for these data, the DAG shown in figure 3.1 is chosen for the 
purposes of this analysis, to simplify the inferred covariate relationships and 
thus demonstrate the utility of the latent variable techniques. 
3.2.2 Literature review 
A literature review is performed to assess risk factors associated with 
survival (or mortality) from colorectal cancer, with specific focus on the 
relationship between socioeconomic deprivation (quantified in these data as 
SES), stage and survival. Much research has been performed within this 
field and this search is not designed to cover it all, but will instead highlight 
the key findings and the methodological approach commonly taken when 
Solid lines indicate causality, while 
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answering this sort of research question. There are two parts to the search: 
(i) determination of the risk factors associated with survival from colorectal 
cancer; and (ii) exploration of the specific association between deprivation 
and stage at diagnosis (regardless of health outcome or other risk factors). 
The results are combined and summarised. 
Medline is selected as the most appropriate database, and a combination of 
keyword searching and medical subject headings (MeSH) are used. The full 
literature search strategy can be seen in Appendix B. Consideration of 
colorectal cancer, survival and risk factors yields 17,853 results while focus 
on socioeconomic deprivation and stage at diagnosis yields 343; these are 
combined to yield 18,018 articles. A restriction to UK articles was thus 
applied, and will ensure generalisability to the example dataset. There is no 
expectation that risk factors will differ across countries, although there may 
be differences in how individuals within the countries are affected by these 
factors (Ait Ouakrim et al., 2015). With further limitations to include only 
articles with abstracts, in English, concerning humans and published within 
the last ten years, 263 results were found. Excluding duplications, 247 
articles remain for consideration. Abstracts were initially reviewed for 
relevance, and additional articles were sourced from citations. 
Screening for colorectal cancer was introduced into the United Kingdom in 
2006, with nationwide availability by 2010, and all individuals aged over sixty 
are eligible (over fifty in Scotland). Uptake is around 54%, on average (von 
Wagner et al., 2011); and lower uptake is associated with younger age, male 
sex and a higher level of deprivation (Mansouri et al., 2013). There is also a 
low uptake in ethnically diverse areas (von Wagner et al., 2011), and for 
obese individuals (Beeken et al., 2014). Since its introduction, the screening 
programme has led to earlier stage diagnoses (Morris et al., 2012; Logan et 
al., 2012; Rees and Bevan, 2013), and patients diagnosed with tumours 
detected by screening have been seen to have better overall survival rates 
(Morris et al., 2012; Gill et al., 2014) compared with patients with non-
screen-detected tumours, and after adjustment for stage at diagnosis. 
Further, screen-detected tumours are more likely to be treated curatively 
(Morris et al., 2012). So far, screening is estimated to have reduced mortality 
due to colorectal cancer by 18% (McClements et al., 2012). 
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Diagnosis or treatment centre may have an impact on survival, due to the 
volume of procedures performed, although study findings vary. Overall 
survival rates have been seen to improve when considering larger-volume 
hospitals (Borowski et al., 2010). Some studies observe improved 
postoperative mortality for high-volume surgeons in elective surgery 
(Borowski et al., 2007; Borowski et al., 2010), while others find no 
association (Burns et al., 2013), nor is there an association seen for 
emergency surgery (Borowski et al., 2007; Faiz et al., 2010). 
Specialist surgical treatment improves survival from elective surgery both 
post-operatively (Brewster et al., 2011; Oliphant et al., 2013a; Oliphant et al., 
2014b) and within five years (Oliphant et al., 2013a; Oliphant et al., 2014b), 
with those treated by a specialist more likely to undergo surgery in a high-
volume hospital (Oliphant et al., 2014b). 
Medication may also have an impact, with use of statins (Cardwell et al., 
2014) or aspirin (Walker et al., 2012; McCowan et al., 2013) seen to reduce 
mortality. Vitamin D use is inconclusive (Zgaga et al., 2014; Jeffreys et al., 
2015). 
Regarding socio-demographic factors, there is a clear relationship between 
older age and higher rates of mortality, with older patients more likely to die 
within thirty days of diagnosis (Brewster et al., 2011; Downing et al., 2013; 
McPhail et al., 2013) (especially if they do not undergo an operation 
(Sheridan et al., 2014)), within thirty days of operation (Widdison et al., 2011; 
Faiz et al., 2011; Morris et al., 2011; Ahmed et al., 2014), and longer term 
(Faiz et al., 2011; Ahmed et al., 2014). Elderly patients are also more likely 
to present as an emergency (McPhail et al., 2013; Downing et al., 2013; 
Oliphant et al., 2014a), which is itself a risk factor for death in the early post-
operative period (Brewster et al., 2011; Morris et al., 2011; Oliphant et al., 
2014a; Askari et al., 2015), longer term (Oliphant et al., 2014a), and 
particularly so for an elderly population (Ihedioha et al., 2013). Patients 
presenting as emergencies are also more likely to receive non-specialist 
surgery (Oliphant et al., 2014a). Rates of emergency surgery are also 
decreasing in the screening age group (Hwang et al., 2014). 
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There are gender disparities in survival, with improved survival for younger 
women compared with younger men (Koo et al., 2008; Hendifar et al., 2009), 
and greater post-surgery mortality for males (McArdle et al., 2003). There 
are suggestions that tumour progression may be slowed by exposure to 
oestrogen (Arem et al., 2015), although consideration is also given to the 
discrepancy between male and female participation in screening (Mansouri 
et al., 2013). 
Ethnic minorities have longer diagnostic and referral intervals (Martins et al., 
2013), although referral route itself has not been shown to have an impact 
on survival (Zafar et al., 2012; Schneider et al., 2013). While surgical delays 
may affect survival (Nachiappan et al., 2015), the effect is not linear 
(Redaniel et al., 2014). South Asians, however, are seen to have an overall 
reduced mortality compared with all other ethnicities (Maringe et al., 2015). 
The relationship between socioeconomic deprivation and survival varies. 
Some studies report increasing deprivation as a significant predictor of 
mortality, after adjusting for other factors, post-operatively (Morris et al., 
2011), in the first year following diagnosis (Downing et al., 2013), and longer 
term (Lejeune et al., 2010); others find this effect only in univariable 
analyses (Smith et al., 2006; Bharathan et al., 2011; Brewster et al., 2011; 
Oliphant et al., 2013b; Oliphant et al., 2014a), while others find no effect at 
all (Nur et al., 2008; McMillan and McArdle, 2009; Nicholson et al., 2011). 
Patients living in more deprived areas are more likely to present for 
emergency surgery rather than elective (Bharathan et al., 2011; Oliphant et 
al., 2013b; McPhail et al., 2013) (although they are also more likely to have a 
specialist surgeon (Oliphant et al., 2013b)), to receive palliative treatment 
rather than curative (Bharathan et al., 2011; Oliphant et al., 2013b; Paterson 
et al., 2014), and to present with a more advanced stage at diagnosis (Jones 
et al., 2008; McPhail et al., 2015). Higher levels of socioeconomic 
deprivation are also associated with more adverse comorbidities (Bharathan 
et al., 2011; Oliphant et al., 2013b) and longer lengths of stay in hospital 
(Smith et al., 2006).  
Socioeconomic deprivation may reflect how patients vary in terms of lifestyle 
factors such as diet and smoking (Davy, 2007; Macdonald et al., 2007). 
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Smoking is associated with increased mortality from colorectal cancer for 
males (Morrison et al., 2011), and there is some evidence that a healthy diet 
can improve survival (Norat et al., 2015). Factors such as body mass index 
(BMI), diabetes, blood pressure and physical activity are shown to have no 
effect on survival in a large-scale cohort study on males (Morrison et al., 
2011), nor is an impact seen for BMI in a large-scale cohort study on 
females (Reeves et al., 2007). Diabetes, however, is associated with 
increased all-cause mortality after five years following a diagnosis of colon 
cancer (Walker et al., 2013). 
Worse survival outcomes are seen for a more advanced stage of disease at 
diagnosis, with associations for early deaths following diagnosis (Brewster et 
al., 2011; Downing et al., 2013; McPhail et al., 2013; McPhail et al., 2015), 
particularly within an older population (Sheridan et al., 2014), for longer-term 
mortality (Nur et al., 2008; McMillan and McArdle, 2009), and for post-
operative mortality (Morris et al., 2011; Nicholson et al., 2011; Ihedioha et 
al., 2013). Some studies do not report an effect of stage, however, after 
adjusting for other risk factors (Smith et al., 2006; Bharathan et al., 2011; 
Brewster et al., 2011; Oliphant et al., 2013b; Oliphant et al., 2014a). Late 
stage disease has also been linked to a higher likelihood of emergency 
surgery (McPhail et al., 2013; Askari et al., 2015). Differences in stage at 
diagnosis partly explain international differences in survival rates (Maringe et 
al., 2013). 
Of the studies that account specifically for both socioeconomic deprivation 
and stage, none make explicit mention of, or accommodation for, potential 
mediation. Most include both deprivation and stage (among other variables) 
within a multivariable regression model (Smith et al., 2006; Nur et al., 2008; 
Lejeune et al., 2010; Morris et al., 2011; Bharathan et al., 2011; Brewster et 
al., 2011; Downing et al., 2013; Oliphant et al., 2013b; Oliphant et al., 
2014a), while others exclude deprivation from multivariable analysis due to 
statistical non-significance within univariable analysis (McMillan and 
McArdle, 2009; Nicholson et al., 2011). Smith et al. (2006) recognise that the 
effect of deprivation is mediated on inclusion of tumour grade into the model, 
however no modifications are made to the analysis. Brewster et al. (2011) 
reflect that further research is required to determine any mediating effects 
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between deprivation and early death, but do not consider mediation within 
the analysis. 
Only three of these studies used multilevel analysis (Smith et al., 2006; 
Morris et al., 2011; Downing et al., 2013), considering postcode districts, 
NHS Trusts, or cancer registries as the upper level for analysis. The 
remainder do not account for the potential multilevel structure of the data.  
3.2.3 MLLC approach to the data 
As discussed in section 2.4.1, MLLC modelling is the preferred analytical 
method to answer the research questions. This approach lies within the 
overarching latent variable framework, which allows modelling both for 
causal inference and for prediction at all levels of a hierarchy. For research 
question (1), causal inference is required at the patient level to determine the 
relationship between SES and survival, while variation at the Trust level is 
essentially ‘nuisance’, i.e. heterogeneity must be accounted for, but no 
inference is required. Broad modelling strategy (i), introduced in section 
2.4.3, is therefore utilised. Thus, both patient and Trust classes are grouped 
together in terms of similar patient characteristics, and latent classes at both 
levels are therefore homogeneous with respect to the relationship between 
patient outcome and model covariates. In this manner, the exposure-
outcome relationship may be determined within the patient-level classes, 
while heterogeneity is accommodated at the provider level. 
The variables available for analysis within the example dataset are 
previously summarised in table 2.3, while the theorised covariate 
relationships are shown in the DAG in figure 3.1. Table 3.1 reiterates the 
available variables and specifies which are included, and how they are 
modelled, within the MLLC analytical approach to this research question. 
As shown in table 3.1, the relationship between SES and survival is 
investigated within the regression part of the model, with adjustment for sex 
and age at diagnosis (centred around the study mean of 71.5 years to 
improve model precision). An age-squared term is also included as age is 
found to have a non-linear relationship with survival; the inclusion of age-
squared allows for an adjustment to the linear effect of age and hence 
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additional accommodation of the non-linear relationship of age as a 
competing exposure. 







Deprivation Deprivation Regression 
Sex Sex Regression 
Age at diagnosis 
Age at diagnosis Regression 
Age-squared Regression 
Stage at diagnosis Stage at diagnosis Class predictor 
ICD-10 ICD-10 Inactive covariate 
Laterality Laterality Inactive covariate 
Treated Treated Inactive covariate 
Deprivation is a measure of SES, measured in these data using TDI. 
 
Stage at diagnosis (coded A to D for increasing severity and missing values 
coded X), as a mediator of the primary relationship, is instead included as a 
class predictor. This removes stage from the regression part of the model 
and hence minimises bias due to the reversal paradox. As stage is also 
measured with error, its inclusion as a class predictor, rather than as a 
standard covariate, also avoids any exacerbated bias due to product 
interaction terms. The latent constructs may also incorporate the additional 
uncertainty due to missing data within the stage variable, although as 
discussed in section 1.2.5, methods to address missing data should 
generally be utilised (although not the focus of this thesis). The resultant 
latent classes may thus be identified by categories of stage, for example 
‘early’ or ‘late’ stage disease at diagnosis. 
The ICD-10 diagnosis code for the tumour, its laterality (position in the 
body), and whether or not curative treatment is received are included as 
inactive covariates, in order to examine their correlation with stage of 
disease, but to remove them from the SES-survival relationship. 
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3.2.4 Parameterisation 
Detailed parameterisations, introduced in section 2.4.4, are summarised 
here with respect to research question (1).  
Intercepts. Patient-class intercepts are designated class independent with 
respect to Trust classes; identical contrasts can therefore be made amongst 
patient classes regardless of which Trust class is considered. Therefore, the 
relative difference between patient classes with, for example, the ‘best’ and 
‘worst’ mortality, remains constant across Trust classes. 
Covariate effects. For SES, patient-class effects are designated class 
independent with respect to Trust classes, to avoid the causal circularity that 
may be introduced by means of the relationship between SES, stage at 
diagnosis, and three-year mortality (see section 2.2.4.1). Thus, SES has the 
same parameter value for each Trust class, and hence the SES-survival 
relationship is constrained to be the same within each patient class. 
For all other covariates, this constraint is relaxed initially and thus patient-
class effects are designated class dependent. If, however, parameter values 
are not seen to vary across the patient classes, this may be switched to 
class independent for parsimony. 
Class sizes. Patient-class sizes are designated class dependent with respect 
to Trust classes, as required for modelling strategy (i), thus accommodating 
heterogeneity at the Trust level. Trust classes may therefore comprise 
differing proportions of each patient class. 
Error variance. This is not applicable for a binary outcome. 
3.2.5 Optimum model 
Optimum model construction follows the process suggested in section 2.2.6, 
whereby a continuous latent variable is initially adopted at the Trust level 
while the preferred number of latent classes are identified at the patient 
level. Log-likelihood statistics (LL, BIC and AIC) and CE are assessed for 
guidance, and the optimum number of patient classes is chosen with 
consideration of both parsimony and interpretability. The continuous latent 
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variable at the upper level is then switched to categorical to identify the 
preferred number of latent classes at the Trust level. The same criteria are 
again considered in selection of the optimum number of Trust classes. 
Model-evaluation statistics determined during model construction are 
presented in section 3.3.3. 
3.2.6 Bootstrapping 
Bootstrapping is a sampling technique, where random samples are drawn 
from a population and similarly modelled to assess the variability around an 
estimate. A useful introduction is provided by Efron and Tibshirani (1993). 
200 bootstrapped datasets are generated, with replacement and with 
samples selected from within each Trust. Each is similarly analysed using 
the chosen MLLC model in order to generate 95% confidence intervals (CIs) 
for the model summary statistics and the model class profiles at both the 
patient and the Trust levels. 
Model summary statistics (size and mortality statistics) are calculated for 
each of the bootstrapped datasets, and CIs are generated using percentile 
confidence intervals (2.5% to 97.5%). 
For model class profiles, means or proportions (as appropriate) are 
calculated for each of the model covariates (SES, age at diagnosis and sex) 
and each of the class predictors (stage at diagnosis, whether treated, tumour 
site and laterality), based on their probabilistic assignment to each class. CIs 
are then calculated in the same manner as for the model summary statistics. 
CIs for the model covariates in the regression part of the model at the patient 
level  are determined directly from MLLC analysis of the example dataset. 
3.2.7 Traditional comparison 
MLLC modelling is compared with a traditional MLM approach, introduced in 
section 1.3.2, where hierarchical data are modelled with patients at the lower 
level and Trusts at the upper level. Within MLM, a continuous latent variable 
is incorporated at the Trust level, and parametric assumptions are made: the 
variation surrounding both intercepts and slopes is assumed to be normally 
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distributed, and independent of the variation in the individual measurements. 
As discussed in section 1.3.3, this may not be tenable in observational 
health data as neither patients nor Trusts are randomly assigned. These 
upper-level assumptions may also be evaluated, as model results will 
indicate whether or not a continuous latent variable at the Trust level is 
sufficient to model appropriately these data. 
A single patient class is used within MLM therefore heterogeneity at the 
patient level cannot be incorporated; the same model is therefore applied to 
all patients and to all Trusts. Again, model results will indicate whether or not 
this is sufficient for these data. 
SES, age at diagnosis, age-squared and sex are included as covariates in 
the regression model. Stage at diagnosis cannot be included, for reasons 
explored in section 3.2.3, and MLM does not have the capacity to model 
covariates as class predictors. The direct comparison between methods 
therefore is between use of MLLC modelling, including stage at diagnosis as 
a class predictor, versus use of MLM excluding stage entirely. 
MLM analysis is performed on the original example dataset only, i.e. no 
bootstrapped datasets are reanalysed. Interest lies in the comparison 
between estimates of the effect of model covariates, and CIs are generated 
for the covariate estimates directly from analysis. Bootstrapping would 
provide CIs for the model statistics only in the MLM analysis, and so is not 
performed. 
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3.3 Results 
3.3.1 Outline 
Results are illustrated for both the MLM and MLLC analysis approaches. 
Table 3.2 summarises the variables contained within each model. Within the 
MLM, all variables are included as covariates within the regression model. 
For the MLLC model, variables may be included either as covariates with the 
regression model, as class predictors, or as inactive covariates, as 
discussed in section 3.2.3.   
Table 3.2 Comparison of variables included in MLM and MLLC model 




Deprivation Deprivation Regression 
Sex Sex Regression 
Age at diagnosis Age at diagnosis Regression 
Age-squared Age-squared Regression 
- Stage at diagnosis Class predictor 
- ICD-10 Inactive covariate 
- Laterality Inactive covariate 
- Treated Inactive covariate 
Deprivation is a measure of SES, measured in these data using TDI. 
 
3.3.2 MLM analysis 
Table 3.3 shows the results of the traditional MLM analysis, with a single 
patient class and a continuous latent variable at the Trust level. incorporating 
SES (measured in these data using the TDI), sex, age at diagnosis and age-
squared as covariates in a multilevel regression model.  Analysis is 
performed on the example dataset only, hence no CIs are available for 
model statistics. 
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Table 3.3 Results from MLM analysis; odds of death within three years 
Model Statistics Mortality 
Overall 51.6% 
Reference Group 49.3% 
Model Covariates 
OR of death within three years 
(95% CI) 
Deprivation (per SD more) 1.18 (1.15, 1.21) 
Female 0.87 (0.83, 0.92) 
Age (per 5 years older) 1.31 (1.30, 1.33) 
Age squared (per 5 years older) 1.006 (1.005, 1.007) 
OR – Odds Ratio, CI – Confidence Interval, SD – Standard Deviation;  
LL = -16,081; Deprivation (measured using TDI) is inversely related to 
social status. 
Overall 12,708 patients (51.6%) died within three years. The reference group 
comprises males of mean age (71.5 years), diagnosed with stage A 
colorectal cancer and attributed a Townsend deprivation score of zero. 
Substantial and statistically significant associations are found between 
increasing deprivation and increased odds of death (OR=1.18, 95% CI 1.15 
to 1.21 per SD increase in Townsend deprivation score); between female 
gender and decreased odds of death (OR=0.87, 95% CI 0.83 to 0.92); 
between increasing age and increased odds of death (OR=1.31, 95% CI 
1.30 to 1.33 per 5-year increase in age); and between increasing age-
squared and increased odds of death (OR=1.006, 95% CI 1.005 to 1.007). 
All covariates included in the analysis are identified as competing exposures 
as per the DAG described in figure 3.1 of section 3.2.1. 
3.3.3 Building the MLLC model 
As discussed in section 3.2.5, a continuous latent variable is initially adopted 
at the Trust level in order to determine the optimum number of patient-level 
classes. Table 3.4 summarises the model-evaluation criteria for the MLLC 
models with a continuous latent variable at the Trust level. 
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Table 3.4 Model-evaluation criteria for the patient classes in the MLLC 
models with a continuous Trust-level latent variable 
Patient 
Classes 





1 class -16,081 32,213 32,173 5 0.0% 
2 classes -12,122 24,396 24,275 15 8.8% 
3 classes -11,985 24,222 24,019 25 23.2% 
4 classes -11,975 24,305 24,021 35 33.2% 
5 classes -11,966 24,386 21,021 45 32.1% 
LL – Log Likelihood, BIC – Bayesian Information Criterion, AIC – Akaike Information 
Criterion, CE – Classification Error. 
Figure 3.4 displays the change in -2LL as the number of patient classes are 
increased. 
Figure 3.4 -2LL plot to determine the optimum number of patient classes in 
the MLLC modelling approach 
 
This approach suggests that three patient classes are optimum by both the 
BIC and AIC, while the LL shows model fit improving as the number of 
patient classes increase, as would be expected with increased model 
complexity and no penalty to invoke parsimony. After marked improvement 
in the LL from one to two patient classes, there is little further improvement 
for increased numbers of patient classes. Considering all other model-
evaluation criteria and model interpretation (to distinguish patient effects), 
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CE at the patient level is 23.2% for the three patient classes, which suggests 
that just under a quarter of observations are split across the classes, when 
considering probabilistic assignment, rather than these patients being 
assigned predominantly to a single patient class. 
The continuous Trust-level latent variable is then switched to categorical in 
order to determine the optimum number of Trust classes; three classes 
remain fixed at the patient level. Table 3.5 summarises the model-evaluation 
criteria for the MLLC models with a categorical latent variable at the Trust 
level, and three latent classes at the patient level.  
Table 3.5 Model-evaluation criteria for the Trust classes in the MLLC models 









Trust   
CE 
1 class -11,988 24,209 24,022 23 22.7% 0.0% 
2 classes -11,983 24,240 24,021 27 23.2% 10.6% 
3 classes -11,981 24,275 24,024 31 23.1% 10.1% 
4 classes -11,980 24,313 24,029 35 23.9% 12.9% 
5 classes -11,978 24,351 24,034 39 23.2% 17.8% 
6 classes -11,978 24,390 24,042 43 24.1% 21.4% 
7 classes -11,978 24,431 24,050 47 24.1% 30.5% 
8 classes -11,978 24,471 24,058 51 24.1% 36.5% 
LL – Log Likelihood, BIC – Bayesian Information Criterion, AIC – Akaike Information 
Criterion, CE – Classification Error. 
This approach suggests that one Trust class is optimum by the BIC, while 
two Trust classes are just optimum by the AIC. The LL shows improved 
model fit as the number of Trust classes are increased, as anticipated, 
although this is a more gradual improvement than that seen for the patient 
classes. More than one Trust class is required at the Trust level to explain 
Trust differences therefore further assessment is made of the LL.  
Figure 3.5 displays the change in -2LL as the number of Trust classes are 
increased. The -2LL value continues to improve up to that for five Trust 
classes. 
  
- 79 - 
Figure 3.5 -2LL plot to determine the optimum number of Trust classes in 
the MLLC modelling approach 
 
 
The traditional MLM approach with a continuous latent variable at the Trust 
level, extended to include three patient classes, shows a LL of -11,985, as 
seen in table 3.4. Results in table 3.5 show that this figure is surpassed by 
using two Trust classes. The -2LL plot, however, shows a gradual 
improvement in model fit with increasing numbers of Trust classes, although 
there is a suggestion that after five Trust classes, the improvement in model 
fit is minimal. Again considering parsimonious model-evaluation criteria and 
model interpretability (to model Trust variability and to improve patient-class 
estimates), the model with five Trust classes is chosen. 
CE at the patient level is unchanged from that seen with a continuous latent 
variable at the Trust level (23.2%), while CE at the Trust level is 17.8%. 
There is little concern regarding the value of the Trust CE, as upper-level 
classes are constructed primarily to account for heterogeneity at the Trust 
level, and thus improve estimates at the patient level. 
3.3.4 Patient classes 
Table 3.6 summarises the model summary statistics for the patient classes 
for the chosen three-patient, five-Trust-class MLLC model, where patients 
are apportioned to one of three groups, labelled post-hoc as ‘good 
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Table 3.6 Model summary statistics for the patient classes in the three-patient, five-Trust-class MLLC model 
Model Summary Statistics 
Good Prognosis Reasonable Prognosis Poor Prognosis 
% patients (bootstrapped 95% CI) 
Class size 38.2 (30.0, 48.9) 27.6 (20.8, 38.2) 34.2 (23.7, 37.0) 
Overall mortality 9.4 (2.2, 17.4) 58.3 (49.3, 72.9) 93.2 (92.0, 99.6) 
Reference group mortality 8.0 (0.1, 16.5) 57.8 (36.7, 78.6) 94.1 (90.8, 100.0) 
CI – Confidence Interval; the reference group comprises males, aged 71.5 years, classified as Stage A at diagnosis and attributed a Townsend 
deprivation score of zero; CIs from bootstrapping calculated using percentiles. 
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The good prognosis class contains 38.2% of cases of which 9.4% died 
within three years, compared with the reasonable prognosis class with 
27.6% of cases of which 58.3% died within three years, and the poor 
prognosis class with 34.2% of cases of which 93.2% died within three years.  
Tables 3.7 and 3.8 are to be interpreted together. Table 3.7 summarises the 
model covariate results for the patient classes in the same model, while 
table 3.8 summarises the mean (for Townsend deprivation score and age) or 
proportional values (for female gender) by patient class to aid the 
interpretation of covariate relationships with three-year mortality. 
The effect of SES is constrained to take the same value across all patient 
classes, as discussed in section 3.2.4, in order to avoid the causal circularity 
between SES, stage at diagnosis, and three-year mortality. SES is therefore 
clearly associated with increased odds of death (Townsend deprivation 
score OR=1.33, 95% CI 1.26 to 1.41) for all patient classes. Mean 
deprivation scores differ somewhat across the classes, with negative values 
indicating greater affluence while positive values indicate greater 
deprivation. Patients in the poor prognosis class generally live in more 
deprived areas (mean 0.09, 95% CI 0.00 to 0.16), compared with patients in 
the good prognosis class, who generally live in more affluent areas (mean -
0.17, 95% CI -0.23 to -0.10).  
The impact of sex differs substantially across the classes. In the good 
prognosis class, females have significantly decreased odds of death 
compared with males (OR=0.59, 95% CI 0.40 to 0.87), while in the 
reasonable and poor prognosis classes the association is less clear 
(reasonable prognosis OR=0.88, 95% CI 0.64 to 1.21; poor prognosis 
OR=1.05, 95% CI 0.83 to 1.32). The proportions of females differ somewhat 
across the classes, with fewer females in the poor prognosis class (42.7%, 
95% CI 41.1% to 44.1%) compared with the good and reasonable prognosis 
classes (good prognosis 44.0%, 95% CI 43.1% to 44.9%; reasonable 
prognosis 45.9%, 95% CI 44.4% to 47.8%), indicating that the majority of 






Table 3.7 Model covariate results for the patient classes in the three-patient, five-Trust-class MLLC model 
Model Covariates 
Good Prognosis Reasonable Prognosis Poor Prognosis Wald       
p-value OR of death within three years (95% CI) 
Deprivation (per SD more) 1.33 (1.26, 1.41) 1.33 (1.26, 1.41) 1.33 (1.26, 1.41) N/A 
Female 0.59 (0.40, 0.87) 0.88 (0.64, 1.21) 1.05 (0.83, 1.32) 0.031 
Age (per 5 years older) 1.46 (1.33, 1.60) 2.13 (1.69, 2.67) 1.46 (1.32, 1.62) 0.018 
Age squared (per 5 years older) 1.011 (1.007,1.015) 1.009 (1.003,1.015) 1.009 (1.005,1.012) 0.710 
OR – Odds Ratio, CI – Confidence Interval, SD – Standard Deviation; the Wald p-value indicates levels of statistical significance for differences in 
effect across the patient classes; CIs directly from analysis. Deprivation (measured using TDI) is inversely related to social status. 
Table 3.8 Model class profiles for the model covariates by patient class in the three-patient, five-Trust-class MLLC model 
Model Class profiles 
Good Prognosis Reasonable Prognosis Poor Prognosis 
mean (bootstrapped 95% CI) 
Deprivation -0.17 (-0.23, -0.10) -0.03 (-0.11, 0.12) 0.09 (0.00, 0.16) 
Age (years) 70.9 (70.7, 71.2) 72.6 (71.9, 73.5) 71.4 (70.7, 71.8) 
 % patients (bootstrapped 95% CI) 
Mean or proportion (95% CI) 
Mean or proportion (95% CI) 
Female 44.0 (43.1, 44.9) 45.9 (44.4, 47.8) 42.7 (41.1, 44.1) 
CI – Confidence Interval; CIs from bootstrapping calculated using percentiles. Deprivation (measured using TDI) is inversely related to social 
status. 
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Across all classes, older age is substantially and significantly associated with 
increased odds of death (good prognosis OR=1.46, 95% CI 1.33 to 1.60; 
reasonable prognosis OR=2.13, 95% CI 1.69 to 2.67; poor prognosis 
OR=1.46, 95% CI 1.32 to 1.62 per 5-year increase in age). Also across all 
classes, age-squared is substantially associated with increased odds of 
death (good prognosis OR=1.011, 95% CI 1.007 to 1.015; reasonable 
prognosis OR=1.009, 95% CI 1.003 to 1.015; poor prognosis OR=1.009, 
95% CI 1.005 to 1.012 per 5-year increase in age). The mean age (in years) 
also differs across the classes (good prognosis 70.9, 95% CI 70.7 to 71.2; 
reasonable prognosis 72.6, 95% CI 71.9 to 73.5; poor prognosis 71.4, 95% 
CI 70.7 to 71.8), indicating that patients in the reasonable prognosis class 
are, on average, older than the patients in either of the other two classes. 
Table 3.9 summarises the model class profiles for the patient classes in the 
same model.  
The profile of stage differs across the patient classes. The good prognosis 
class corresponds to early-stage diagnosis with 70.8% (95% CI 66.0% to 
75.1%) of the stage A and B patients compared with 36.3% (95% CI 8.2% to 
44.0%) in the reasonable prognosis class and 6.0% (95% CI 4.2% to 13.1%) 
in the poor prognosis class. The poor prognosis class corresponds to late-
stage diagnosis with 65.4% (95% CI 55.9% to 81.9%) of the stage D patients 
compared with 0.5% (95% CI 0.1% to 17.0%) in the reasonable prognosis 
class and 0.7% (95% CI 0.0% to 2.2%) in the good prognosis class. The 
reasonable prognosis class contains a large proportion of patients with 
missing values for stage (30.5%, 95% CI 20.6% to 47.1%). 
A higher proportion of patients are treated in the good prognosis class 
(98.8%, 95% CI 97.6% to 99.4%) compared to either the reasonable 
prognosis class (81.4%, 68.2% to 86.7%) or the poor prognosis class 
(68.3%, 65.9% to 72.6%), which may be partly due to their stage at 
diagnosis, as early-stage patients are more likely to receive curative 






Table 3.9 Model class profiles for the patient classes in the three-patient, five-Trust-class MLLC model 
Model Class Profiles 
Good Prognosis Reasonable Prognosis Poor Prognosis 
% patients (bootstrapped 95% CI) 
Stage A 23.2 (21.2, 25.1) 9.9 (0.2, 12.9) 0.0 (0.0, 2.1) 
Stage B 47.6 (44.8, 50.0) 26.4 (8.0, 31.1) 6.0 (4.2, 11.0) 
Stage C 26.5 (23.8, 28.4) 32.6 (26.9, 37.4) 17.2 (8.2, 19.7) 
Stage D 0.7 (0.0, 2.2) 0.5 (0.1, 17.0) 65.4 (55.9, 81.9) 
Missing stage 1.9 (0.0, 4.1) 30.5 (20.6, 47.1) 11.4 (0.2, 15.3) 
Patients receiving treatment 98.8 (97.6, 99.4) 81.4 (68.2, 86.7) 68.3 (65.9, 72.6) 
ICD-10 C18 (colon) 58.5 (57.5, 59.6) 56.0 (54.7, 58.0) 61.7 (60.6, 63.9) 
ICD-10 C19 (rectosigmoid junction) 10.8 (10.2, 11.6) 9.7 (9.2, 10.5) 10.8 (9.9, 11.6) 
ICD-10 C20 (rectum) 30.7 (29.7, 31.5) 34.3 (32.2, 35.7) 27.5 (25.3, 28.5) 
Tumour on left side 68.7 (68.0, 69.5) 68.2 (65.2, 69.0) 61.2 (59.4, 62.4) 
Tumour on right side 28.0 (27.1, 28.7) 25.2 (23.7, 26.7) 28.2 (27.0, 29.6) 
Tumour across both sides 3.3 (2.9, 3.7) 6.6 (5.6, 9.8) 10.6 (9.5, 11.6) 
CI – Confidence Interval; CIs from bootstrapping calculated using percentiles. Stage is modelled as a class predictor; patients receiving treatment, 
ICD-10 diagnosis code and laterality are modelled as inactive covariates. 
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There is some indication that the poor prognosis class contains a higher 
proportion of patients diagnosed with cancer of the colon (61.7%, 95% CI 
60.6% to 63.9%), compared with the good and reasonable prognosis 
classes (good prognosis 58.5%, 95% CI 57.5% to 59.6%; reasonable 
prognosis 56.0%, 95% CI 54.7% to 58.0%), and a lower proportion of 
patients diagnosed with cancer of the rectum (27.5%, 95% CI 25.3% to 
28.5%; versus good prognosis 30.7%, 95% CI 29.7% to 31.5%; and 
reasonable prognosis 34.3%, 95% CI 32.2% to 35.7%). This is also reflected 
in the results for laterality, as, while colon tumours may present on either 
side of the body, rectal tumours occur solely on the left side of the body.  
There is no clinical rationale why the poor prognosis class should contain a 
higher proportion of colon tumours compared with rectal tumours, or those 
split across both sides of the body, compared with left side only; rather the 
difference is likely to be by stage (Lee et al., 2013). 
The results seen for model covariates, in table 3.7, do not differ markedly 
from those obtained when different numbers of Trust classes are 
considered. Table 3.10 summarises the model covariate results for the three 
patient classes when considering between two and six Trust classes, with 
results grouped by model covariate for ease of interpretation. 
SES remains clearly associated with increased odds of death across all 
classes and in all models (Townsend deprivation score OR ranges from 1.33 
(95% CI 1.26 to 1.41, for five Trust classes) to 1.39 (95% CI 1.03 to 1.89, for 
six Trust classes)). 
Females maintain decreased odds of death in the good prognosis class (OR 
ranges from 0.53 (95% CI 0.18 to 1.57, for six Trust classes) to 0.60 (95% CI 
0.41 to 0.86, for three Trust classes)), although this only reaches statistical 
significance when considering three or five Trust classes. The association 
remains less clear, though consistent, in the reasonable and poor prognosis 
classes. 
Older age remains substantially and significantly associated with increased 
odds of death across all classes, which is again consistent across all 
models. Age-squared also remains substantially associated with increased 









Good Prognosis Reasonable Prognosis Poor Prognosis Wald       
p-value OR of death within three years (95% CI) 
Deprivation (per SD 
more) 
2 1.34 (1.16, 1.55) 1.34 (1.16, 1.55) 1.34 (1.16, 1.55) N/A 
3 1.34 (1.27, 1.41) 1.34 (1.27, 1.41) 1.34 (1.27, 1.41) N/A 
4 1.37 (1.12, 1.68) 1.37 (1.12, 1.68) 1.37 (1.12, 1.68) N/A 
5 1.33 (1.26, 1.41) 1.33 (1.26, 1.41) 1.33 (1.26, 1.41) N/A 
6 1.39 (1.03, 1.89) 1.39 (1.03, 1.89) 1.39 (1.03, 1.89) N/A 
Female 
2 0.58 (0.31, 1.10) 0.97 (0.73, 1.28) 1.06 (0.71, 1.58) 0.250 
3 0.60 (0.41, 0.86) 0.88 (0.66, 1.18) 1.05 (0.83, 1.34) 0.046 
4 0.54 (0.24, 1.23) 0.94 (0.70, 1.25) 1.04 (0.53, 2.04) 0.190 
5 0.59 (0.40, 0.87) 0.88 (0.64, 1.21) 1.05 (0.83, 1.32) 0.031 
6 0.53 (0.18, 1.57) 0.92 (0.69, 1.24) 1.02 (0.35, 2.96) 0.220 
OR – Odds Ratio, CI – Confidence Interval, SD – Standard Deviation; the Wald p-value indicates levels of statistical significance for differences in 









Good Prognosis Reasonable Prognosis Poor Prognosis Wald       
p-value OR of death within three years (95% CI) 
Age (per 5 years older) 
2 1.49 (1.39, 1.60) 2.20 (1.82, 2.66) 1.35 (1.15, 1.59) <0.001 
3 1.47 (1.34, 1.61) 2.17 (1.72, 2.74) 1.45 (1.31, 1.61) 0.008 
4 1.48 (1.28, 1.72) 2.15 (1.74, 2.66) 1.39 (1.11, 1.74) 0.003 
5 1.46 (1.33, 1.60) 2.13 (1.69, 2.67) 1.46 (1.32, 1.62) 0.018 
6 1.49 (1.15, 1.94) 2.21 (1.45, 3.37) 1.41 (1.11, 1.79) 0.008 
Age squared (per 5 
years older) 
2 1.010 (1.001, 1.019) 1.011 (1.007, 1.015) 1.008 (1.002, 1.013) 0.730 
3 1.011 (1.007, 1.015) 1.010 (1.004, 1.015) 1.009 (1.005, 1.012) 0.710 
4 1.011 (1.002, 1.020) 1.010 (1.005, 1.015) 1.007 (0.999, 1.015) 0.870 
5 1.011 (1.007,1.015) 1.009 (1.003,1.015) 1.009 (1.005,1.012) 0.710 
6 1.012 (1.001, 1.023) 1.011 (1.001, 1.021) 1.007 (0.997, 1.017) 0.910 
OR – Odds Ratio, CI – Confidence Interval, SD – Standard Deviation; the Wald p-value indicates levels of statistical significance for differences in 
effect across the patient classes; CIs directly from analysis. 
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3.3.5 Patient-class comparison with MLM 
Interest lies in the comparison between the patient classes identified in the 
MLLC model versus the MLM, with comparison between stage included as a 
class predictor in the MLLC model or excluded entirely in the MLM. Table 
3.11 compares the MLM and MLLC patient-class results from tables 3.3, 3.6 
and 3.7 side by side. 
A single patient class is identified in the MLM with 51.6% of patients dying 
within three years of diagnosis. In contrast, the MLLC model identifies three 
patient classes that are distinct with respect to prognosis, representing 
variability in the patient groups. Proportions of patients dying within three 
years ranges from 9.4% (95% CI 2.2% to 17.4%) in the good prognosis 
class to 93.2% (95% CI 92.0% to 99.6%) in the poor prognosis class. 
Although SES is constrained to be the same across the patient classes in 
the MLLC model, the effect size is greater than that seen in the MLM (MLLC 
OR=1.33, 95% CI 1.26 to 1.41; MLM OR=1.18, 95% CI 1.15 to 1.21; both 
per standard deviation increase). 
For females, the MLM shows reduced odds of death compared with males 
(OR=0.87, 95% CI 0.83 to 0.92). In the MLLC model, this relationship is 
seen in the good prognosis class only (OR=0.59, 95% CI 0.40 to 0.87), 
suggesting an improved effect for females, compared with males, in early-
stage diagnoses only. 
Increased age at diagnosis, and higher values of age-squared, remain 
associated with increased odds of death both in the MLM and across all 
classes of the MLLC model. Effect sizes are greater in the MLLC model, with 
the OR for age ranging from 1.46 in both the good and poor prognosis 
classes (good prognosis 95% CI 1.33 to 1.60; poor prognosis 95% CI 1.32 to 
1.62) to 2.13 in the reasonable prognosis class (95% CI 1.69 to 2.67), 






Table 3.11 Comparison of results from MLM and MLLC analyses; odds of death within three years 
Model Summary Statistics MLM 
MLLC 
Good 
Prognosis / Early 
Stage Diagnosis 
Reasonable 
Prognosis / Mid 
Stage Diagnosis 
Poor 




 % patients (bootstrapped 95% CI for MLLC model) 
Overall mortality 51.6 9.4 (2.2, 17.4) 58.3 (49.3, 72.9) 93.2 (92.0, 99.6) N/A 
Reference group mortality 49.3 8.0 (0.1, 16.5) 57.8 (36.7, 78.6) 94.1 (90.8, 100.0) N/A 
Model Covariates OR of death within three years (95% CI) 
Deprivation (per SD more) 1.18 (1.15, 1.21) 1.33 (1.26, 1.41) 1.33 (1.26, 1.41) 1.33 (1.26, 1.41) N/A 
Female 0.87 (0.83, 0.92) 0.59 (0.40, 0.87) 0.88 (0.64, 1.21) 1.05 (0.83, 1.32) 0.031 
Age (per 5 years older) 1.31 (1.30, 1.33) 1.46 (1.33, 1.60) 2.13 (1.69, 2.67) 1.46 (1.32, 1.62) 0.018 
Age squared (per 5 years older) 1.006 (1.005, 1.007) 1.011 (1.007,1.015) 1.009 (1.003,1.015) 1.009 (1.005,1.012) 0.710 
The reference group comprises males, aged 71.5 years, classified as Stage A at diagnosis and attributed a Townsend deprivation score of zero; 
OR – Odds Ratio, CI – Confidence Interval, SD – Standard Deviation; the Wald p-value indicates levels of statistical significance for differences in 
effect across the MLLC patient classes; CIs directly from analysis unless otherwise stated; LL (MLM) = -16,081, LL (MLLC) = -11,985. Deprivation 
(measured using TDI) is inversely related to social status. 
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3.3.6 Trust classes 
Table 3.12 summarises the model summary statistics for the Trust classes 
from the chosen three-patient, five-Trust-class MLLC model, where Trusts 
are apportioned to one of five groups.  
Trust classes are defined in order to account for heterogeneity at the Trust 
level, however interest lies in their comparison with the traditional MLM. In 
table 3.3, the MLM showed 12,708 patients (51.6%) dying within three years 
of diagnosis. In contrast, the MLLC model distinguishes five Trust classes 
with mean outcome (mortality) varying from 49.6% (95% CI 46.9% to 50.8%) 
to 54.5% (95% CI 52.6% to 59.6%) of patients dying within three years; 
Trust classes are hence labelled post-hoc from ‘best’ to ‘worst’ prognosis. 
Although ordered and labelled by prognosis, this is not to imply that Trusts 
within some classes perform better or worse than Trusts within other 
classes, as Trust classes contain differing profiles of patient characteristics, 
which will be described. 
Class sizes range from 10.4% of patients (95% CI 5.2% to 47.0%; worst 
prognosis class) to 37.3% of patients (95% CI 3.7% to 51.6%; class 4). 
Confidence intervals are wide, indicating that the ordering of the best to 
worst prognosis classes varies considerably across bootstrapped datasets. 
In the example dataset, by modal assignment, the best and worst prognosis 
classes contain only two Trusts each, class 2 contains three Trusts, class 
three contains five Trusts, and class four contains seven Trusts. 
Table 3.13 summarises the model class profiles for the Trust classes from 
the same model. Point values of SES differ somewhat across the Trust 
classes, with Trusts in the best prognosis class receiving patients on 
average from more affluent areas (mean Townsend score -0.39, 95% CI -
1.04 to 1.53), while Trusts in class 2 receive patients on average from more 
deprived areas (mean Townsend score 0.38 (95% CI -1.18 to 1.33). Trusts 
in the worst prognosis class, however, receive the most affluent patients on 
average (mean Townsend score -0.45, 95% CI -1.22 to 0.45). Confidence 
intervals are very wide, however, indicating much variability in the values of 





Table 3.12 Model summary statistics for the Trust classes in the three-patient, five-Trust-class MLLC model 
Model Summary Statistics 
Best prognosis Trust Class 2 Trust Class 3 Trust Class 4 Worst prognosis 
% patients (bootstrapped 95% CI) 
Class size 11.1 (6.0, 38.0) 14.3 (6.0, 51.4) 26.9 (6.0, 54.3) 37.3 (3.7, 51.6) 10.4 (5.2, 47.0) 
Mortality 49.6 (46.9, 50.8) 50.7 (48.5, 52.1) 50.9 (49.6, 53.5) 52.1 (50.8, 55.9) 54.5 (52.6, 59.6) 
CI – Confidence Interval; CIs from bootstrapping calculated using percentiles. 
 
Table 3.13 Model class profiles for the Trust classes in the three-patient, five-Trust-class MLLC model 
Model Class Profiles 
Best prognosis Trust Class 2 Trust Class 3 Trust Class 4 Worst prognosis 
mean (bootstrapped 95% CI) 
Mean deprivation -0.39 (-1.04, 1.53) 0.38 (-1.18, 1.33) -0.05 (-1.11, 1.12) 0.05 (-1.49, 0.86) -0.45 (-1.22, 0.45) 
Mean age (years) 71.2 (70.7, 72.6) 71.6 (70.8, 72.5) 71.8 (71.0, 72.3) 71.5 (71.0, 72.5) 71.4 (71.0, 73.1) 
 % patients (bootstrapped 95% CI) 
Female 43.4 (41.1, 47.6) 44.1 (42.1, 47.0) 44.3 (41.8, 47.2) 44.0 (41.6, 47.2) 44.6 (42.2, 47.8) 






Table 3.13 continued Model class profiles for the Trust classes in the three-patient, five-Trust-class MLLC model 
Model Class Profiles 
Best prognosis Trust Class 2 Trust Class 3 Trust Class 4 Worst prognosis 
% patients (bootstrapped 95% CI) 
Stage A 12.2 (9.9, 13.7) 11.6 (9.5, 14.4) 11.6 (9.0, 13.6) 11.6 (9.4, 13.6) 10.8 (9.4, 13.3) 
Stage B 26.9 (24.6, 29.7) 26.9 (24.7, 29.5) 27.1 (24.7, 29.4) 28.0 (24.9, 30.6) 28.6 (25.3, 34.2) 
Stage C 25.3 (21.3, 28.2) 24.0 (22.4, 29.2) 26.6 (22.5, 29.8) 24.7 (21.5, 29.5) 22.9 (18.6, 26.7) 
Stage D 22.7 (20.8, 25.2) 23.7 (20.4, 24.6) 23.0 (20.8, 24.7) 22.5 (20.3, 24.3) 22.0 (18.2, 24.2) 
Missing stage 12.9 (9.9, 15.3) 13.8 (10.3, 14.8) 11.7 (10.3, 16.4) 13.2 (10.2, 16.0) 15.7 (11.5, 18.7) 
Patients receiving treatment 84.5 (81.4, 87.7) 82.7 (82.1, 86.8) 84.7 (80.7, 87.5) 83.0 (81.2, 87.0) 81.7 (78.8, 84.6) 
ICD-10 C18 (colon) 59.1 (54.9, 63.8) 57.3 (55.5, 61.5) 58.9 (55.5, 62.5) 58.5 (56.6, 63.1) 61.8 (57.2, 64.7) 
ICD-10 C19 (rectosigmoid junction) 11.1 (8.8, 12.6) 10.9 (7.5, 12.6) 10.2 (5.5, 12.2) 10.9 (5.3, 12.3) 8.9 (7.5, 13.0) 
ICD-10 C20 (rectum) 29.8 (25.4, 34.6) 31.8 (27.6, 33.7) 30.9 (27.9, 34.6) 30.7 (27.9, 35.8) 29.2 (24.3, 32.8) 
Tumour on left side 64.8 (63.3, 70.0) 67.2 (64.1, 69.2) 67.1 (63.4, 69.5) 65.7 (62.3, 68.9) 63.9 (61.7, 67.8) 
Tumour on right side 27.3 (24.7, 30.3) 26.7 (24.7, 29.7) 27.7 (24.5, 29.3) 27.7 (25.1, 29.7) 25.3 (23.5, 29.6) 
Tumour across both sides 7.9 (4.2, 9.8) 6.1 (4.2, 9.4) 5.2 (4.4, 10.2) 6.6 (4.2, 11.1) 10.8 (5.4, 12.0) 
CI – Confidence Interval; CIs from bootstrapping calculated using percentiles. Stage is modelled as a class predictor; patients receiving treatment, 
ICD-10 diagnosis code and laterality are modelled as inactive covariates. 
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Both the mean age of patients and the proportion of females remain 
consistent across the classes. Mean age ranges from 71.2 years (95% CI 
70.7 to 72.6; best prognosis class) to 71.8 years (95% CI 71.0 to 72.3; class 
3), while the proportion of females ranges from 43.4% (95% CI 41.1% to 
47.6%; best prognosis class) to 44.6% (95% CI 42.2% to 47.8%; worst 
prognosis class). 
Proportions of patients within each of the stage categories also remain 
consistent across the classes, although there may be an indication that the 
worst prognosis class contains slightly more patients with missing values for 
stage (15.7%, 95% CI 11.5% to 18.7%) compared with the other classes. 
The worst prognosis class also contains the fewest patients receiving 
curative treatment (81.7%, 95% CI 78.8% to 84.6%). Although not significant 
differences, taken together, there may be an indication that the two Trusts in 
this class are not treating as many early-stage patients as other Trusts. 
Consistency is also predominantly seen across the classes for both the type 
and position of tumour, although there may be an indication that the worst 
prognosis class has the highest proportion of colon tumours (61.8%, 95% CI 
57.2% to 64.7%) and the lowest proportion of tumours of the rectosigmoid 
junction (8.9%, 95% CI 7.5% to 13.0%). With colon tumours presenting 
across both sides of the body, and tumours of the rectosigmoid junction 
presenting entirely on the left side of the body, this may partly explain why 
the worst prognosis class also has the lowest proportion of tumours on the 
right side of the body (25.3%, 95% CI 23.5% to 29.6%) and the highest 
proportion of tumours split across both sides of the body (10.8%, 95% CI 
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3.4 Discussion 
The MLLC model provided a better interpretation of the data compared with 
the MLM analysis. The MLM found sizeable and significant associations 
between increasing values of the Townsend deprivation score and increased 
odds of death, between being female and decreased odds of death, and 
between older age and increased odds of death. The MLLC analysis 
categorised patients into three latent classes (labelled as good, reasonable 
and poor prognosis), and in all classes, the overall impact of both SES 
(measured in these data using the TDI) and age was found to agree with the 
MLM. For sex, females had decreased odds of death in the good prognosis 
class, but less association in the reasonable and poor prognosis classes, 
thus recognising that the relationship between sex and mortality differs 
somewhat by prognosis. These differences indicate that a single patient 
class, as in the MLM, is not sufficient to model these data, due to 
heterogeneity at the patient level. 
As stage at diagnosis was identified as a mediator of the relationship 
between SES and three-year mortality, its inclusion in a traditional 
regression model would introduce bias due to the reversal paradox; hence, it 
was excluded from the MLM. It was, however, included as a class predictor 
in the MLLC model. This therefore established the contrast between the two 
models as a comparison with and without the inclusion of stage. Good, 
reasonable and poor prognosis classes corresponded to early-, mid- and 
late-stage diagnosis respectively, with the majority of the advanced stage 
patients in the poor prognosis class. Females are seen to have decreased 
odds of death compared with males for early-stage disease.  
The effect of SES was constrained to be the same across all patient classes, 
in order to avoid the causal circularity between SES, stage and survival. 
This, however, may not avoid some degree of residual bias due to the 
reversal paradox, as the exposure-outcome relationship is unlikely to be 
independent of within-class intercepts, which effectively are ‘adjusted’ by the 
consideration of stage as a class predictor. Stage could therefore be 
removed entirely from the MLLC model, and other studies have shown that 
latent classes remain similarly defined whether or not stage is included 
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(Downing et al., 2010). The removal of stage represents a cultural shift in 
approach, however, as it is commonly included in traditional analyses. 
Utilisation of a novel technique in addition to the removal of a covariate 
previously considered to be fundamental when modelling survival 
relationships may take time to be adopted. 
Across all classes, the odds of death for both the Townsend deprivation 
score and age at diagnosis were greater in the MLLC model results, 
compared with the MLM analysis. This is perhaps due in part to the 
appropriate inclusion of stage in the model, and in an improved model fit (LL 
= -16,081 for the MLM versus -11,978 for the three-patient, five-Trust-class 
MLLC model), leading to improved estimates. 
Although models with differing numbers of Trust classes could have been 
chosen, differences in output were minimal and the same patterns of 
association were seen for all model covariates. The five Trust classes 
identified outlying Trusts, indicating that the traditional MLM with a single, 
continuous latent variable at the Trust level, is not sufficient to model these 
data. Patient casemix differences can be seen across the Trust classes (e.g. 
in the different mean values of the Townsend deprivation score) and no 
adjustment has been made for these differences, so there can be no 
inference from this analysis as to the performance of the NHS Trusts 
included in the Trust classes. An alternative approach of grouping Trusts 
according to differences in characteristics is discussed in Chapter 4, where 
differences in survival at the Trust level may be as a result of underlying 
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Chapter 4 
Research Question (2); Casemix Adjustment 
4.1 Introduction 
Chapter 4 examines the second application of the latent variable 
methodological approach introduced in Chapter 1 and further defined in 
Chapter 2. The first application was seen in Chapter 3, where MLLC 
modelling was utilised to investigate the relationship between model 
covariates at the patient level, while accounting for heterogeneity at the 
provider level. Discrete latent classes, class predictors and unique class 
features were used to exactly specify model configurations, while accounting 
for data challenges specific to the example dataset. 
Chapter 4 explores research question (2), again using the example dataset 
(although with minor differences in the number of deaths compared with the 
data used in Chapter 3): 
(2) How does the performance of a healthcare provider vary after 
accommodating patient differences? 
This is an important question within healthcare delivery, where provider 
performance may be assessed and compared in order to identify best 
practice and advocate changes in under-performing institutions. Some 
providers may perform better or worse than others in terms of average 
survival rates, for example, but these differences may reflect the 
characteristics of their patients rather than underlying differences in their 
effectiveness. Section 1.2.3 introduced the concept of patient ‘casemix’ 
leading to differential selection based on patient heterogeneity.  
Results in Chapter 3 included a discussion of differences in prognosis 
across Trust-level latent classes (see section 3.3.6), and it was clear that 
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Trust performance could not be directly compared using patient-outcome 
differences, due to differences in patient-profile characteristics.  
In this chapter, model parameterisation thus differs substantially from that 
seen in Chapter 3, with differential selection (due to patient heterogeneity 
and casemix differences) separated from the potential causal structure of 
factors influencing provider performance. Initially, for simplification, no 
provider-level covariates are considered. This allows for a focus on the 
accommodation of differential selection at the patient level, and enables 
comparison with traditional methodologies. Chapter 5 extends the approach 
to explore the principle of evaluating causal factors operating to influence 
provider performance. 
Section 4.2 summarises the data and methods relevant to this research 
question, including the modelling approach, patient-level covariate 
configuration to account for differential selection, detailed parameterisation, 
optimum model construction and calculation of Trust performance rankings. 
Calculation of the SMR is identified as the traditional comparison.  
Section 4.3 contains all results, including model construction, a summary of 
the composition of both patient and Trust classes, and the comparison of 
performance ranking between the MLLC approach and calculation of SMRs. 
Section 4.4 provides a discussion of the methods and results. 
This chapter contains work based on two publications (Gilthorpe et al., 2011; 
Harrison et al., 2012). 
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4.2 Data and methods 
4.2.1 MLLC approach to the data 
The example dataset described in Chapter 2 is again utilised, containing 
data on 24,640 patients diagnosed with colorectal cancer between 1998 and 
2004; 12,856 patients (52.2%) died within three years of diagnosis, which, 
due to coding differences, slightly differs from the number of deaths seen in 
Chapter 3, as discussed in section 2.3.4. The same covariates are available 
for inclusion as summarised in section 2.3.4, although not all are utilised, as 
explained in section 4.2.2. 
A MLLC approach is preferred to answer the research questions, for reasons 
discussed in section 2.4.1. As identified in section 2.4.2, these data have a 
two-level hierarchical structure with NHS Trust at the upper level, used here 
as an example of an area-level healthcare provider. Other datasets may 
contain different organisational groupings, such as clinical commissioning 
groups (CCGs), for example. There is likely to be heterogeneity at both 
levels; patient groups may differ in their characteristics, leading to differential 
selection, and thus Trusts may differ in their patient casemix. MLLC 
modelling can accommodate the data structure, while maintaining an 
overarching framework that can separate modelling for causal inference and 
for differential selection across different levels of a hierarchy.  
Broad modelling strategy (ii), introduced in section 2.4.3, is utilised. While 
patient classes are constructed based on similarities in patient 
characteristics, Trust classes are instead determined based on differences in 
patient characteristics, and the same proportion of each patient class is 
allocated to each Trust class. Trust classes are therefore generated that are 
identical with respect to patient characteristics, i.e. they are patient casemix 
‘adjusted’. Trust-class outcomes (for example mean three-year mortality), 
may differ, but these differences will then be due to underlying differences in 
Trust performance, due to unmodelled factors (potential covariates) 
operating at the Trust level, rather than patient casemix. 
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4.2.2 Casemix adjustment 
As discussed in section 3.2.1, stage at diagnosis remains an imprecise 
measure, potentially exacerbating bias due to measurement error, 
particularly if interaction terms are considered, and stage contains missing 
data (though categorised for analysis). The DAGs constructed in figures 3.1, 
3.2 and 3.3 demonstrate differing complex theorised relationships between 
covariates at the patient level, with the DAG shown in figure 3.1 also chosen 
for the purposes of analysis within this chapter. Although potential causality 
has been identified between SES, stage and survival, there are no concerns 
regarding bias due to the reversal paradox in this analysis, since there is no 
attempt to seek causal inference or to make any confounder adjustment at 
the patient level. Casemix adjustment can be viewed as purely predictive 
modelling, to maximally explain the outcome with respect to the model 
covariates, with no regard for their causal relationship. 
The variables available for analysis within the example dataset are 
previously summarised in table 2.3. Table 4.1 reiterates the available 
variables and specifies which are included, and how they are modelled, 
within the MLLC analytical approach to this research question. 







Deprivation Deprivation Regression 
Sex Sex Regression 
Age at diagnosis 
Age at diagnosis Regression 
Age-squared Regression 
Stage at diagnosis Stage at diagnosis Regression 
ICD-10 - - 
Laterality - - 
Treated - - 
Deprivation is a measure of SES, measured in these data using TDI. 
Thus, optimum outcome prediction is sought by modelling patient 
characteristics in order to accommodate casemix differences. Consequently, 
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SES (measured in these data using the TDI), sex and age at diagnosis 
(centred around the study mean of 71.5 years) are included in the regression 
part of the model at the patient level, along with stage at diagnosis (coded A 
to D for increasing severity and missing values coded X), because stage 
plays a crucial role in affecting survival outcomes. Uncertainty due to 
measurement error, and to unmeasured covariates, is incorporated through 
the latent constructs. 
An age-squared term is again included, to model appropriately the non-linear 
relationship between age and survival. Patient-level covariates are otherwise 
simplified for inclusion into the casemix-adjusted model, however, as interest 
lies in Trust-level comparisons rather than patient-level relationships. 
Generalised additive models (GAMs) (West, 2012) are used to visually 
identify threshold values for both SES and age, beyond which values 
become uncommon and thus relationships may become atypical. These tails 
of the distributions are then ‘trimmed’; for age, rare values less than -10 
(equivalent to 61.5 years of age) were assigned to equal -10, while for SES, 
rare values greater than 5 were assigned to equal 5. 
No class predictors or inactive covariates are included, as this modelling 
configuration is designed to account for patient-level variation in the 
differentiation of Trust-level outcomes, rather than to investigate patient-
class differences. Therefore, variables previously included as inactive for 
analysis in Chapter 3, i.e. tumour site (using ICD-10 diagnosis code), 
laterality and whether or not the patient received curative treatment, are 
excluded from analysis. 
4.2.3 Parameterisation 
Detailed parameterisations, introduced in section 2.4.4, are summarised 
here with respect to research question (2). 
Intercepts. Class-independent intercepts are set for the patient classes, in 
relation to Trust classes, as also utilised in Chapter 3. Identical contrasts can 
thus be made amongst patient classes, within all Trust classes. Detailed 
interpretation of patient classes is not intended, however, as focus is on the 
Trust classes and their implications on Trust-level outcome differences. 
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Covariate effects. All patient-class covariate effects are initially designated 
Trust-class dependent, thus allowing parameter values to vary across the 
Trust classes and hence, for the relationship between each exposure and 
outcome to differ across the patient classes. Prediction modelling, rather 
than modelling for causal inference, is required at the patient level to 
account for patient casemix, therefore there are no concerns regarding any 
causal circularity between SES, stage and survival. It is not necessary, 
therefore, to constrain the effect of SES across the classes.  
Nevertheless, any of the covariate effects may be constrained to be Trust-
class independent for parsimony, if there is evidence that a relationship does 
not vary across the patient classes. 
Class sizes. In contrast to Chapter 3, patient-class sizes are designated 
class independent with respect to Trust classes, as required for modelling 
strategy (ii). This ensures that each Trust class contains the same proportion 
of each patient class; thus Trust classes each contain the same patient 
casemix. 
Error variance. This is not applicable for a binary outcome. 
4.2.4 Optimum model 
Optimum model construction again follows the process suggested in section 
2.2.6. Initially, a continuous latent variable is adopted at the Trust level while 
the number of patient classes are sequentially increased from one to identify 
the optimum number of patient-level classes based on interpretability, but 
with parsimonious assessment from model-evaluation criteria and CE. The 
continuous latent variable is then switched to categorical to identify the 
optimum Trust-level structure. Log-likelihood statistics, model parsimony and 
CE are again explored, although also with a mind on utility, since a minimum 
of two Trust classes is both necessary and sufficient to exhibit discretised 
Trust-class differences in patient outcomes. Indeed, it may be desirable to 
consider more than two Trust classes to obtain optimal utility from this 
approach, even if model likelihood statistics are not improved by an 
increased number of Trust classes. 
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A description of model construction for the MLLC approach, using the 
example dataset, is presented in section 4.3.2. 
4.2.5 Bootstrapping 
200 bootstrapped datasets are generated, following the same process as 
described in section 3.2.6, both for dataset generation and calculation of 
95% confidence intervals (CI) for the model summary statistics and model 
class profiles, using percentiles (2.5% to 97.5%), with model class profile 
figures based on probabilistic assignment to classes. The chosen MLLC 
model, as constructed in section 4.3.2 is utilised.  
There are no model class profiles at the patient level, as all covariates are 
included in the regression part of the model; CIs for the model covariates are 
determined directly from MLLC analysis of the example dataset. 
The primary utility of the bootstrapped datasets within this chapter, however, 
is in the comparison of Trust performance rankings, as described in sections 
4.2.6 and 4.2.7.  
4.2.6 Trust performance rankings 
In a MLLC analysis, Trust classes will exhibit a graduated patient outcome 
(i.e. three-year mortality), which is used to generate ranks of Trust 
performance. Trusts are ordered based on their probabilistic assignment to 
the best survival Trust class, thus generating a performance ranking for each 
Trust that is comparable across Trusts. Across the nineteen Trusts, a rank of 
one indicates that a Trust has a high probabilistic assignment to the best 
survival Trust class while a rank of nineteen indicates that a Trust has a low 
probabilistic assignment to the best survival Trust class.  
In order to ascertain the variability of the Trust performance rankings, MLLC 
analysis is replicated for each of the 200 bootstrapped datasets, using the 
chosen model as selected in section 4.3.2. Trusts are ranked from one to 
nineteen within each dataset; thus a median rank can be calculated together 
with a credible interval (CI; 2.5% to 97.5%) (Marshall and Spiegelhalter, 
1998) for each Trust, over all datasets. 
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4.2.7 Traditional comparison 
Trust performance ranking using MLLC modelling is compared with 
calculation of the SMR, an indirect standardisation approach introduced in 
section 1.3.4. As an indirect adjustment, a standard population distribution is 
not required; instead, a comparison of rates is utilised. For the SMR, 
comparison is therefore made between the number of observed and 
expected deaths within each Trust (scaled by Trust size), with the observed 
data used to calculate the figures for both the observed and expected 
deaths. 
Logistic regression is first performed across the entire dataset, using the 
same exposure and outcome variables as for the MLLC analysis. The 
probability of death within three years can then be determined for each 
patient, based on (i.e. standardised by) observed values of age, sex, SES 
and stage. The number of expected deaths per Trust is calculated as the 
sum of these probabilities across all patients within a Trust. The number of 
observed deaths within a Trust is straightforward, and available explicitly 
within the example dataset. 
Once numbers of observed and expected deaths are determined for each 
Trust, the SMR can be calculated using the equation: 
𝑆𝑀𝑅 = 𝑛𝑜. 𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑑𝑒𝑎𝑡ℎ𝑠 𝑛𝑜. 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑑𝑒𝑎𝑡ℎ𝑠⁄  
An SMR value equal to one indicates that the numbers of expected and 
observed deaths are the same, while a figure greater than one indicates a 
higher number of observed deaths than expected and a figure less than one 
indicates a lower number of observed deaths than expected. The difference 
from a SMR value of one is calculated for each Trust, with negative values 
indicating better outcomes and positive values indicating worse outcomes, 
compared with expected figures. 
This SMR difference is scaled by the Trust population size (by dividing by 
the square root of the Trust size), to calculate a scaled value that can be 
used to make direct comparisons across Trusts. Trusts are ranked from one 
to nineteen in increasing order of this scaled difference. Thus, a rank of one 
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is given to the ‘best’ survival Trust, while a rank of nineteen is given to the 
‘worst’. 
As for the MLLC modelling, the same 200 bootstrapped datasets are 
similarly analysed by calculation of the scaled SMR difference, and each 
Trust within each dataset is ranked from one to nineteen as described 
above. Again, the median rank and CI (2.5% to 97.5%) is calculated for each 
Trust, over all datasets.  
Each Trust therefore has a median rank and CI calculated by each 
approach, which can thus be contrasted. 
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4.3 Results 
4.3.1 Outline 
Results are illustrated for the MLLC analysis approach, with comparison 
made in section 4.3.5 between Trust performance ranks generated using 
this approach and by calculation of the SMR. Table 4.2 summarises the 
variables contained within each model. For both approaches, all variables 
are included as covariates within the regression model, as discussed in 
sections 4.2.2 and 4.2.7.  
Table 4.2 Comparison of variables included in MLLC model and calculation 
of SMR 




Age at diagnosis Age at diagnosis 
Age-squared Age-squared 
Stage at diagnosis Stage at diagnosis 
Deprivation is a measure of SES, measured in these data using TDI. 
4.3.2 Building the MLLC model 
As described in section 4.2.4, a continuous latent variable is initially adopted 
at the Trust level in order to ascertain the optimum number of latent classes 
at the patient level. Table 4.3 summarises the model-evaluation criteria for 
the MLLC patient classes in this situation. 
One patient class is seen to be optimum according to the BIC, the statistic 
that favours maximum parsimony, whilst selection of four patient classes 
minimises the value of the AIC, also geared to favour parsimony, although 
less so. As seen in Chapter 3, and as expected due to the lack of 
accommodation for parsimony, the LL shows continual improvement in 
model fit as the number of patient classes are increased, although this 
increase slows beyond two patient classes.  
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Table 4.3 Model-evaluation criteria for the patient classes in the MLLC 
models with a continuous Trust-level latent variable 
 Patient 
Classes 





1 class -12,027 24,156 24,075 10 0.0% 
2 classes -11,976 24,165 23,994 21 34.6% 
3 classes -11,960 24,244 23,984 32 48.1% 
4 classes -11,948 24,330 23,981 43 42.2% 
5 classes -11,937 24,420 23.982 54 54.2% 
LL – Log Likelihood, BIC – Bayesian Information Criterion, AIC – Akaike Information 
Criterion, CE – Classification Error. 
Figure 4.1 displays the change in -2LL for increasing numbers of patient 
classes. 
Figure 4.1 -2LL plot to determine the optimum number of patient classes in 
the MLLC modelling approach 
 
Patient CE also increases with the number of patient classes, with 54.2% for 
five patient classes indicating that the majority of patients are split 
probabilistically across these classes, rather than being assigned mostly to a 
single class; the patient classes thus become generally more ‘virtual’ as the 
number of classes are increased. CE is not a concern, however, when 
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Considering the model-evaluation criteria for guidance, and recognising that 
more than one patient class is preferred to fully model patient variability, two 
patient classes are chosen. 
Table 4.4 shows the model-evaluation criteria for the Trust classes, when 
the continuous latent variable at the Trust level is switched to categorical. 
Two patient classes remain fixed. 
Table 4.4 Model-evaluation criteria for the Trust classes in the MLLC models 









Trust   
CE 
1 class -11,979 24,150 23,996 19 35.0% 0.0% 
2 classes -11,977 24,166 23,995 21 35.4% 18.6% 
3 classes -11,976 24,184 23,998 23 35.6% 22.1% 
4 classes -11,976 24,204 24,002 25 35.6% 24.6% 
5 classes -11,976 24,225 24,006 27 35.6% 25.4% 
LL – Log Likelihood, BIC – Bayesian Information Criterion, AIC – Akaike Information 
Criterion, CE – Classification Error. 
Figure 4.2 displays the change in -2LL for increasing numbers of Trust 
classes. 
Figure 4.2 -2LL plot to determine the optimum number of Trust classes in 







1 2 3 4 5
-2
LL
Number of Trust classes
- 109 - 
The BIC shows one Trust class to be optimum, whilst the AIC just prefers 
two. The LL shows some improvement as the number of Trust classes are 
increased, up to three Trust classes, although differences are small and care 
must be taken not to over-interpret within this narrow range of figures. Again, 
the model-evaluation criteria are considered for guidance only. As discussed 
in section 4.2.4, at least two Trust classes are required in order to distinguish 
Trust-class differences, therefore two Trust classes are chosen on this 
occasion. The impact of a greater number of Trust classes is explored 
through simulations in Chapter 5. 
The chosen model therefore contains two patient classes and two Trust 
classes. Patient CE is 35.4% and Trust CE is 18.6%, indicating that the 
patient classes are more ‘virtual’ than the Trust classes, which is acceptable 
for predictive modelling at the patient level. 
4.3.3 Patient classes 
Table 4.5 summarises the patient classes in the two-patient, two-Trust-class 
MLLC model selected in section 4.3.2. 
Patients are assigned to two latent classes of similar size, one labelled ‘best’ 
prognosis (45.7% of cases (95% CI 18.1% to 82.2%), of which 39.3% (95% 
CI 33.3% to 48.2%) died within three years), and one labelled ‘worst’ 
prognosis (54.3% of cases (95% CI 17.8% to 81.9%), of which 63.0% (95% 
CI 54.9% to 84.5%) died within three years). The reference group comprises 
males of mean age (71.5 years), classified as stage A colorectal cancer at 
diagnosis, and attributed a Townsend deprivation score of zero. 
While prognosis classes are categorised by overall mortality, and there are 
two distinct classes (considering the range of the CIs), both class size and 
reference group mortality are more variable. This is due to the variability in 








Table 4.5 Results for the patient classes in the two-patient, two-Trust-class MLLC model; odds of death within three years 
Model Summary Statistics 
Best prognosis Worst prognosis 
% of patients (bootstrapped 95% CI) 
Class size 45.7 (18.1-82.2) 54.3 (17.8-81.9) 
Overall mortality 39.3 (33.3-48.2) 63.0 (54.9-84.5) 
Reference group mortality 7.0 (0.0-86.2) 23.2 (1.3-69.4) 
Model Covariates OR of death within three years (95% CI) 
Deprivation (per SD more) 1.03 (0.81-1.31) 1.32 (1.21-1.43) 
Female 0.58 (0.38-0.88) 0.94 (0.78-1.14) 
Age (per 5 years older) 2.53 (1.31-4.90) 1.51 (1.42-1.60) 
Age squared (per 5 years older) 0.984 (0.960-1.008) 1.005 (0.997-1.012) 
Stage = B 0.55 (0.21-1.43) 2.40 (1.63-3.54) 
Stage = C 1.74 (0.75-4.06) 7.72 (4.61-12.94) 
Stage = D Infinite† 20.19 (8.88-45.89) 
Stage = X 33.41 (7.93-140.68) 6.30 (1.89-20.97) 
OR – Odds Ratio, CI – Confidence Interval; CIs directly from analysis unless otherwise stated; †The odds ratio cannot be estimated as there were 
zero patients who survived 3 years in this subcategory. Deprivation (measured using TDI) is inversely related to social status. 
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Although patient classes are determined using predictive modelling, i.e. to 
account for differential selection, interest remains regarding any differences 
in covariate effects across the classes. Interpretation is cautious, as, for 
example, stage at diagnosis has not been modelled appropriately for causal 
inference. Thus, it is the differences across the classes that are of interest, 
rather than the overall magnitude of the relationships. 
A significant association is seen between increasing deprivation and 
increased odds of death in the worst prognosis class (Townsend deprivation 
score OR=1.32, 95% CI 1.21 to 1.43), compared with little association in the 
best prognosis class (OR=1.03, 95% CI 0.81 to 1.31). In contrast, a 
significant association is seen between female gender and decreasing odds 
of death in the best prognosis class (OR=0.58, 95% CI 0.38 to 0.88), 
compared with little association in the worst prognosis class (OR=0.94, 95% 
CI 0.78 to 1.14). Substantial and significant associations are seen between 
older age and increased odds of death in both classes (best prognosis 
OR=2.53, 95% CI 1.31 to 4.90; worst prognosis OR=1.51, 95% CI 1.42 to 
1.60). Little association is seen for age-squared in either class (best 
prognosis OR=0.984, 95% CI 0.960 to 1.008; worst prognosis OR=1.005, 
95% CI 0.997 to 1.012), perhaps due to the ‘trimming’ of the tail of the age 
distribution, as described in section 4.2.2. 
Model covariate relationships therefore generally agree with those seen in 
Chapter 3, where both increasing deprivation and older age were associated 
with increased odds of death across three patient classes. Further, females 
were shown to have decreased odds of death compared with males in the 
good prognosis class only, as also seen here. 
The effect of stage at diagnosis also differs across the patient classes; stage 
A (earliest stage) is designated as the comparison group. In the worst 
prognosis class, all other stage categories are associated with increased 
odds of death, and the odds increase as severity increases (stage B 
OR=2.40, 95% CI 1.63 to 3.54; stage C OR=7.72, 95% CI 4.61 to 12.94; 
stage D OR=20.19, 95% CI 8.88 to 45.89). Odds of death are also increased 
for missing values of stage, compared with stage A at diagnosis (OR=6.30, 
95% CI 1.89 to 20.97). In the best prognosis class, the association is not as 
- 112 - 
clear, although there remains a graduation in point values of odds of death 
with increasing severity from early- to late-stage diagnosis. There is little 
association seen, however, either between stage B or C at diagnosis (stage 
B OR=0.55, 95% CI 0.21 to 1.43; stage C OR=1.74, 95% CI 0.75 to 4.06), 
compared with stage A. The association for missing values of stage remains 
evident (OR=33.41, 95% CI 7.93 to 140.68), but the association between 
stage D at diagnosis and three-year mortality cannot be estimated, as all 
patients in this category died. 
There is a noticeable pattern in deaths by stage and prognosis categories, 
as summarised in table 4.6, based on modal class assignment (i.e. by 
allocation of patients to classes according to their largest class probability). 
All patients in the worst prognosis class diagnosed at either stage B or C 
died within three years; in the best prognosis class, all patients diagnosed at 
stage A, B or C survived, while all patients diagnosed at stage D died. This 
difference is anticipated, as stage at diagnosis is an important predictor of 
survival. Thus, while all of the early- and mid-stage patients survived at three 








Table 4.6 Deaths by stage and patient class, for the two-patient, two-Trust-class MLLC model 
Stage at 
Diagnosis 
Modal Class;  
No. (%) of patients died within three years 
Best prognosis Worst prognosis 
Survived Died Total Survived Died Total 
A 1,210 (100.0%) 0 (0.0%) 1,210 1,099 (66.6%) 550 (33.3%) 1,649 
B 4,829 (100.0%) 0 (0.0%) 4,829 0 (0.0%) 1,955 (100.0%) 1,955 
C 3,437 (100.0%) 0 (0.0%) 3,437 0 (0.0%) 2,736 (100.0%) 2,736 
D 0 (0.0%) 1,962 (100.0%) 1,962 437 (12.0%) 3,202 (88.0%) 3,639 
Missing (X) 359 (79.8%) 91 (20.2%) 450 413 (14.9%) 2,360 (85.1%) 2,773 
Total 9,835 (82.7%) 2,053 (17.3%) 11,888 1,949 (15.3%) 10,803 (84.7%) 12,752 
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4.3.4 Trust classes 
Table 4.7 summarises the Trust classes in the two-patient, two-Trust-class 
MLLC model selected in section 4.3.2. 
Trusts are also assigned to two latent classes of similar size, one labelled 
‘best’ prognosis (53.1% of cases (95% CI 25.7% to 92.5%), of which 51.3% 
(95% CI 49.6% to 52.3%) died within three years), and one labelled ‘worst’ 
prognosis (46.9% of cases (95% CI 7.5% to 74.3%), of which 53.2% (95% 
CI 52.6% to 60.0%) died within three years). 
Classes are ordered and labelled by prognosis, and although there is only a 
small difference in overall mortality, classes are again distinct, considering 
the range of the CIs. Class size ranges, however, are again wide, due to 
variability in class size across the bootstrapped datasets. 
Model class profiles are balanced across the Trust classes, as would be 
expected for a casemix-adjusted model. A direct comparison between the 
Trust-class results in table 4.7 and those in tables 3.12 and 3.13, generated 
by means of the three-patient, five-Trust-class MLLC model, would not be 
appropriate due to the substantial differences in model parameterisations. 
While the Trust classes defined in analysis in Chapter 3 deliberately contain 
different proportions of patient classes, leading to differences in patient 
composition across the classes, those in table 4.7 are adjusted for 






Table 4.7 Results for the Trust classes in the two-patient, two-Trust-class MLLC model; odds of death within three years 
Model Summary Statistics Best prognosis Worst prognosis 
 % patients (bootstrapped 95% CI) 
Class Size 53.1 (25.7-92.5) 46.9 (7.5-74.3) 
Mortality 51.3 (49.6-52.3) 53.2 (52.6-60.0) 
Model Class Profiles Mean (bootstrapped 95% CI) 
Mean deprivation -0.13 (-0.48 to 0.00) -0.25 (-1.05 to 0.02) 
Mean age (years) 73.1 (72.9-73.5) 73.0 (72.8-74.3) 
 % patients (bootstrapped 95% CI) 
Female 44.2 (43.3-45.2) 44.0 (42.8-47.1) 
Stage A 11.9 (10.9-12.4) 11.3 (10.1-12.6) 
Stage B 27.2 (26.4-28.6) 28.0 (26.7-33.3) 
Stage C 25.2 (24.2-26.4) 24.9 (19.3-26.3) 
Stage D 23.1 (22.2-23.8) 22.3 (19.0-23.5) 
Missing stage 12.7 (11.7-13.7) 13.5 (11.9-17.3) 
CI – Confidence Interval; CIs from bootstrapping calculated using percentiles. Deprivation (measured using TDI) is inversely related to social 
status. 
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4.3.5 Performance ranking comparison 
Results comparing Trust performance rankings between the MLLC approach 
and the calculation of SMRs are summarised in table 4.8; a low ranking 
value indicates a better survival rate than expected. Trusts are ordered by 
their median probability of belonging to the best survival MLLC Trust class, 
by methods described in section 4.2.6. 
Table 4.8 Trust ranks from the MLLC model and the calculation of Trust 
SMRs 
Trust 
Median probability of 
belonging to best 
survival Trust class 
Median Rank (95% CI) 
MLLC SMR 
1 1.000 1 (1-9.5) 6 (2-11) 
2 0.999 3 (1-11) 4 (1-10.5) 
3 0.997 4 (1-11) 3 (1-10.5) 
4 0.996 4 (1-15) 8 (3-14.5) 
5 0.993 5 (1-12.5) 5 (1-13) 
6 0.956 8 (2-16) 9 (2-17) 
7 0.912 9 (3-17) 5 (1-17) 
8 0.908 9 (2-17) 6 (1-18) 
9 0.897 9 (3-18) 5 (1-18) 
10 0.816 10 (3-17) 8 (1-18) 
11 0.575 11 (3.5-18) 11 (3-17) 
12 0.476 13 (5.5-18) 12.5 (3-18) 
13 0.372 12 (4-18.5) 11.5 (5.5-17) 
14 0.359 12 (3-19) 12 (7-17) 
15 0.152 14 (5.5-19) 15 (4.5-18) 
16 0.070 14 (4-19) 13 (7-18) 
17 0.070 15 (7.5-19) 16 (7.5-18) 
18 0.003 18 (7-19) 15 (10-18) 
19 0.002 18 (13.5-19) 19 (18-19) 
CI – Credible interval (2.5% to 97.5%); point values from interpolation. 
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Figure 4.3 then provides a graphical representation of these results, in order 
of increasing median probability of belonging to the best survival Trust class 
by the MLLC analytical approach. 
 
Figure 4.3 Trust median ranks and 95% CIs, ordered by the MLLC analysis 
 
Differences in the median rank of Trust performance between the MLLC 
approach and the calculation of Trust SMRs are within their estimated CIs, 
which are very wide, indicating a large amount of heterogeneity remaining by 
both methods. The MLLC approach is thus comparable with the traditional 
approach. 
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4.4 Discussion 
The MLLC modelling approach within this chapter incorporates available 
patient-level covariates and models patient-class uncertainty associated with 
unavailable patient-level covariates, to ensure that the resulting Trust-class 
differences in patient outcome are effectively adjusted for casemix. Model 
parameterisation has separated differential selection at the patient level (due 
to patient heterogeneity and casemix differences), from the potential causal 
structure of factors influencing Trust performance. Therefore, while the 
variation in Trust outcomes seen in Chapter 3 was attributable to explicit 
variation due to differential selection, in this chapter, differences are instead 
attributable to residual variation due to the influence of latent factors 
operating at the Trust level. This variation depends upon unmeasured Trust-
level characteristics, for example, differences in healthcare delivery 
processes. This analytical strategy has considerable prognostic utility to 
inform health service providers of disparities within patient care. 
Similar results are seen in Trust rankings across the two approaches, with 
estimates well within the CIs. The same general Trust-rank progression can 
be seen, with both methods broadly identifying the ‘best’ and ‘worst’ NHS 
Trusts based on patient outcome. Results are not identical, however, and 
those from the MLLC model should be preferred, as the method 
demonstrates a more sophisticated approach to the research question by 
accounting for uncertainty due to patient heterogeneity and measurement 
error. Use of the SMR does not fully accommodate patient casemix or 
imprecise measurements. The assumption of patient casemix only to the 
point of entry into the healthcare system is naïve, however, as heterogeneity 
may remain. Section 1.2.1 highlighted the complex relationships between 
the patient, treatment, and healthcare provider, thus the inclusion of 
treatment characteristics may further accommodate heterogeneity and 
narrow the CIs. This information is not available within the example dataset, 
however. 
The probabilities of Trust-class membership in table 4.8 are marked, with 
most Trusts belonging entirely or predominantly to one Trust class, by the 
MLLC approach. This is unsurprising, as there is only a modest difference 
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between the two classes in median survival, and probabilistic assignment 
differentiates between the two, providing a class-weighted combined survival 
rate. It is not feasible, however, for a Trust to be assigned a class-weighted 
survival rate below that of the worst survival class, or above that of the best 
survival class. This is an implicit constraint on the estimated weighted 
survival for Trusts allocated entirely to one of the two Trust classes. To 
alleviate this, more Trust classes could be sought, increasing the number 
until no Trust has a probabilistic assignment of exactly one, for classes at 
the extremities of the range of Trust outcome means. Further inclusion of 
Trust classes is considered through simulations in Chapter 5, but as applied 
here, the estimated ranks are robust. 
This chapter demonstrates an interim solution, extending the latent variable 
approach only as far as is feasible to still be able to make comparisons to a 
traditional approach. This comparison therefore shows proof of principle for 
the novel techniques. While the traditional methodologies cannot develop 
further, however, MLLC analysis offers improvement and extension to 
include both patient pathway adjustment (i.e. treatment differences, where 
available) and provider-level process variables. Further, the causal inference 
that may be investigated at the Trust level is now free from the patient-level 
differential selection issues that may conflate predictive modelling with 
causal inference modelling. 
Chapter 5 explores the principle of evaluating causal factors operating to 
influence Trust performance, while accommodating patient casemix. 
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Chapter 5 
Research Question (3); Provider-level Covariates 
5.1 Introduction 
Chapters 1 and 2 introduced and further defined the latent variable 
methodologies, putting MLLC approaches into context within an overarching 
causal framework. Model aspects and features were fully described, 
demonstrating how to precisely configure modelling approaches. Three 
research questions were posed, together with examination of the example 
dataset and a broad MLLC approach to each question.  
Analysis within Chapter 3 applied this approach to the example dataset to 
investigate covariate effects at the patient level, while accounting for 
heterogeneity at the provider level. Analysis within Chapter 4 applied the 
same approach, with different parameterisation, to investigate performance 
comparison at the provider level, while accounting for differential selection 
(i.e. patient casemix) at the patient level. This analysis was necessarily 
simplified by not considering provider-level covariates. 
Chapter 5 thus extends the investigation commenced in Chapter 4, to 
incorporate covariates at the provider level within a latent variable framework 
that also accounts for differential selection. Incorporation of organisational 
level features (such as surgeon speciality or available beds) can lead to 
improved comparisons and hence a more appropriate assessment of 
differences in levels of patient care. There are, however, no provider-level 
covariates in the example dataset. Data are therefore simulated, with both 
the data structure and the distribution of patient-level covariates based on 
values sourced from the example dataset. 
The research question appropriate to this chapter is therefore: 
(3) Can causal provider-level covariate effects be identified, after 
accommodating patient differences? 
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Use of simulated data allows for proof of principle to be demonstrated by the 
recovery of provider-level covariate effects as designed into the data 
simulations. Both continuous and binary outcome variables are investigated, 
with binary outcomes analogous to those explored in Chapters 3 and 4, i.e. 
three-year mortality. The continuous outcomes, as generated, do not 
represent a true survival outcome but may be considered to represent other 
outcomes, such as cost of care, and as such they are an important 
consideration for this and future research. There is no traditional comparison 
to the MLLC approach to this research question, as traditional techniques 
commonly adjust only for patient characteristics up to the point of entry into 
the healthcare system. 
Both binary and continuous covariate effects are considered, although for 
simplification, they are analysed separately. A further simplification is to 
simulate a homogeneous patient group, such that focus may be placed on 
the accommodation of covariates at the provider level.  
Section 5.2 describes the simulation approach, including consideration of the 
data structure, calculation of patient outcomes and of Trust-level coefficient 
effects. Simulated data combinations are described and the sensitivity of the 
approach is assessed. 
Section 5.3 explores the modelling approach, considering the MLLC 
modelling strategy, adjustment for patient casemix, model parameterisation 
and construction, and the process of recovering the Trust-level coefficient 
values. 
Section 5.4 contains all model results for both continuous and binary 
outcomes, with full interpretation, and further assessment as appropriate for 
each outcome and its findings. 
Section 5.5 provides a discussion of the methods and results. 
The Stata code used for data simulation can be seen in Appendix C. 
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5.2 Simulation approach 
5.2.1 Data structure 
Figure 5.1 graphically displays the overarching simulation approach to the 
patient and Trust levels; 24,640 patients and nineteen Trusts are utilised, to 
correspond to the example dataset. Trust size is allowed to vary, thus 
reflecting differing Trust sizes by geographical area. 
 
μ – mean, σ – standard deviation, N – total number of unique observations at 
patient or Trust level 
Figure 5.1 Overarching simulation approach to the patient and Trust levels 
 
The patient-level covariates sex, SES and age at diagnosis are simulated 
first using a trivariate covariance matrix, and values are drawn from a 
random normal distribution. Sex is defined as either male or female and 
there are approximately equal numbers of each. SES and age are centred 
on zero, with standard deviations as per descriptive statistics of the example 
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dataset (see table 2.3 in Chapter 2: Townsend deprivation score (used to 
measure SES) SD = 3.18, age SD = 11.6). Each patient is then assigned to 
one of nineteen Trusts, and randomisation ensures that no pattern is 
generated in the distribution of either Trusts or Trust-level covariates.  
The binary Trust-level covariate equals approximately ±0.5, and a random 
normal distribution (with a small standard deviation of 0.01) is used to 
introduce some variability around these figures. Values are randomly 
allocated across Trusts, thus allowing for variability in the number of Trusts 
assigned each value within each simulated dataset. While this may widen 
the uncertainty when estimating the covariate effect due to boundary values 
that may not easily be modelled, it is a strength of the simulation to allow for 
a majority one way or the other as this reflects real-world Trust-level effects. 
The continuous Trust-level covariate ranges from -0.5 to +0.5 across the 
nineteen Trusts, using a random uniform distribution to allocate values to 
Trusts. Values are generated without replacement, thus allowing for 
duplication, again to reflect real-world possibilities. 
5.2.2 Patient outcomes 
Patient outcomes are based on a linear predictor, as shown in figure 5.1, 
and calculated using the equation: 
𝐿𝑖𝑛𝑒𝑎𝑟 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑜𝑟 = 𝛽0𝑖 + (𝛽1𝑖 × 𝑠𝑒𝑥) + (𝛽2𝑖 × 𝑆𝐸𝐵) + (𝛽3𝑖 × 𝑎𝑔𝑒) 
+ (𝛽𝑇 × 𝑇𝑟𝑢𝑠𝑡 𝑙𝑒𝑣𝑒𝑙 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒) 
where 𝛽0𝑖 is a constant term at the patient level 𝑖, 𝛽1𝑖, 𝛽2𝑖 and 𝛽3𝑖 are the 
effects of the patient-level covariates sex, SES and age respectively, and 𝛽𝑇 
is the coefficient effect of the Trust-level covariate (binary or continuous) as 
set during simulation. Values of 𝛽0𝑖, 𝛽1𝑖, 𝛽2𝑖 and 𝛽3𝑖 are log odds values 
taken from the MLM analysis of the example dataset in Chapter 3 (OR can 
be seen in table 3.3), with 𝛽0𝑖 =  −0.0265, 𝛽1𝑖 =  −0.1368, 𝛽2𝑖 = 0.0527 and 
𝛽3𝑖 = 0.0547, and a range of 𝛽𝑇 values (defined in section 5.2.3) are utilised. 
The linear predictor therefore includes the same effect of the patient 
covariates, but a different Trust-level effect dependent on the simulated 
values of the Trust-level covariate and coefficient effect.  
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Two outcomes are then generated for each Trust-level covariate. The 
continuous outcome is equal to the value of the linear predictor plus a 
normally distributed error term; a range of error variances are utilised, as 
described in section 5.2.4. The binary outcome is drawn from a random 
binomial distribution based on the inverse logit of the linear predictor, with a 
fixed error variance of 𝜋2 3⁄  at the patient level (Snijders and Bosker, 1999). 
This fixed binomial error term has implications on the effect of the variance 
structure at other levels, which is discussed further in section 5.5. 
5.2.3 Trust-level coefficient effects 
A range of values are utilised for the coefficient effect at the Trust level (𝛽𝑇), 
to show consistency of recovery from the simulated value and to allow for 
graphical representation of the relationship between simulated and 
recovered values. 
As an informed basis for analysis, patient-level coefficient values are 
selected from previous analyses; the MLM analysis of the example dataset 
performed in Chapter 3 is again utilised, with applicable effects recorded in 
section 5.2.2. For the binary Trust-level covariate, the absolute effect of sex 
is used (0.137) while for the continuous Trust-level covariate, the effect of 
deprivation is used (0.053). Five coefficient values are investigated for each 
Trust-level covariate: the effect of the chosen coefficient, one fifth the effect, 
five times the effect, and two additional values within this range. Table 5.1 
summarises the values used for each Trust-level covariate. 
Table 5.1 Trust-level coefficient values for the binary and continuous 
Trust-level covariates 
𝜷𝑻 Effect 





One fifth effect 0.027 0.011 
Effect of sex or deprivation 0.137 0.053 
Additional value 0.250 0.120 
Additional value 0.500 0.200 
Five times effect 0.684 0.264 
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5.2.4 Error variance 
Normally distributed error terms are included in the calculation of each 
continuous outcome, as shown in figure 5.1. As the variance of these terms 
is unknown, a range of values are utilised; the error variance is calculated as 
33%, 50% or 67% of the median variance of the outcome, when calculated 
without error. Error terms are therefore generated as normally distributed 
random numbers with mean equal to zero and variance equal to each error 
variance described above, before being added to the linear predictor to 
generate each continuous outcome. Table 5.2 summarises the values of the 
error variance used for each Trust-level covariate. 
Table 5.2 Values of the error variance for the binary and continuous 
Trust-level covariates 
Error variance (%) 





33% 0.150 0.144 
50% 0.225 0.218 
67% 0.300 0.293 
   
5.2.5 Simulated data combinations 
In addition to the five Trust-level coefficient values (𝛽𝑇) described in section 
5.2.3 and the three error variances described in section 5.2.4, three 
simulation seeds are also used to generate unique sets of 100 simulated 
datasets. Thus for the continuous outcome, forty-five sets are simulated, 
while for the binary outcome, fifteen sets are simulated (as there are no 
associated error variances). Table 5.3 summarises the combinations used; 







Table 5.3 Summary of combinations used in data simulation for both continuous and binary outcomes 
Simulation seed Error variance 
𝜷𝑻 coefficient 
One fifth effect 
Effect of 
sex or deprivation 
Additional value Additional value Five times effect 
Continuous outcome 
Seed 1 
33% 15 sets of 100 datasets Seed 2 
Seed 3 
Seed 1 
50% 15 sets of 100 datasets Seed 2 
Seed 3 
Seed 1 




N/A 15 sets of 100 datasets Seed 2 
Seed 3 
𝛽𝑇 coefficient effects differ by Trust-level covariate; sets are thus produced for each covariate. 
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5.2.6 Sensitivity of the simulation approach 
Some of the choices described in the previous sections may have an impact 
on modelling outcomes. The sensitivity of these choices is therefore 
assessed. 
In section 5.2.1, nineteen Trusts are simulated. This relatively small number 
may not give robust results for either fixed or random effects, therefore the 
implication of up to fifty Trusts may also be considered, as appropriate. 
In section 5.2.1, Trust size is allowed to vary. Restricting Trust size to be the 
same throughout has no effect on the modelling outcomes. 
In section 5.2.1, for the binary Trust-level covariate, ±0.5 is selected such 
that, if balanced across Trusts, values would average to zero. On balancing 
these values, there is little difference seen in the modelling outcomes. 
Examination showed that, when values were not balanced across Trusts, the 
smallest number of Trusts to be allocated to one of the binary categories is 
four. Additional uncertainty surrounding covariate effect estimates due to 
boundary values is thus minimised. Alternative values of 0/+1 or -1/0 are 
also considered, and the effect of eliminating the normally distributed 
variation is investigated, however neither option introduces much variability 
into the modelling outcomes obtained. 
In section 5.2.1, for the continuous Trust-level covariate, the range from -0.5 
to +0.5 is also selected such that, across all Trusts, values would average to 
zero. Although duplication of values is allowed, on investigation, all values 
were found to be unique within each simulated dataset. 
In section 5.2.5, sets of 100 simulated datasets are described. Initial 
investigation increased the number to 1,000 (per combination of Trust-level 
coefficient value (𝛽𝑇), error variance and simulation seed) but there is no 
measurable difference in the recovered values of 𝛽𝑇 obtained. Therefore, to 
minimise computational requirements, 100 simulated datasets per 
combination are utilised. 
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5.3 Modelling approach 
5.3.1 MLLC approach to the data 
MLLC analysis is used to analyse the simulated data. While the simulation 
approach starts at the patient level and progresses upwards, modelling 
consideration starts at the Trust level with a latent construct, followed by 
casemix adjustment. There is therefore no direct overlap of simulation to 
analysis, thus allowing a more robust assessment of the analytical strategy. 
These data have a hierarchical structure, with patients at the lower level and 
NHS Trusts at the upper level. Although patients are simulated as a single 
homogeneous group, accommodation is made for differential selection within 
the modelling strategy and parameterisation, and the use of a latent variable 
approach explicitly accommodates uncertainty within the latent structures at 
both levels. This approach may therefore also be utilised for heterogeneous 
patient groups, and thus, heterogeneous Trust groups (due to different 
patient casemix), as both are common within observational health datasets. 
The modelling configuration is based on broad modelling strategy (ii), 
introduced in section 2.4.3, and demonstrated in Chapter 4, where patients 
are grouped into latent classes based on similarities in characteristics, while 
Trust classes are determined based on differences in patient characteristics. 
Trust classes therefore contain the same mixture of patient characteristics, 
i.e. they are balanced with respect to patient casemix. Differences in patient 
outcome are therefore due to effects operating at the Trust level. These 
effects are simulated within these data and interest thus lies in the 
comparison between simulated and recovered Trust-level coefficient values. 
5.3.2 Casemix adjustment 
Simulated values of sex, SES and age are included in the regression part of 
the model, at the patient level. No higher order terms, class predictors or 
inactive covariates are included. Bias is not a concern, since modelling at 
the patient level is required only to account for heterogeneity due to 
differential selection, and no causal inference will be made. Additional 
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covariates, such as stage at diagnosis, may therefore be included easily if 
available in observational data  
MLLC modelling is utilised to partition modelling for prediction at the patient 
level from modelling for causal inference at the Trust level, although as 
binary and continuous Trust-level covariates are investigated separately, no 
assessment of potential causal relationships between covariates at the 
upper level are required for these data. Any combination of Trust-level 
effects could be incorporated however, with construction of a DAG to model 
relationships at the Trust level. 
5.3.3 Parameterisation 
Parameterisation, as introduced in section 2.4.4, is of a similar set-up to that 
described in section 4.2.3. 
Intercepts. Class-independent intercepts are set such that identical contrasts 
may be made amongst patient classes, regardless of Trust class. 
Covariate effects. Class-dependent covariate effects are set such that 
patient-class parameter values may vary across Trust classes, to allow 
covariate-outcome relationships to vary across the patient classes. 
Class sizes. Class-independent patient-class sizes are required for 
modelling strategy (ii), to balance patient casemix across Trust classes. 
Error variance. For the continuous outcome measure, class-independent 
error variances are adopted. This restricts error variances to be the same 
across the Trust classes, thus patient classes are set to be homoscedastic 
(i.e. the variance of the outcome remains the same within each patient 
class). This is appropriate, as no heteroscedasticity is built in to the 
simulated patient-level data. 
5.3.4 Optimum model 
A range of models are explored to allow for Trust-level variation. Two Trust 
classes are required as a minimum, in order to distinguish outcome 
differences, and this is increased as required to fully model variation at the 
Trust level. Models are not selected on the basis of model-evaluation 
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criteria, parsimony, CE or interpretability; rather, Trust classes are increased 
from two to a point of no further improvement in recovered Trust-level 
coefficient values. 
Patient-level variation is incorporated by a single patient class, as patient-
level data are simulated to be homogeneous. The parameterisation detailed 
in section 5.3.3 details how the patient classes are to be organised within the 
Trust classes and hence, with only one patient class, there is essentially no 
difference between Trust-class dependence or independence. Nevertheless, 
the intent is to model as described, which will appropriately accommodate 
any increase in the number of patient classes utilised in future modelling. 
As Trust classes are increased, the time required to complete the modelling 
also increases. For each outcome and Trust-level covariate, fifteen sets of 
100 datasets are simulated, as described in section 5.2.5, for each 
combination of error variance (continuous outcome only), Trust-level 
coefficient and simulation seed.  
For models using two or three Trust classes, fifteen sets of 100 datasets can 
usually be analysed overnight. For four Trust classes, an additional half a 
day is often required, while for five Trust classes, a further overnight session 
should be allowed. Timings are estimated as they are affected by other 
computational issues such as disk space and system failures. Thus, to 
obtain the results seen in table 5.4, for example, where fifteen sets of 100 
datasets are analysed using three different MLLC models (with two, three 
and four Trust-classes) across three error variances, a minimum of ten days 
may be required. If additional modelling using five Trust-classes is 
necessary, as seen in table 5.5, a further six days may be required. 
There is no measureable difference in time required to perform the modelling 
for either nineteen or fifty Trusts. There is, however, a large increase in time 
required when considering MLLC models with ten Trust classes. To analyse 
just five sets of 100 datasets (considering only one simulation seed), using 
ten Trust classes, may take up to one week. Thus, two weeks are required 
to achieve the results seen in table 5.8. 
These computational requirements necessarily limit the scope and range of 
the models considered within the time available, however sufficient models 
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are conducted and presented within this chapter to assess the utility of the 
methodological approach to recover simulated values of the Trust-level 
coefficient effects. 
5.3.5 Trust-level coefficient recovery 
Each simulated dataset is similarly modelled using the approach described. 
A weighted mean outcome for each Trust is calculated, based on the overall 
weighted mean outcome within each Trust class and the probabilistic 
assignment of each Trust to each Trust class. As highlighted in section 
5.3.1, differences in mean outcome are due to simulated Trust-level 
covariate effects. Recovered values of the Trust-level coefficient (𝛽𝑇) are 
therefore obtained by performing single level regression analysis to regress 
the Trust weighted mean outcome on the relevant binary or continuous 
Trust-level covariate. This process is repeated for each simulated dataset, 
with medians and credible intervals (CIs; 2.5% to 97.5%) calculated over 
each set of 100 datasets, for each combination of MLLC model, simulated 
Trust-level coefficient value, and error variance (where appropriate). 
Recovered values are averaged over the three simulation seeds. 
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5.4 Results 
5.4.1 Continuous outcome 
5.4.1.1 Binary Trust-level covariate 
Table 5.4 shows the results of the analysis using a continuous outcome and 
a binary Trust-level covariate. Results are consistent across simulation 
seeds; models contained one patient class (1P) and up to four (4T) Trust 
classes. 
For all combinations, the simulated values of the Trust-level coefficient (𝛽𝑇) 
are found to be within the credible intervals for each recovered 𝛽𝑇 value, and 
results are very consistent across the different models and error variances. 
In general, as the error variance increases, the credible intervals became 
gradually wider, as would be expected, but the difference is small. For 
example, for simulated 𝛽𝑇 = 0.250, 1P-2T model, the 33% error returns a 
credible interval of 0.239 to 0.259, the 50% error returns 0.237 to 0.261 and 
the 67% error returns 0.235 to 0.263. 
The median recovered 𝛽𝑇 is almost identical to the simulated 𝛽𝑇 for all 
simulated values except the lowest, regardless of error variance or MLLC 
model. There is some suggestion that, for the lowest simulated 𝛽𝑇 = 0.027, 
the recovered 𝛽𝑇 value reduces as the error variance is increased. At the 
33% error variance, recovered 𝛽𝑇 ranges from 0.017 to 0.018 across the 
MLLC models, at 50% it ranges from 0.014 to 0.015 and at 67%, this is 
0.012 to 0.013. For this lowest simulated 𝛽𝑇, it was not possible to combine 
the results from all datasets in order to produce an estimate of the recovered 
𝛽𝑇 value. At the 33% error variance, across the MLLC models and simulation 
seeds, between 0 and 1 datasets are excluded from each set of 100. At the 
50% error variance, this increased to between 0 and 5, and at the 67% error 
variance, to between 4 and 11. As would be expected, there are more 
datasets excluded for higher values of the error variance 
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Table 5.4 Simulated and recovered values of the Trust-level coefficient for 















1P-2T 0-1 0.017 (0.005-0.030) 
1P-3T 0-1 0.018 (0.005-0.031) 
1P-4T 0-1 0.018 (0.005-0.031) 
0.137 
1P-2T 0 0.137 (0.126-0.146) 
1P-3T 0 0.136 (0.126-0.146) 
1P-4T 0 0.136 (0.126-0.146) 
0.250 
1P-2T 0 0.250 (0.239-0.259) 
1P-3T 0 0.250 (0.239-0.259) 
1P-4T 0 0.250 (0.239-0.259) 
0.500 
1P-2T 0 0.499 (0.489-0.509) 
1P-3T 0 0.499 (0.489-0.509) 
1P-4T 0 0.499 (0.489-0.509) 
0.684 
1P-2T 0 0.683 (0.672-0.693) 
1P-3T 0 0.683 (0.673-0.693) 




1P-2T 0-5 0.014 (0.002-0.029) 
1P-3T 0-5 0.015 (0.003-0.030) 
1P-4T 0-5 0.015 (0.003-0.030) 
0.137 
1P-2T 0 0.136 (0.123-0.148) 
1P-3T 0 0.136 (0.123-0.148) 
1P-4T 0 0.136 (0.123-0.149) 
0.250 
1P-2T 0 0.250 (0.237-0.261) 
1P-3T 0 0.250 (0.237-0.261) 
1P-4T 0 0.250 (0.237-0.261) 
0.500 
1P-2T 0 0.499 (0.486-0.511) 
1P-3T 0 0.499 (0.486-0.511) 
1P-4T 0 0.499 (0.486-0.511) 
0.684 
1P-2T 0 0.683 (0.670-0.695) 
1P-3T 0 0.683 (0.670-0.695) 
1P-4T 0 0.683 (0.670-0.695) 
𝛽𝑇 – Trust-level coefficient value; median averaged over 3 simulation seeds; CI – 
Credible Interval. 
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Table 5.4 continued Simulated and recovered values of the Trust-level 
coefficient for the continuous outcome and binary Trust-level covariate; 














1P-2T 4-10 0.012 (0.002-0.028) 
1P-3T 4-10 0.013 (0.002-0.029) 
1P-4T 4-11 0.013 (0.002-0.029) 
0.137 
1P-2T 0 0.136 (0.119-0.149) 
1P-3T 0 0.136 (0.118-0.150) 
1P-4T 0 0.136 (0.118-0.150) 
0.250 
1P-2T 0 0.250 (0.235-0.263) 
1P-3T 0 0.249 (0.235-0.263) 
1P-4T 0 0.249 (0.235-0.263) 
0.500 
1P-2T 0 0.499 (0.484-0.513) 
1P-3T 0 0.499 (0.484-0.512) 
1P-4T 0 0.499 (0.485-0.513) 
0.684 
1P-2T 0 0.683 (0.668-0.697) 
1P-3T 0 0.683 (0.668-0.696) 
1P-4T 0 0.683 (0.668-0.697) 
𝛽𝑇 – Trust-level coefficient value; median averaged over 3 simulation seeds; CI – 
Credible Interval.  
 
- 136 - 
The reason for these exclusions is that these datasets, when analysed, 
show exactly the same weighted mean outcome for each Trust class and the 
same probability of class membership for each of the nineteen Trusts. 
Hence, the weighted mean outcome by Trust is also identical for all Trusts 
and so the regression analysis cannot be performed, as the outcome does 
not vary. The 𝛽𝑇 coefficient cannot therefore be recovered. There is 
consistency across the models i.e. no more or less datasets are excluded on 
average for the models using four Trust classes compared to those using 
two Trust classes. All simulated datasets are included in the results for all 
other values of 𝛽𝑇. It is hypothesised that, at very small values of 𝛽𝑇, the 
noise introduced when simulating the data dominates the value of the 𝛽𝑇 
coefficient and hence the modelling process is unable to divide the Trusts 
into identifiably different Trust classes. As the numbers of excluded datasets 
are relatively small, the simulated 𝛽𝑇 = 0.027 value remains included in the 
results, although some bias may remain in the recovered 𝛽𝑇 value. This may 
explain why these recovered 𝛽𝑇 values are seen to reduce as the error 
variance is increased. Given this possibility of bias, it is reassuring that the 
simulated 𝛽𝑇 = 0.027 value remains within the 95% credible intervals of the 
recovered values throughout. 
Figure 5.2 shows the results from table 5.4 plotted by error variance, 
demonstrating that the line of equality (where recovered 𝛽𝑇 equals simulated 
𝛽𝑇) lies almost exactly on the data points and is well within the credible 
intervals. All MLLC models are included and no distinction is made between 








Figure 5.2 Plot showing 𝛽𝑇 relationship for the continuous outcome and binary Trust-level covariate 
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5.4.1.2 Continuous Trust-level covariate 
Table 5.5 shows the results of the analysis using a continuous outcome and 
a continuous Trust-level covariate, for nineteen simulated Trusts. Results 
are again consistent across simulation seeds. Again, just one patient class 
(1P) was used in the modelling, but up to five Trust classes (5T) are initially 
used to reflect the gradual improvement seen as the number of Trust 
classes are increased. 
For all combinations, the median recovered values of the Trust-level 
coefficient (𝛽𝑇) are lower than those simulated, although most simulated 
values are within the credible intervals for each recovered 𝛽𝑇 value, for 
models with three Trust classes or more. As seen when modelling the binary 
Trust-level covariate, credible intervals widen as error variance increases, 
but for the continuous Trust-level covariate models, they also widen as the 
simulated 𝛽𝑇 value is increased.  
Estimates are better for smaller values of the error variance (e.g. for the 
simulated 𝛽𝑇 = 0.120, 1P-2T model: 33% error variance returns 0.090, 50% 
error variance returns 0.087 and 67% error variance returns 0.085), and this 
pattern is seen for all simulated values of 𝛽𝑇 except the lowest. This 
indicates that an increase in simulated error variance may be dominating the 
value of the 𝛽𝑇 coefficient such that the modelling process is less able to 
separate the Trusts into distinct Trust classes. For the larger simulated 𝛽𝑇 
values, estimates also improve as the number of Trust classes are increased 
(e.g. for the simulated 𝛽𝑇 = 0.120, 33% error variance: 1P-2T returns 0.090, 
1P-3T returns 0.105, 1P-4T returns 0.107 and 1P-5T returns 0.109). This 
pattern is seen for all values of the error variance. This relationship is 
expected, as more Trust classes are required in order to fully distinguish 
differences between values of the continuous Trust-level covariate. 
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Table 5.5 Simulated and recovered values of the Trust-level coefficient for 















1P-2T 45-53 0.003 (-0.001 to 0.013) 
1P-3T 42-50 0.003 (-0.001 to 0.014) 
1P-4T 43-52 0.003 (-0.001 to 0.014) 
1P-5T 41-47 0.003 (-0.001 to 0.014) 
0.053 
1P-2T 0 0.032 (0.011-0.051) 
1P-3T 0 0.036 (0.012-0.056) 
1P-4T 0 0.036 (0.012-0.056) 
1P-5T 0 0.036 (0.012-0.056) 
0.120 
1P-2T 0 0.090 (0.063-0.113) 
1P-3T 0 0.105 (0.079-0.124) 
1P-4T 0 0.107 (0.084-0.127) 
1P-5T 0 0.109 (0.085-0.127) 
0.200 
1P-2T 0 0.153 (0.113-0.184) 
1P-3T 0 0.182 (0.154-0.201) 
1P-4T 0 0.188 (0.165-0.207) 
1P-5T 0 0.191 (0.168-0.210) 
0.264 
1P-2T 0 0.201 (0.153-0.241) 
1P-3T 0 0.240 (0.207-0.263) 
1P-4T 0 0.250 (0.223-0.269) 
1P-5T 0 0.254 (0.230-0.274) 
𝛽𝑇 – Trust-level coefficient value; median averaged over 3 simulation seeds; CI – 
Credible Interval.  
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Table 5.5 continued Simulated and recovered values of the Trust-level 
coefficient for the continuous outcome and continuous Trust-level 














1P-2T 51-57 0.003 (-0.002 to 0.015) 
1P-3T 46-52 0.003 (-0.002 to 0.015) 
1P-4T 47-53 0.003 (-0.002 to 0.015) 
1P-5T 43-50 0.003 (-0.002 to 0.015) 
0.053 
1P-2T 0-4 0.029 (0.008-0.052) 
1P-3T 0-4 0.031 (0.008-0.055) 
1P-4T 0-4 0.032 (0.008-0.055) 
1P-5T 0-3 0.031 (0.007-0.055) 
0.120 
1P-2T 0 0.087 (0.058-0.115) 
1P-3T 0 0.101 (0.071-0.126) 
1P-4T 0 0.103 (0.073-0.126) 
1P-5T 0 0.104 (0.073-0.129) 
0.200 
1P-2T 0 0.152 (0.111-0.185) 
1P-3T 0 0.180 (0.148-0.203) 
1P-4T 0 0.186 (0.159-0.209) 
1P-5T 0 0.188 (0.161-0.210) 
0.264 
1P-2T 0 0.202 (0.149-0.242) 
1P-3T 0 0.240 (0.203-0.264) 
1P-4T 0 0.249 (0.218-0.271) 
1P-5T 0 0.252 (0.225-0.277) 
𝛽𝑇 – Trust-level coefficient value; median averaged over 3 simulation seeds; CI – 
Credible Interval.  
  
- 141 - 
Table 5.5 continued Simulated and recovered values of the Trust-level 
coefficient for the continuous outcome and continuous Trust-level 














1P-2T 53-61 0.003 (-0.003 to 0.017) 
1P-3T 50-58 0.003 (-0.002 to 0.017) 
1P-4T 51-57 0.003 (-0.002 to 0.017) 
1P-5T 46-53 0.004 (-0.003 to 0.017) 
0.053 
1P-2T 3-6 0.027 (0.003-0.052) 
1P-3T 3-6 0.028 (0.004-0.055) 
1P-4T 2-6 0.028 (0.004-0.054) 
1P-5T 2-6 0.028 (0.005-0.054) 
0.120 
1P-2T 0 0.085 (0.054-0.115) 
1P-3T 0 0.098 (0.062-0.126) 
1P-4T 0 0.099 (0.063-0.127) 
1P-5T 0 0.100 (0.063-0.129) 
0.200 
1P-2T 0 0.151 (0.109-0.186) 
1P-3T 0 0.178 (0.143-0.205) 
1P-4T 0 0.183 (0.149-0.209) 
1P-5T 0 0.186 (0.154-0.212) 
0.264 
1P-2T 0 0.202 (0.147-0.243) 
1P-3T 0 0.238 (0.202-0.266) 
1P-4T 0 0.248 (0.213-0.274) 
1P-5T 0 0.251 (0.220-0.277) 
𝛽𝑇 – Trust-level coefficient value; median averaged over 3 simulation seeds; CI – 
Credible Interval.  
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There is less of a pattern seen for the lowest simulated 𝛽𝑇 values. In fact, for 
the lowest simulated 𝛽𝑇 value of 0.011, neither the median returned value 
nor the credible interval show much difference at all across the error 
variances or models. Additionally, for the second lowest simulated 𝛽𝑇 value 
of 0.053, while there is improvement for reduced amounts of error, and initial 
improvement between models containing two and three Trust classes, there 
is no additional improvement as the number of Trust classes are increased 
further. 
As seen in analysis using the binary Trust-level covariate, not all datasets 
are able to be included in calculation of the median recovered 𝛽𝑇 coefficient, 
for the same reasons. There are more datasets excluded here, however, for 
the same reasons as examined in section 5.4.1.1, and these figures can also 
be seen in table 5.5. For the lowest simulated 𝛽𝑇 value of 0.011, between 41 
and 61 datasets are excluded, with more exclusions seen at increased 
values of the error variance. For the second lowest simulated 𝛽𝑇 value of 
0.053, between 0 and 6 datasets are excluded, following the same pattern 
across values of the error variance. Exclusions again remain consistent 
across MLLC models. The lowest simulated 𝛽𝑇 value of 0.011 is therefore 
excluded from further investigation into the relationship between simulated 
and recovered values, as too many datasets have been excluded to rely on 
the results seen. The second lowest value of 0.053 remains included, as 
numbers of exclusions are small, although some bias may remain. It is again 
reassuring that the simulated 𝛽𝑇 = 0.053 value remains within credible 
intervals, for MLLC models with at least three Trust classes. 
Figures 5.3, 5.4 and 5.5 show the results from table 5.5, excluding the 
lowest value of 𝛽𝑇 = 0.011, plotted for 33%, 50% and 67% error variance 
respectively, and showing the gradually improving relationship between the 
simulated and recovered values of the Trust-level coefficient as the number 





















Figure 5.5 Plot showing 𝛽𝑇 relationship for the continuous outcome and continuous Trust-level covariate; 67% error variance 
- 146 - 
5.4.1.3 Fifty Trusts 
As discussed in section 5.2.6, interest lies in the implication of increasing the 
number of simulated Trusts from nineteen to fifty, to investigate the idea that 
use of a greater number of Trusts may lead to improved results. No other 
changes are made to the simulation process. Only 50% error variance is 
considered, as the intent here is merely to ascertain whether improved 
results are seen, rather than to replicate the entire set of results. 
Table 5.6 shows the results of the analysis for the binary Trust-level 
covariate, while table 5.7 shows the results for the continuous Trust-level 
covariate. The same models are used for fifty Trusts, as were used for 
nineteen Trusts. For the binary Trust-level covariate, therefore, up to four 
(4T) Trust classes are considered, to compare directly to model results in 
table 5.4. For the continuous Trust-level covariate, up to five (5T) Trust 
classes are considered, to compare directly to model results in table 5.5. 
For the binary Trust-level covariate, results are consistent across MLLC 
models, as also seen for nineteen Trusts. Recovered estimates, however, 
are reduced for fifty Trusts, for the lowest 𝛽𝑇 values of 0.027, 0.137 and 
0.250. Whilst, for nineteen Trusts, all simulated 𝛽𝑇 values lie within the 
credible intervals of the recovered values, this is not the case for 𝛽𝑇 = 0.027 
when considering fifty Trusts. At this lowest value of 𝛽𝑇, credible intervals 
are much reduced. The rest of the recovered values lie within credible 
intervals, however. 
For the continuous Trust-level covariate, recovered estimates are reduced 
for fifty Trusts, compared with those seen for nineteen Trusts, across all 
values of 𝛽𝑇. Recovered estimates increase as the number of Trust classes 
are increased, as also seen for nineteen Trusts, for all values of 𝛽𝑇, and 
credible intervals are generally narrower. Whilst, for nineteen Trusts, 
simulated 𝛽𝑇 values lie within the credible intervals of the recovered values 
when considering at least three Trust classes, this is not the case for fifty 
Trusts, where most recovered values lie outside of the credible intervals for 
any number of Trust classes. 
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Table 5.6 Simulated and recovered values of the Trust-level coefficient for 















1P-2T 2-9 0.008 (0.001-0.019) 
1P-3T 2-9 0.008 (0.001-0.019) 
1P-4T 2-9 0.008 (0.001-0.019) 
0.137 
1P-2T 0 0.133 (0.115-0.146) 
1P-3T 0 0.133 (0.118-0.147) 
1P-4T 0 0.133 (0.118-0.147) 
0.250 
1P-2T 0 0.249 (0.235-0.261) 
1P-3T 0 0.249 (0.236-0.262) 
1P-4T 0 0.249 (0.233-0.262) 
0.500 
1P-2T 0 0.499 (0.486-0.512) 
1P-3T 0 0.499 (0.483-0.512) 
1P-4T 0 0.499 (0.485-0.512) 
0.684 
1P-2T 0 0.683 (0.667-0.696) 
1P-3T 0 0.683 (0.669-0.696) 
1P-4T 0 0.683 (0.670-0.696) 
𝛽𝑇 – Trust-level coefficient value; median averaged over 3 simulation seeds; CI – 
Credible Interval; comparison to 19 Trusts in table 5.4. 
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Table 5.7 Simulated and recovered values of the Trust-level coefficient for 

















1P-2T 51-60 0.001 (-0.003 to 0.010) 
1P-3T 47-59 0.002 (-0.003 to 0.010) 
1P-4T 46-58 0.002 (-0.003 to 0.011) 
1P-5T 43-59 0.002 (-0.003 to 0.013) 
0.053 
1P-2T 4-6 0.018 (0.003-0.034) 
1P-3T 4 0.019 (0.003-0.037) 
1P-4T 4 0.019 (0.003-0.038) 
1P-5T 4 0.019 (0.003-0.037) 
0.120 
1P-2T 0 0.076 (0.053-0.099) 
1P-3T 0 0.085 (0.056-0.107) 
1P-4T 0 0.086 (0.058-0.109) 
1P-5T 0 0.086 (0.058-0.109) 
0.200 
1P-2T 0 0.144 (0.116-0.170) 
1P-3T 0 0.169 (0.141-0.190) 
1P-4T 0 0.174 (0.146-0.197) 
1P-5T 0 0.175 (0.146-0.199) 
0.264 
1P-2T 0 0.195 (0.163-0.225) 
1P-3T 0 0.230 (0.202-0.251) 
1P-4T 0 0.239 (0.212-0.262) 
1P-5T 0 0.243 (0.214-0.266) 
𝛽𝑇 – Trust-level coefficient value; median averaged over 3 simulation seeds; CI – 
Credible Interval; comparison to 19 Trusts in table 5.5. 
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5.4.1.4 Apparent 𝜷𝑻 suppression 
Analysis for nineteen Trusts using a continuous outcome and a binary Trust-
level covariate demonstrates consistent results with median recovered 𝛽𝑇 
values seen to be almost identical to the simulated values for all values 
except the lowest. See section 5.4.1.1 and table 5.4 for these results. For a 
continuous outcome and a continuous Trust-level covariate, however, there 
is some attenuation of the effect seen. As indicated in section 5.4.1.2, and 
seen in table 5.5, median recovered 𝛽𝑇 values are lower than those 
simulated throughout, although estimates are generally better both for 
smaller values of the error variance, and for a greater number of Trust 
classes. 
When considering fifty Trusts, further attenuation is seen. For a continuous 
outcome and a binary Trust-level covariate, recovered estimates are 
reduced in comparison those seen for nineteen Trusts, for the lowest 
simulated 𝛽𝑇 values, as indicated in section 5.4.1.3, and seen in table 5.6. 
For a continuous outcome and a continuous Trust-level covariate, recovered 
estimates are again reduced for all simulated values of 𝛽𝑇, when compared 
with those seen for nineteen Trusts, as also indicated in section 5.4.1.3, and 
seen in table 5.7. Similar to the results seen for nineteen Trusts, however, 
estimates are generally better for a greater number of Trust classes. Only a 
50% error variance was used when considering fifty Trusts, so no further 
comment can be made on the effect of different sizes of error variance on 
the recovered estimates. 
This apparent suppression of recovered 𝛽𝑇 values is important when 
performing analyses using this methodological approach. Results showing 
the effect of Trust-level covariates should be interpreted cautiously, with 
consideration that effects seen may be lower than the ‘true’ effects, 
particularly for larger numbers of Trusts, greater values of the error variance, 
and smaller numbers of Trust classes. 
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5.4.1.5 Ten Trust classes 
Tables 5.5 and 5.7 show that, for a continuous outcome and a continuous 
Trust-level covariate, there is a gradual improvement in estimates of the 
recovered value of 𝛽𝑇 as the number of Trust classes are increased. Interest 
lies in whether this improvement continues beyond five Trust classes, for 
either nineteen or fifty Trusts.  
Table 5.8 shows the results of the analysis using a one patient-class (1P), 
ten Trust-class (10T) MLLC model. Due to the computational resources 
required to run these larger models, only a 50% error variance is considered, 
and just one simulation seed is used to generate the simulated datasets. 
Results do not generally show improvement compared to the one patient-
class (1P) five Trust-class (5T) MLLC models for either nineteen or fifty 
Trusts. For nineteen simulated Trusts, all simulated values of 𝛽𝑇 lie within 
the recovered credible intervals for both 5T and 10T models, whilst for fifty 
simulated Trusts, only simulated values of 𝛽𝑇 = 0.011 or 0.264 lie within 
recovered credible intervals for either of the 5T or 10T models. 
Table 5.8 Simulated and recovered values of the Trust-level coefficient for 

















19 48 0.004 (-0.001 to 0.016) 
50 54 0.001 (-0.004 to 0.011) 
0.053 
19 4 0.032 (0.009 to 0.056) 
50 4 0.018 (0.003-0.035) 
0.120 
19 0 0.104 (0.070-0.127) 
50 0 0.086 (0.051-0.109) 
0.200 
19 0 0.190 (0.160-0.211) 
50 0 0.175 (0.144-0.199) 
0.264 
19 0 0.256 (0.226-0.278) 
50 0 0.244 (0.212-0.266) 
𝛽𝑇 – Trust-level coefficient value; simulation seed 1 only; CI – Credible Interval. 
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5.4.2 Binary outcome 
Table 5.9 shows the results of the analysis using a binary outcome and a 
binary Trust-level covariate. Results are again consistent across simulation 
seeds; models contain one patient class (1P) and up to four (4T) Trust 
classes. 
The simulated values of the Trust-level coefficient (𝛽𝑇) are not found within 
the credible intervals for any of the recovered 𝛽𝑇 values, with all recovered 
estimates lying considerably lower than the respective simulated values. 
Results are, however, very consistent across the different models, indicating 
that further modelling with more Trust classes is unlikely to improve the 
estimates. Again, not all datasets are able to be included in calculation of the 
average recovered 𝛽𝑇 coefficient, for the same reasons as explained in 
section 5.4.1.1, with figures also shown in table 5.9. Exclusions again remain 
consistent across MLLC models. Due to the high number of exclusions, the 
lowest simulated value of 𝛽𝑇 = 0.027 is therefore excluded from further 
investigation into the relationship between simulated and recovered values, 
while the second lowest value of 𝛽𝑇 = 0.137 remains included, although 
some bias may be present. 
Figure 5.6 shows the results from table 5.9, excluding the lowest value of 
𝛽𝑇 = 0.027. All MLLC models are included and no distinction is made 
between the number of Trust classes, as results are consistent. A linear 
regression line is added to aid interpretation and to show the pattern of the 
recovered 𝛽𝑇 values compared with those simulated. It is clear that the line 
of equality (where recovered 𝛽𝑇 equals simulated 𝛽𝑇)  does not lie within the 
credible intervals of the recovered 𝛽𝑇 values.  
As yet, the rationale behind this observed relationship is unknown and 
further investigation is required. There may be a scalar effect operating to 
distort the relationship, which may be a function of the intraclass correlation 
coefficient (ICC), or the association may be more complex. Section 5.5 
discusses the ICC, while section 6.5 considers suggestions for further study. 
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Table 5.9 Simulated and recovered values of the Trust-level coefficient for 








Median Recovered 𝜷𝑻 
Coefficient (CI) 
0.027 
1P-2T 48-60 0.001 (-0.002 to 0.010) 
1P-3T 46-57 0.002 (-0.002 to 0.010) 
1P-4T 46-57 0.002 (-0.002 to 0.010) 
0.137 
1P-2T 1-2 0.018 (0.007 to 0.037) 
1P-3T 1-2 0.018 (0.007 to 0.037) 
1P-4T 1-2 0.018 (0.007 to 0.037) 
0.250 
1P-2T 0 0.051 (0.034 to 0.066) 
1P-3T 0 0.050 (0.034 to 0.066) 
1P-4T 0 0.050 (0.034 to 0.066) 
0.500 
1P-2T 0 0.112 (0.097 to 0.125) 
1P-3T 0 0.112 (0.097 to 0.126) 
1P-4T 0 0.113 (0.097 to 0.126) 
0.684 
1P-2T 0 0.154 (0.140 to 0.167) 
1P-3T 0 0.154 (0.140 to 0.168) 
1P-4T 0 0.154 (0.140 to 0.168) 








Figure 5.6 Plot showing 𝛽𝑇 relationship for the continuous outcome and binary Trust-level covariate 
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5.5 Discussion 
The MLLC modelling approach to the recovery of Trust-level coefficient 
values shows a successful recovery for both a binary and a continuous 
Trust-level covariate, when a continuous outcome is investigated. For the 
binary Trust-level covariate, recovered values are almost equal to the 
simulated values, for all except the lowest value, across MLLC models, 
simulated coefficients and error variances; all simulated values are within 
credible intervals of the recovered values. For the continuous Trust-level 
covariate, median estimates are lower than simulated values throughout, 
showing some attenuation of effect as described in section 5.4.1.4. 
Improvement is seen, however, as the number of Trust classes are 
increased; all simulated values are within credible intervals of the recovered 
values when the number of Trust classes are at least three. This difference 
is anticipated, as more Trust classes are required to fully distinguish 
differences between values of a continuous Trust-level covariate. Additional 
covariates between the binary and continuous could be explored, i.e. three 
or more categories would be simulated, and the same analysis performed. 
Lower simulated values of the Trust-level covariate are not recovered as well 
as higher values. It is possible that the variation introduced during simulation 
dominates the coefficient value such that it is harder to identify within the 
modelling process. The additional variation in the continuous Trust-level 
covariate may also mean that a small simulated value may be even harder 
to identify, thus higher values of the Trust-level covariate are recovered 
more successfully. 
The use of fifty Trusts does not improve estimates when compared to 
nineteen Trusts. Estimates, in fact, are lower, with some simulated values of 
the Trust-level coefficient lying outside recovered credible intervals. Whilst 
simulations with fifty Trusts can support more Trust classes compared with 
those with nineteen Trusts, there is no evidence that this is a solution. An 
increase to ten Trust classes does not improve estimates compared with 
MLLC models with up to five Trust classes, for simulated data with either 
nineteen or fifty Trusts.  
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When investigating a binary outcome, results are not as clear. Consideration 
is given to the possibility of a scalar effect operating to distort the 
relationship between simulated and recovered values of the Trust-level 
coefficient, which may be a function of the ICC, as discussed in section 
5.4.2. In a MLLC model, the binomial error variance at the lower level is fixed 
at a value of 𝜋2 3⁄ , as indicated in section 5.2.2, while the variance at the 
upper level is allowed to vary. The modelling process includes sex, SES and 
age at the lower level, thus explaining some of the variability at this level. 
Since the lower-level variance is fixed, however, this may impact on the 
upper-level variance, creating a scalar effect in the results. The effect of 
𝜋2 3⁄ = 3.290 alone, however, does not appear to explain the relationship 
seen in figure 5.6. Further research is therefore required, which is discussed 
in section 6.5. 
Nevertheless, the MLLC approach as demonstrated here has many 
advantages. Modelling for prediction and for causal inference are partitioned, 
thus performing adjustment for differential selection at the patient level, while 
allowing for a causal inference structure at the provider level. This approach 
is feasible only through use of latent variable methodologies; traditional 
approaches cannot replicate the modelling performed here. Although upper-
level covariates are included individually in this analysis, there is much 
scope to extend by consideration of multiple covariates at the provider level. 
A multivariable DAG could be constructed at this level in order to adjust 
appropriately for multiple provider-level covariates within a single analytical 
framework, and is discussed further in section 6.5. 
  





This study set out to explore the utility of unexploited, novel statistical 
techniques in the analysis of complex observational health data. A more 
advanced modelling approach has been demonstrated that lies within an 
overarching causal framework, thus allowing for different modelling 
approaches to be partitioned across levels of a hierarchy, while 
accommodating uncertainty within the model covariates. Through the 
exploration of three research questions, aspects of the patient journey have 
been highlighted for detailed methodological consideration by latent variable 
techniques, and compared (where feasible) with traditional modelling 
approaches. The process was not, however, straightforward. While proof of 
principle has been demonstrated in most of the explored circumstances, 
care must be taken in the interpretation of results, due to inherent limitations 
within the available data. 
Observational health data (as described in the Preface) are commonly 
obtained by routine data collection as patients progress through the 
healthcare system, with events recorded and linked to the patient. Thus, 
data are collected by distinct organisations, for differing purposes 
(Department of Health, 2011). Specifically for cancer registrations, data may 
be recorded such that incidence and mortality statistics can be calculated 
and monitored (The National Cancer Registration and Analysis Service, 
2017), and to assess whether targets, such as the two week wait process 
(NICE, 2017b), are met within a population. As discussed in section 1.2.1, 
data have not been collected in response to a specific research question, 
which raises additional challenges to be addressed during analysis, due to 
the structure and complexity of the available data.  
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Within the field of cancer research, single level regression methods are most 
commonly used to analyse observational health data, as discussed in 
section 3.2.2. Multilevel analysis is not commonly used, as also discussed, 
despite the fact that there are clearly distinct organisations within which 
patients are diagnosed and treated. Stage at diagnosis is frequently included 
in analysis, although its relationship with other covariates may not be 
carefully considered or explored, as indicated in section 3.2.2. When 
accommodation for patient casemix is sought, approaches are commonly 
restricted to the casemix adjustment strategies discussed in section 1.3.4, 
for example, the use of direct or indirect standardisation procedures (Haynes 
et al., 2009; Fidler et al., 2015). MLLC analysis has not often been utilised in 
the context of observational health data, as indicated in section 1.4.5, with 
only one of the five multilevel latent variable approaches considering data 
similar to that described within this thesis. 
It is possible that routinely collected data, such as that utilised here, may not 
be amenable to improved assessment or evaluation. Further, the 
requirements and rationale behind data collection, as described within this 
section, may not promote the production of datasets that benefit from 
sophisticated analytical developments to address service-relevant questions. 
Although this thesis demonstrates that latent variable methods can be 
applied, it should be recognised that observational health datasets may not 
be the most appropriate context within which to test or to develop these 
novel methods of data analysis. 
Section 6.2 summarises the findings from analysis of the three research 
questions. 
Section 6.3 considers the strengths and limitations of the analytical approach 
to the available data. 
Section 6.4 discusses the implications of the study. 
Section 6.5 considers recommendations for future research. 
Section 6.6 offers conclusions to the thesis as a whole, taking into account 
strengths, limitations and future research.  
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6.2 Summary of findings 
6.2.1 Research question (1) 
(1) What is the relationship between a health exposure (SES) and 
outcome (three-year mortality), and what other factors affect this 
relationship? 
For this research question, causal inference was sought at the patient level, 
whilst accommodating variation at the provider level. Use of MLLC analysis 
allowed for the appropriate modelling of patient-level covariates; stage at 
diagnosis was identified as a mediator of the SES-survival relationship, and 
is an imprecise measure, thus stage was removed from the regression part 
of the model and instead included as a class predictor. Bias due to both the 
reversal paradox and measurement error was therefore minimised. A range 
of DAGs demonstrated that alternative models could have been selected, 
which will be addressed in section 6.5. 
MLLC modelling provided a better interpretation of the data, compared with 
the traditional MLM approach, and offered an enhanced interpretation based 
on three latent classes at the patient level. MLM found increasing Townsend 
deprivation score (as a measure of SES) and increasing age to increase the 
odds of death, while female gender decreased the odds. MLLC modelling 
found similar effects (although of a greater magnitude) for deprivation and 
age, while reduced odds of death for females were seen only in the good 
prognosis (early stage) class. 
Five Trust-level latent classes were chosen, identifying outlying Trusts and 
thus indicating that a continuous latent variable at the Trust level (as 
required for MLM), was not sufficient to model these data. Differences in 
prognosis at the Trust level were due primarily to patient casemix 
differences. 
Classification of patients and Trusts was not straightforward, and a different 
number of patient and Trust classes could have been chosen, potentially 
resulting in different results and interpretation. Sensitivity analyses are 
described in section 6.5. 
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6.2.2 Research question (2) 
(2) How does the performance of a healthcare provider vary after 
accommodating patient differences? 
For this research question, accommodation for differential selection was 
sought at the patient level such that differences in patient outcome at the 
provider level were then considered to be due to underlying organisational 
factors, rather than patient casemix. There was no concern regarding bias at 
the patient level, as causal inference was not required. Thus, all modelled 
covariates were included in the regression part of the model. 
In the MLLC approach, two patient classes were chosen to model patient-
level variability, and two Trust classes were identified, which showed a small 
but distinct difference in overall prognosis. A Trust performance ranking was 
allocated to each Trust based on its probability of membership of the best 
survival Trust class. In the traditional comparison, each Trust was assigned 
a rank based on its scaled difference from an SMR of one (where numbers 
of expected deaths equalled those of observed deaths). 
The approaches were shown to be comparable, providing similar results with 
the same general Trust-rank progression. MLLC modelling is preferred, 
however, due to the use of a more sophisticated method that has 
accommodated both heterogeneity and measurement error. Confidence 
intervals were wide, and may be improved by the addition of treatment 
characteristics. This is discussed further in section 6.3.2. 
Again, a different number of patient and Trust classes could have been 
chosen, potentially resulting in different results and interpretation. Sensitivity 
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6.2.3 Research question (3) 
(3) Can causal provider-level covariate effects be identified, after 
accommodating patient differences? 
This research question is an extension of research question (2), considering 
covariates at the provider level. Simulation was performed to assess proof of 
principle of the approach to accommodate patient casemix whilst performing 
causal modelling at the provider level. Assessment was made of the ability 
of the MLLC approach to recover simulated values of either a binary or 
continuous provider-level covariate, when combined with either a binary or 
continuous outcome measure. No traditional comparison was available. 
A homogeneous patient group was simulated, hence MLLC models 
incorporated only one patient class. This is discussed further in section 6.5. 
A range of Trust classes were utilised, from two upwards until no further 
improvement was seen in recovered estimates. 
Initial simulations generated nineteen Trusts, comparable to those within the 
example dataset. Consistent results were seen for a continuous outcome 
and a binary Trust-level covariate, with simulated values of the Trust-level 
coefficient within confidence intervals of the recovered values throughout. 
For the same outcome, with a continuous Trust-level covariate, estimates 
were slightly lower than simulated values throughout, showing some 
attenuation of effect, although they improved as the number of Trust classes 
were increased. Simulated values of the Trust-level coefficient were within 
confidence intervals of the recovered values, however, for three or more 
Trust classes. The use of fifty Trusts showed further attenuation of effect, 
which is addressed in section 6.5.   
When considering a binary outcome and a binary Trust-level covariate, 
recovered values of the Trust-level coefficient were considerably lower than 
simulated values throughout. The rationale behind this observed association 
is unknown and thus requires further research, as discussed in section 6.5. 
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6.3 Strengths and limitations 
6.3.1 Improvements over traditional techniques 
In a traditional multilevel setting, where a continuous latent variable is 
adopted at the upper level, the implicit assumption is that provider-level 
outcomes have an underlying normal distribution (conditional on provider-
level covariates) (see section 1.3.2). Healthcare providers are therefore 
effectively treated as a random sample of a larger (infinite) population. 
Providers are not, however, randomly placed geographically, nor are 
patients randomly assigned to providers (see section 1.2.3). The latent 
variable approach allows for parametric assumptions to be circumvented by 
the inclusion of discrete latent classes at the upper level, although there may 
remain a degree of geographical dependency that is not accounted for.  
The use of latent classes at any level accommodates heterogeneity, with 
covariate relationships identified within each latent class, rather than over all 
observations, as seen in traditional regression approaches. 
Within the latent variable approach, class membership models allow 
covariates to be removed from the regression part of the model, offering the 
capability to model appropriately moderators or mediators of an exposure-
outcome relationship, and thus to minimise bias due to the reversal paradox. 
If imprecisely measured covariates are also included as class predictors, 
interactions are implicit, so exacerbated bias due to measurement error is 
also minimised. This approach was demonstrated for research question (1), 
and other scenarios may also benefit. Traditional approaches do not have 
this capability; all covariates are included within a single model, risking bias. 
Modelling for differential selection can be accommodated at the patient level, 
as demonstrated for research question (2). As an advantage over traditional 
casemix adjustment techniques, latent variable approaches can also 
incorporate modelling for causal inference at the provider level, as 
demonstrated for research question (3). Traditional casemix adjustment 
strategies may increase bias and none can be extended to partition 
modelling approaches in the same manner (see section 1.3.4). 
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6.3.2 Limitations 
Stage at diagnosis contained 13.1% missing data in the example dataset. To 
demonstrate proof of principle for the latent variable approach, this limitation 
was avoided by the inclusion of an additional category for stage, such that all 
observations could be included in analysis. The missing data category was 
therefore interpreted separately. Although considered sufficient for the focus 
of this thesis, generally, missing data techniques should be implemented. 
Techniques such as multiple imputation (MI) or inverse probability weighting 
(IPW) could be employed (Carpenter et al., 2006; Cattle et al., 2011; 
Seaman and White, 2013). Each method requires careful specification of the 
relevant imputation model for each variable with missing data, including 
investigation of parametric assumptions. Further, the congeniality principle 
(Meng, 1994) requires that the imputation models are compatible with the 
analytical model, which becomes more complex when there are interactions 
or non-linear relationships (Sterne et al., 2009; von Hippel, 2009; White et 
al., 2011).  Ideally, latent variable modelling would lie within an integrated 
framework that includes approaches to the problems of missing data, but 
this is not yet resolved for large and complex datasets incorporating 
multilevel data. Methods are in development to (i) perform MI within a 
multilevel framework, and (ii) develop latent class approaches to imputation 
techniques that can be applied to Big Data. Missing data is hence an 
important challenge to be recognised and addressed in other work. 
For research questions (1) and (2), survival was represented by a binary 
outcome of mortality status at three years. This was a necessary 
simplification in order to be comparable to existing research. Survival 
analysis in the standard methodological sense has not been explored within 
the proposed latent variable methodological framework. Results are 
therefore expressed as odds ratios of death within three years. It would be 
common to explore survival as a continuous measure, for example using 
Cox proportional hazards regression (Armitage et al., 2002), which is 
technically feasible within the proposed latent variable methodological 
framework, although more powerful software would be required, e.g. MPlus 
(Muthén and Muthén, 1998-2015), and this extension is left for future work. 
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SES (as a measure of socioeconomic deprivation) is included at the patient 
level, although it is derived at the small-area level (see section 1.2.2). Again, 
this limitation has not been addressed by the methodological approach. This 
can lead to the ecological fallacy, as discussed in section 1.2.2. Thus, strictly 
speaking, interpretation of the relationship between SES and survival should 
be made at the small-area level, while effects may vary for individuals within 
each small area. SES should ideally be considered as a separate level, 
effectively cross-classified with the Trust level, as discussed in section 1.2.5. 
More sophisticated and as yet unavailable alternative software would be 
required to accommodate a latent variable approach with a cross-classified 
level of analysis; MPlus is under development to achieve cross-classified 
Cox proportional hazards regression, thus eventually addressing the 
limitations of both a binary outcome and use of a small-area measure 
simultaneously. Much more complex modelling is possible with MLLC 
analysis, but all models must be thought through and the context in which 
they are interpreted carefully considered.  
Patients were identified as attending the healthcare organisation at which 
they received their latest diagnosis (see section 2.3.3), so that all patients 
could be included in analysis regardless of whether or not they received 
treatment. There may be error introduced, however, due to patients 
attending multiple centres throughout their care. This error is mitigated by 
modelling with Trust of diagnosis at the upper level, rather than by hospital, 
as a higher proportion of patients who are treated remain within their Trust of 
diagnosis throughout their care (74.3%) compared with those who remain 
within their hospital of diagnosis throughout (59.2%). Nevertheless, some 
variability may remain, which could impact upon the CE of the chosen 
models. These inaccuracies could be further addressed by screening each 
patient journey to determine where the majority of interventions take place, 
or by using multilevel multiple membership models (Goldstein, 2011) for 
multiple treatment centres. 
Accommodation for differential selection has thus far considered only patient 
characteristics. Ideally, patient pathways through the healthcare system (e.g. 
treatment effects) would also be included, as introduced in section 1.1, and 
considered with respect to research question (2) in section 4.4. While the 
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latent variable approach will extend to accommodate these, no information 
was available in the example dataset. Thus, their inclusion has not been 
addressed within the analysis, which may impact upon the width of the 
confidence intervals around the Trust ranks in figure 4.3, when comparing 
Trust performance for research question (2). The inclusion of treatment 
effects in the analysis may explain more of the variability in the outcome, 
potentially reducing the confidence intervals, if this information were 
available. Nevertheless, the latent variable approach may still offer an 
improved alternative over traditional techniques when evaluating treatment 
effects in an observational setting. As discussed in section 1.3.4, the 
propensity score is commonly used to accommodate patient differences and 
compare treatment subgroups, but this approach conflates modelling for 
prediction with that for causal inference. 
Additionally, it may be challenging to make the analyses presented within 
this thesis accessible to potential users, such as health service policy 
makers or healthcare providers. The methodological approach applied when 
using the example dataset, i.e. for research questions (1) and (2), was 
unable to entirely address the difficulty in selection of the optimum number of 
both patient and Trust classes, as discussed in sections 6.2.1 and 6.2.2. 
Thus, the results and interpretations presented may be somewhat 
speculative. Discussion of future research in section 6.5 makes 
recommendations as to how best to achieve accessibility to users. 
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6.4 Implications of the study 
This study has shown that latent variable modelling has utility in the analysis 
of a complex, hierarchical dataset, with improved accommodation of the data 
challenges in comparison to traditional techniques, and the ability to 
incorporate both differential selection and causal inference within the same 
modelling approach. It must be noted, however, that observational health 
datasets may not be the most appropriate context within which to explore 
these novel techniques, and that further research is necessary to minimise 
potentially speculative results and interpretation. Nevertheless, a 
generalised framework has been demonstrated, which offers the opportunity 
to utilise the methods in other contexts.  
Potential area-level factors are numerous, and are not limited to known 
subgroups (e.g. communities, healthcare providers or schools); any 
environmental features utilised by groups of individuals may be modelled 
(e.g. access to fast food outlets, opportunities for physical activity or 
availability of green space). Possibilities to assess health outcomes are also 
numerous. For example, both the availability of fast food outlets, and  
opportunities for physical activity may impact on levels of obesity (Coombes 
et al., 2010; Williams et al., 2015). An integrated approach could therefore 
be pursued, considering the interplay between characteristics of both 
individuals and areas within an single analytical framework.  
Further, preliminary investigation of observational data using latent variable 
techniques may inform prospective cluster-randomised trials targeted at 
improving public health outcomes. Trials can then focus on the modification 
of either individual or area characteristics identified by the MLLC approach 
as potential causes of differences in health outcomes. This pertains to 
existing approaches for quality improvement research, and is consistent with 
the principles of the Medical Research Council (MRC) framework for the 
development and evaluation of complex interventions (Craig et al., 2008). 
Latent variable techniques may also be utilised alongside the cluster-
randomised trial approach (e.g. to assess compliance), to minimise the bias 
that may occur when small numbers of clusters are considered (Campbell et 
al., 2007) by accommodating uncertainty within the latent constructs. 
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6.5 Recommendations for future research 
As discussed in sections 6.2.1 and 6.2.2, the selection of both patient and 
Trust classes for research questions (1) and (2) was not straightforward, 
which may lead to differing results and interpretation, and potentially 
speculative results, as discussed in section 6.3.2. In analysis for research 
question (1), the same patterns of association were seen for all model 
covariates when the number of patient classes was fixed at three, and 
different numbers of Trust classes were investigated (see table 3.10). 
Comprehensive sensitivity analyses should, however, be performed with 
respect to both patient and Trust classification. For both these research 
questions, alternative numbers of classes could have been selected, based 
on model-evaluation criteria. Further analyses should therefore be 
performed to investigate the effect of selecting the number of patient classes 
either side of the initial selection. Re-assessment of Trust classes would 
then follow for each new selection of patient classes, with comparisons 
made between the sets of results achieved. Thus, assessment could be 
made regarding the sensitivity of results and interpretation to the 
classification of both patients and Trusts. Further, for research question (2), 
more than two Trust classes may be required at the Trust level to show 
optimal utility from the latent variable approach, even if model likelihood 
statistics are not improved by an increased number of Trust classes. 
In analysis for research question (1), stage at diagnosis was included as a 
class predictor in the MLLC model, while it was excluded entirely in the MLM 
analysis, as MLM does not have the capacity to model covariates as class 
predictors. MLM could, however, be stratified by stage, in order to make a 
more direct comparison between the two analytical methods. It must be 
noted, however, that this amounts to introducing stage at diagnosis explicitly 
as a covariate, which may introduce bias due to the reversal paradox where 
causal interpretation is sought. Equivalent results may be achieved by the 
exclusion of stage entirely in the MLLC analysis (Downing et al., 2010), 
although this approach may not be well received by healthcare organisations 
because, as considered in section 3.4, stage at diagnosis is commonly 
considered to be a key covariate.  
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Discrete latent variables have been utilised at the provider level throughout, 
to avoid the parametric assumptions required when using a continuous 
latent variable. It may be appropriate in some situations to consider both 
continuous and discrete latent variables within a single model approach. 
Studies have shown that use of a continuous latent variable, in place of 
discrete latent classes, may provide a better fit to the data (Downing et al., 
2010; Henry and Muthén, 2010). Continuous and discrete latent variables, if 
combined, may prove more parsimonious, with variation within each 
provider-level class captured by the continuous latent variable, potentially 
leading to fewer provider classes needed to describe overall provider-level 
variation. For research question (2), use of a continuous Trust-level latent 
variable alongside the discrete Trust-level latent variables may alleviate the 
probabilities of Trust-class membership in table 4.8 being so marked, 
although the estimation of Trust survival rates would then become more 
complex. 
In analysis for research question (3), simulated data were modelled in order 
to assess the utility of the latent variable modelling approach to recover 
simulated values of covariates at the Trust level. Nineteen Trusts were 
simulated initially, with an extension to fifty Trusts also considered. Modelling 
for a continuous outcome and a continuous Trust-level covariate showed 
some suppression of recovered values, as described in section 5.4.1.4, with 
increased suppression for fifty Trusts compared with nineteen Trusts. The 
rationale behind this effect is as yet unclear and additional research to 
further investigate simulations that generate larger numbers of Trusts (i.e. 
upper level units) would be beneficial. 
Results seen for research question (3) with respect to the binary outcome 
were inconclusive (see sections 5.4.2 and 5.5). Further investigation is 
required to ascertain the rationale behind the observed association before 
proof of principle can be said to be complete. There are a number of 
potential approaches that could be employed. Much larger simulated values 
of the Trust-level coefficient could be explored to investigate whether or not 
the relationship remains linear over a wider range. Mathematical formulas 
could be studied, to investigate the expected relationship between the 
explained variance at each level of the hierarchy. Further estimation 
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procedures could be performed under controlled situations, perhaps by 
initially simulating very simple models without the inclusion of Trust-level 
covariates. Alternative statistical software could be utilised to reproduce 
models and compare results, or the parameters of the Latent GOLD 
software could be varied. Which method may yield the most useful 
information is, as yet, unknown. 
In simulations for research question (3), analysis incorporated a single latent 
class only at the patient level, as data were simulated for a homogeneous 
patient group. As described in section 5.3.4, this meant that the 
parameterisation used to accommodate patient casemix was essentially 
irrelevant, as there were no multiple patient cases to be organised across 
the Trust classes. Nevertheless, this step was important, as it allowed 
demonstration of recovery of the provider-level covariates. An extension to 
the analysis as performed could be to simulate, and thus model, a 
heterogeneous patient group to assess whether there is any impact on 
Trust-level covariate recovery. 
Analysis for research question (3) incorporated the assessment of individual 
provider-level covariates. Simulation methods can be extended to 
incorporate multiple covariates at the provider level, as indicated in section 
5.3.2, with causal inference modelling supported by the construction of a 
DAG at this level. Thus, many potential provider-level effects may be 
modelled together, including both binary (e.g. whether or not the surgeon is 
a specialist) and continuous (e.g. volume of procedures). Interest may lie in 
the extent to which additional complexities in casemix (e.g. patient pathway 
variables; discussed in section 6.3.2) and multiple provider-level covariates 
(both competing exposures and confounders) may dilute the precision of 
estimates sought for a main provider-level covariate under investigation. 
The utility of DAGs can thus be explored further, and extended to other 
applications or different healthcare contexts. While identification of covariate 
relationships is relatively straightforward for small numbers of variables, 
construction of a DAG becomes more complex if many covariates are 
included, for example in Big Data. As such, a web application ‘DAGitty’ 
(Textor et al., 2011) has been developed, whereby causal diagrams can be 
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produced and analysed. DAGitty can identify sets of covariates that should 
be included in the model in order to minimise bias in the estimate of the main 
exposure-outcome effect, thus aiding identification of appropriate models 
when using larger datasets. Additionally, the R package ‘dagitty’ has been 
developed (Textor et al., 2016), whereby the functionally of the web 
application, and additional capabilities, can be accessed from within the R 
software. 
Finally, as raised in section 6.3.2, there are challenges to be addressed in 
order to make the work within this thesis accessible to potential users within 
healthcare organisations. Although the methodology presented offers a 
novel, integrated approach to the analysis of complex observational health 
data, with improvements seen over traditional techniques, findings remain 
somewhat speculative due to the limitations previously discussed. A guide to 
‘best practice’ in the use of MLLC methodological approaches could assist. 
This guidance document, publishable as a review article, would consider the 
use of multilevel latent variable approaches within health research to 
accommodate patient casemix, aid performance comparison, and thus 
identify potentially causal effects that may affect provider performance. 
Publishing of analyses presented so far has been piecemeal, with modelling 
approaches described independently with reference to data-specific 
research questions (Gilthorpe et al., 2011; Harrison et al., 2012; Harrison et 
al., 2013). It would aid uptake of the methods presented to make explicit the 
integrated analytical approach such that other researchers could utilise the 
same techniques, with adaptation or extension as applicable to their data. It 
remains, however, that observational health datasets may not be the most 
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6.6 Conclusions 
In conclusion, a generalised multilevel latent framework has been developed 
whereby individual and area characteristics can be modelled appropriately to 
assess their contribution to a health outcome. The research detailed within 
this thesis demonstrates one area of application, in the field of cancer 
survival, showing speculative results and interpretation due to inherent 
limitations within observational health data and the appropriateness of the 
methods within this context. Nevertheless, the framework may offer an 
enhanced analytical approach with extension to accommodate missing data, 
and future research allows opportunities to further extend the capabilities of 
the approach in the area of causal inference modelling. 
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Appendix A 
Literature search strategies for the review of 
comparable latent variable approaches 
Searches performed 16 September 2016; for articles from 1996 to 
September Week 1 2016. 
Index Search Terms 
Results (N) 
Medline PsycINFO 
1 Multilevel OR multi-level 17,416 15,409 
2 MeSH: Multilevel Analysis 1,041 - 
3 1 OR 2 17,416 15,409 
4 Latent variable OR latent class 3,869 4,884 
5 Latent AND (mixture model*) 511 719 
6 4 OR 5 4,095 5,161 
7 3 AND 6 60 220 
8 
Limit 7 to (abstracts AND English 
language AND humans AND 
year=”2006-current” AND journals only)  
52 122 
 TOTAL 174 
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Appendix B 
Literature search strategy for the review of risk 
factors associated with survival (or mortality) from 
colorectal cancer 
Search performed 23 September 2016; for articles from 1996 to September 
Week 2 2016. Medline only. 
Index Search Terms Results (N) 
1 MeSH: Colorectal Neoplasms 61,980 
2 
Cancer AND (colorectal OR colon OR rectum OR 
rectosigmoid OR bowel) 
111,723 
3 1 OR 2 124,273 
4 Survival OR MeSH: survival 718,775 
5 Mortality OR MeSH: mortality 421,963 
6 4 OR 5 1,036,600 
7 
MeSH: (risk factors OR prognosis OR diagnosis-
related groups) 
817,794 
8 Factor* 3,124,064 
9 7 OR 8 3,276,853 
10 
3 AND 6 AND 9 
(i.e. colorectal cancer + survival + risk factors) 
17,853 
11 MeSH: (socioeconomic factors OR poverty) 111,547 
12 
Deprivation OR poverty OR socioeconomic status 
OR socio-economic status OR SES OR 
socioeconomic background OR socio-economic 
background OR SEB 
112,286 
13 11 OR 12 182,657 
14 Stage 415,920 
15 
3 AND 13 AND 14 
(i.e. colorectal cancer + deprivation + stage) 
343 
16 10 OR 15 18,018 
 
Continued on next page  
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Index Search Terms Results (N) 
17 
MeSH: (Great Britain OR United Kingdom OR 




Great Britain OR United Kingdom OR England OR 
Wales OR Scotland OR Northern Ireland 
227,356 
19 17 OR 18 227,356 
20 16 AND 19 385 
21 
Limit 20 to (abstracts AND English language 
AND humans AND year=”2006-current”)  
263 
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Appendix C 
Stata code for data simulation 
This code is in two parts: code is defined in the first program, and run in a 
loop in the second to generate 100 similarly defined datasets.  
*  or /* preceding text indicates a comment. 
 
1. Define programs 
******************************************************************************* 
* SIMULATE TRUST MEMBERSHIP 
* allocate patients to Trusts by blocks of a random normal variable (p) 
******************************************************************************* 
 
capture program drop hosmembership 
program define hosmembership 
 * generate p = random uniform distribution (by patient) 
 gen p = uniform() 
  
 * generate 19 hospitals, of differing sizes 
 qui gen HosID = . 
 local pstart = 0 
 local bit = -0.04 
 local pend = `pstart' + (1/19) + `bit' 
 * loop to create HosID for values of p 
 forvalues i = 1/19 {        
  qui replace HosID = `i' if p>`pstart' & p<`pend' 
  local bit = `bit'  + (0.08/18) 
  local pstart = `pend' 
  local pend = `pstart' + (1/19) + `bit'  
 } 
  
 * randomise hospitals & generate pT (for continuous outcome) 
 qui sort HosID p 
 qui by HosID: gen oldcode = HosID if _n==1  
 sort oldcode HosID p       
 qui gen flag=uniform() in 1/19 
 sort flag in 1/19 
 qui gen newcode = _n in 1/19 
 qui gen pTcode=uniform() in 1/19 
 sort HosID p 
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 * set HosID = new (randomised) HosID code 
 by HosID: egen newHosID = max(newcode) 
 * generate pT = random uniform distribution (by Trust) 
 by HosID: egen pT = max(pTcode)     
  
 * tidy dataset 
 drop HosID oldcode flag newcode pTcode 
 rename newHosID HosID 




* GENERATE SEX, DEP & AGE VARIABLES 
* uses trivariate covariance matrix 
* deprivation SD=3.18, age SD=11.6 
* draws from a normal distribution, converts sex to 0/1 
************************************************************** 
 
capture program drop demog 
program define demog 
 matrix A = (1,0,0 \ 0,3.18^2,0 \ 0,0,11.6^2) 
 drawnorm sex dep age, cov(A)  




* BINARY TRUST-LEVEL COVARIATE EFFECT (HGrp) 
* equals 0.5 or -0.5 (centred on zero) with error SD=0.01 
* sets local betas, calculates Trust linear predictor (hlp1) 
* simulates binary outcome (dth_bin) and continuous outcome (oc_bin) 
******************************************************************************** 
 
capture program drop dth_bin   
program define dth_bin 
 * generate blank binary Trust-level covariate 
 qui gen HGrp=. 
 
 * calculate 19 binary Trust-level covariates (SD=0.01) 
 forvalues i = 1/19 { 
  local mult = rnormal(0.5,0.01) - rbinomial(1,0.5) 
  qui replace HGrp = `mult' if HosID == `i' 
 } 
  
 * set local betas (described in section 5.2.2) 
 local b0 = -0.0265     
 local b1 = -0.1368   
 local b2 = 0.0527    
 local b3 = 0.0547   
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 local HBeta = -`b1'  /*Trust-level coefficient effect*/ 
  
 * calculate linear predictor 
 gen hlp1 = `b0' + `b1'*sex + `b2'*dep + `b3'*age + `HBeta'*HGrp  
 * calculate binary outcome 
 gen dth_bin = rbinomial(1,invlogit(hlp1)) 
  
 * set error for continuous outcome (error variance = 0.225 (50%)) 
 gen error=(sqrt(0.225))*invnormal(uniform()) 
 * calculate continuous outcome 
 gen oc_bin=hlp1+error 
  
 * tidy dataset 




* CONTINUOUS TRUST-LEVEL COVARIATE EFFECT (HVal) 
* ranges from -0.5 to +0.5 (centred on zero) 
* sets local betas, calculates Trust linear predictor (hlp2) 
* simulates binary outcome (dth_con) and continuous outcome (oc_con) 
********************************************************************************** 
 
capture program drop dth_con 
program define dth_con 
 * generate continuous Trust-level covariate (by Trust, uses pT) 
 gen HVal = 0.5-pT 
  
 * set local betas (described in section 5.2.2) 
 local b0 = -0.0265   
 local b1 = -0.1368   
 local b2 = 0.0527   
 local b3 = 0.0547   
 local HBeta = `b2'  /*Trust-level coefficient effect*/   
  
 * calculate linear predictor 
 gen hlp2 = `b0' + `b1'*sex + `b2'*dep + `b3'*age + `HBeta'*HVal  
 * calculate binary outcome 
 gen dth_con = rbinomial(1,invlogit(hlp2)) 
  
 * set error for continuous outcome (error variance = 0.218 (50%)) 
 gen error=(sqrt(0.218))*invnormal(uniform()) 
 * calculate continuous outcome 
 gen oc_con=hlp2+error 
 
 * tidy dataset 
 drop hlp2 error p pT 
end 
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2. Run programs 
****************************************************************************** 
* RUN PROGRAMS TO SIMULATE DATA FOR MLLC MODELLING 





set more off 
* set working directory 
cd "N:\...\2016 Trust level covars\Data simulation\Datasets\Run 1" 
 
* set and record seeds (use different seed for multiple runs) 
capture log close 
capture log using "seeds.log", replace     
set seed 1073741823 
*set seed 484848484 /*not active for this run*/ 
*set seed 8493829  /*not active for this run*/ 
 
* loop to generate 100 datasets with same specification 
forvalues i = 1/100 {      
 * set up Stata with 24,640 observations (patients)    
 di `i' 
 clear 
 qui set obs 24640 
 gen patID = _n 
 






 * export to csv 
 qui export delimited using "simulated`i'.csv" 
 
 * increment seed 
 set seed `c(seed)' 
 di c(seed) 
 } 
capture log close 
 
 
